<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S0223523420309065</prism:url><dc:identifier>doi:10.1016/j.ejmech.2020.112934</dc:identifier><eid>1-s2.0-S0223523420309065</eid><prism:doi>10.1016/j.ejmech.2020.112934</prism:doi><pii>S0223-5234(20)30906-5</pii><dc:title>Design, synthesis, biological activity evaluation of 3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives as potent JAK 2/3 and aurora A/B kinases multi-targeted inhibitors </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>fla</pubtype><prism:issn>02235234</prism:issn><prism:volume>209</prism:volume><prism:startingPage>112934</prism:startingpage><prism:pageRange>112934</prism:pagerange><articleNumber>112934</articlenumber><dc:format>text/xml</dc:format><prism:coverDate>2021-01-01</prism:coverdate><prism:coverDisplayDate>1 January 2021</prism:coverdisplaydate><prism:copyright>© 2020 Elsevier Masson SAS. All rights reserved.</prism:copyright><prism:publisher>Elsevier Masson SAS.</prism:publisher><dc:creator>Zheng, You-Guang</dc:creator><dc:creator>Wang, Jin-An</dc:creator><dc:creator>Meng, Long</dc:creator><dc:creator>Pei, Xin</dc:creator><dc:creator>Zhang, Ling</dc:creator><dc:creator>An, Lin</dc:creator><dc:creator>Li, Cheng-Lin</dc:creator><dc:creator>Miao, Ying-Long</dc:creator><dc:description>
                  In this study, a series of 3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives were designed, synthesized, and evaluated for their biological activities. Upon performing kinase assays, most of the compounds exhibited potent inhibition against JAK2/3 and Aurora A/B with the IC50 values ranging from 0.008 to 2.52 μM. Among these derivatives, compound 10e expressed the most moderate inhibiting activities against all the four kinases with the IC50 values of 0.166 μM (JAK2), 0.057 μM (JAK3), 0.939 μM (Aurora A), and 0.583 μM (Aurora B), respectively. Moreover, most of the derived compounds exhibited potent cytotoxicity against human chronic myeloid leukemia cells K562 and human colon cancer cells HCT116, while compound 10e expressed antiproliferative activities against K562 (IC50=6.726  μM). According to western blot analysis, compound 10e down-regulated the phosphorylation of STAT3, STAT5, Aurora A, and Aurora B in a dose-dependent manner in K562 and HCT116 cells. Cell cycle analysis revealed that compound 10e inhibited the proliferation of cells by inducing cell cycle arrest in the G2 phase. The molecular modeling suggested that compound 10e could maintain a binding mode similar to the binding mode of AT9832, a common JAK 2/3 and Aurora A/B kinases multi-target kinase inhibitor. Therefore, compound 10e might be a potential agent for cancer therapy deserving further research.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><dcterms:subject>JAK2/3</dcterms:subject><dcterms:subject>Aurora kinases</dcterms:subject><dcterms:subject>Pyrazole derivatives</dcterms:subject><dcterms:subject>Multi-targeted inhibitors</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S0223523420309065" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S0223523420309065" rel="scidir"/></link></coredata><objects><object ref="fx19" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="33" height="27" size="648">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx19.jpg?httpAccept=%2A%2F%2A</object><object ref="sc1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="713" height="341" size="34799">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-sc1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="535" height="877" size="158293">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="fx5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="35" height="28" size="634">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx5.jpg?httpAccept=%2A%2F%2A</object><object ref="fx23" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="128" height="85" size="2609">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx23.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="77" height="77" size="1863">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx9" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="35" height="28" size="630">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx9.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="712" height="414" size="44934">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="35" height="28" size="633">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="713" height="173" size="22067">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx20" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="40" height="48" size="924">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx20.jpg?httpAccept=%2A%2F%2A</object><object ref="sc2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="713" height="412" size="29942">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-sc2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="55" height="35" size="962">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx8.jpg?httpAccept=%2A%2F%2A</object><object ref="fx14" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="58" height="39" size="977">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx14.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="500" height="158" size="20439">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="380" height="260" size="21318">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="fx18" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="50" height="35" size="959">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx18.jpg?httpAccept=%2A%2F%2A</object><object ref="fx4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="40" height="36" size="840">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx4.jpg?httpAccept=%2A%2F%2A</object><object ref="fx13" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="29" height="27" size="590">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx13.jpg?httpAccept=%2A%2F%2A</object><object ref="fx15" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="33" height="27" size="643">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx15.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="379" height="359" size="35244">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="fx24" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="41" height="49" size="1069">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx24.jpg?httpAccept=%2A%2F%2A</object><object ref="fx17" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="33" height="27" size="645">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx17.jpg?httpAccept=%2A%2F%2A</object><object ref="fx16" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="52" height="35" size="990">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx16.jpg?httpAccept=%2A%2F%2A</object><object ref="fx21" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="31" height="23" size="630">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx21.jpg?httpAccept=%2A%2F%2A</object><object ref="fx12" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="40" height="48" size="911">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx12.jpg?httpAccept=%2A%2F%2A</object><object ref="fx10" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="53" height="39" size="959">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx10.jpg?httpAccept=%2A%2F%2A</object><object ref="fx6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="55" height="39" size="1007">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx6.jpg?httpAccept=%2A%2F%2A</object><object ref="fx11" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="35" height="28" size="633">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx11.jpg?httpAccept=%2A%2F%2A</object><object ref="fx22" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="36" height="44" size="767">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx22.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="713" height="864" size="121945">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="fx7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="35" height="28" size="633">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx7.jpg?httpAccept=%2A%2F%2A</object><object ref="fx19" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="147" height="122" size="1561">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx19.sml?httpAccept=%2A%2F%2A</object><object ref="sc1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="105" size="4154">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-sc1.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="100" height="164" size="9333">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="fx5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="155" height="123" size="1771">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx5.sml?httpAccept=%2A%2F%2A</object><object ref="fx23" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="146" size="3867">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx23.sml?httpAccept=%2A%2F%2A</object><object ref="fx2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="164" height="164" size="3935">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx2.sml?httpAccept=%2A%2F%2A</object><object ref="fx9" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="155" height="123" size="1830">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx9.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="127" size="4780">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="fx3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="155" height="123" size="1751">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx3.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="53" size="2969">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="fx20" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="180" height="215" size="2729">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx20.sml?httpAccept=%2A%2F%2A</object><object ref="sc2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="126" size="3347">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-sc2.sml?httpAccept=%2A%2F%2A</object><object ref="fx8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="139" size="3970">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx8.sml?httpAccept=%2A%2F%2A</object><object ref="fx14" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="147" size="4015">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx14.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="69" size="4983">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="150" size="5326">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="fx18" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="153" size="4197">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx18.sml?httpAccept=%2A%2F%2A</object><object ref="fx4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="180" height="162" size="2353">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx4.sml?httpAccept=%2A%2F%2A</object><object ref="fx13" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="131" height="123" size="1502">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx13.sml?httpAccept=%2A%2F%2A</object><object ref="fx15" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="148" height="123" size="1645">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx15.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="173" height="164" size="12709">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="fx24" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="185" height="220" size="2955">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx24.sml?httpAccept=%2A%2F%2A</object><object ref="fx17" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="148" height="123" size="1372">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx17.sml?httpAccept=%2A%2F%2A</object><object ref="fx16" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="146" size="4176">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx16.sml?httpAccept=%2A%2F%2A</object><object ref="fx21" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="141" height="106" size="1748">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx21.sml?httpAccept=%2A%2F%2A</object><object ref="fx12" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="180" height="215" size="2740">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx12.sml?httpAccept=%2A%2F%2A</object><object ref="fx10" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="161" size="4045">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx10.sml?httpAccept=%2A%2F%2A</object><object ref="fx6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="153" size="3985">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx6.sml?httpAccept=%2A%2F%2A</object><object ref="fx11" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="155" height="123" size="1768">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx11.sml?httpAccept=%2A%2F%2A</object><object ref="fx22" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="162" height="197" size="2603">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx22.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="135" height="164" size="6878">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="fx7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="155" height="123" size="1792">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx7.sml?httpAccept=%2A%2F%2A</object><object ref="fx19" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="147" height="122" size="2800">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx19_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3158" height="1512" size="279202">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-sc1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2370" height="3886" size="1320339">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="155" height="123" size="3088">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx23" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="568" height="378" size="18872">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx23_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="341" height="340" size="12840">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx9" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="155" height="123" size="3074">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx9_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3151" height="1830" size="357916">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="155" height="123" size="3091">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3158" height="768" size="170923">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx20" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="180" height="215" size="4821">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx20_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3158" height="1824" size="252600">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-sc2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="244" height="155" size="5313">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx14" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="258" height="173" size="5402">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx14_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2213" height="698" size="147492">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1682" height="1152" size="160955">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx18" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="222" height="155" size="4860">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx18_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="180" height="162" size="3940">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx13" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="131" height="123" size="2493">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx13_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx15" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="148" height="123" size="2748">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx15_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1681" height="1592" size="320461">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx24" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="185" height="220" size="5586">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx24_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx17" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="148" height="123" size="2744">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx17_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx16" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="233" height="155" size="5076">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx16_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx21" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="141" height="106" size="3051">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx21_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx12" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="180" height="215" size="4766">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx12_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx10" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="236" height="173" size="5019">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx10_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="247" height="173" size="5190">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx11" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="155" height="123" size="3092">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx11_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx22" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="162" height="197" size="4551">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx22_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3158" height="3827" size="946207">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="155" height="123" size="3082">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-fx7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="mmc1" category="standard" type="APPLICATION" multimediatype="Microsoft Word file" mimetype="application/word" size="4583761">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-mmc1.docx?httpAccept=%2A%2F%2A</object><object ref="mmc2" category="standard" type="APPLICATION" multimediatype="ZIP file" mimetype="application/zip" size="7133783">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-mmc2.zip?httpAccept=%2A%2F%2A</object><object ref="si2" category="thumbnail" type="ALTIMG" multimediatype="Scalable Vector Graphics file" mimetype="image/svg+xml" size="20170">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-si2.svg?httpAccept=%2A%2F%2A</object><object ref="si3" category="thumbnail" type="ALTIMG" multimediatype="Scalable Vector Graphics file" mimetype="image/svg+xml" size="1239">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-si3.svg?httpAccept=%2A%2F%2A</object><object ref="si4" category="thumbnail" type="ALTIMG" multimediatype="Scalable Vector Graphics file" mimetype="image/svg+xml" size="1613">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-si4.svg?httpAccept=%2A%2F%2A</object><object ref="si1" category="thumbnail" type="ALTIMG" multimediatype="Scalable Vector Graphics file" mimetype="image/svg+xml" size="40090">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-si1.svg?httpAccept=%2A%2F%2A</object><object ref="am" category="standard" type="AAM-PDF" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="1417549">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420309065-am.pdf?httpAccept=%2A%2F%2A</object></objects><scopus-id>85093934692</scopus-id><scopus-eid>2-s2.0-85093934692</scopus-eid><pubmed-id>33109396</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85093934692" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20201021">2020-10-21</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20201021">2020-10-21</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20201213">2020-12-13</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20201213">2020-12-13</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2021-01-23T00:43:00</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S0223523420309065</xocs:eid>
      <xocs:pii-formatted>S0223-5234(20)30906-5</xocs:pii-formatted>
      <xocs:pii-unformatted>S0223523420309065</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2020.112934</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.2</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523420X00225</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20210123">2021-01-23T03:49:46.267728Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20210101</xocs:date-search-begin>
      <xocs:year-nav>2021</xocs:year-nav>
      <xocs:indexeddate epoch="1603262563">2020-10-21T06:42:43.228734Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articlenumber articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table e-component body mmlmath acknowledge affil appendices articletitle auth authfirstini authfull authkeywords authlast footnotes grantnumber grantsponsor grantsponsorid highlightsabst primabst pubtype ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>209</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>209</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 209</xocs:vol-iss-suppl-text>
      <xocs:sort-order>72</xocs:sort-order>
      <xocs:first-fp>112934</xocs:first-fp>
      <xocs:article-number>112934</xocs:article-number>
      <xocs:pages>
         <xocs:first-page>112934</xocs:first-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20210101</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>1 January 2021</xocs:cover-date-text>
      <xocs:cover-date-start>2021-01-01</xocs:cover-date-start>
      <xocs:cover-date-year>2021</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Full papers</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>fla</xocs:document-subtype>
      <xocs:copyright-line>© 2020 Elsevier Masson SAS. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>DESIGNSYNTHESISBIOLOGICALACTIVITYEVALUATION34PHENYL1HIMIDAZOL2YL1HPYRAZOLEDERIVATIVESPOTENTJAK23AURORAABKINASESMULTITARGETEDINHIBITORS</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>ZHENG</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>Y</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>Results and discussion</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Biological activities</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>
                     <ce:italic>In vitro</ce:italic> inhibition activities studies of kinases</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Antiproliferation assay</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Compound <ce:bold>10e</ce:bold> blocks JAKs and Aurora kinases phosphorylation in K562 and HCT116 cell</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Cell cycle arrest</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Binding mechanism of <ce:bold>10e</ce:bold> to the JAK2, JAK3, Aurora A and Aurora B</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Conclusions</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>4</xocs:item-toc-label>
            <xocs:item-toc-section-title>Experimental</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>4-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-3-carboxylic acid (2)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>1-(4-(bromomethyl)phenyl)ethan-1-one (4)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedure for the preparation of the compounds (<ce:bold>5</ce:bold>)</xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>1-(4-(morpholinomethyl)phenyl)ethan-1-one (<ce:bold>5a</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>1-(4-(piperidin-1-ylmethyl)phenyl)ethan-1-one (<ce:bold>5b</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.3</xocs:item-toc-label>
                     <xocs:item-toc-section-title>1-(4-(pyrrolidin-1-ylmethyl)phenyl)ethan-1-one (<ce:bold>5c</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedure for the preparation of the compounds (<ce:bold>6</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.5</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedure for the preparation of the compounds (<ce:bold>7</ce:bold>)</xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>2-Oxo-2-(4-(pyrrolidin-1-ylmethyl)phenyl)ethyl 4-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrrole-3-carboxylate (<ce:bold>7c</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.6</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedure for the preparation of the compounds (<ce:bold>8</ce:bold>)</xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.6.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>4-(4-(2-(4-nitro-1H-pyrazol-3-yl)-1H-imidazol-4-yl)benzyl)morpholine (<ce:bold>8a</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.7</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedure for the preparation of the compounds (<ce:bold>9</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.8</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedure for the preparation of the target compounds (<ce:bold>10a-10i</ce:bold>)</xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.8.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>N-(3-(4-(4-(morpholinomethyl)phenyl)-1H-imidazol-2-yl)-1H-pyrazol-4-yl)benzamide (<ce:bold>10a</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.8.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>4-methoxy-N-(3-(4-(4-(morpholinomethyl)phenyl)-1H-imidazol-2-yl)-1H-pyrazol-4-yl)benzamide (<ce:bold>10b</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.8.3</xocs:item-toc-label>
                     <xocs:item-toc-section-title>4-methoxy-N-(3-(4-(4-(morpholinomethyl)phenyl)-1H-imidazol-2-yl)-1H-pyrazol-4-yl)benzamide (<ce:bold>10c</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.8.4</xocs:item-toc-label>
                     <xocs:item-toc-section-title>4-chloro-N-(3-(4-(4-(morpholinomethyl)phenyl)-1H-imidazol-2-yl)-1H-pyrazol-4-yl)benzamide (<ce:bold>10d</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.8.5</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-chloro-N-(3-(4-(4-(morpholinomethyl)phenyl)-1H-imidazol-2-yl)-1H-pyrazol-4-yl)benzamide (<ce:bold>10e</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.8.6</xocs:item-toc-label>
                     <xocs:item-toc-section-title>4-nitro-N-(3-(4-(4-(pyrrolidin-1-ylmethyl)phenyl)-1H-imidazol-2-yl)-1H-pyrazol-4-yl)benzamide (<ce:bold>10f</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.8.7</xocs:item-toc-label>
                     <xocs:item-toc-section-title>4-methoxy-N-(3-(4-(4-(piperidin-1-ylmethyl)phenyl)-1H-imidazol-2-yl)-1H-pyrazol-4-yl)benzamide (<ce:bold>10g</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.8.8</xocs:item-toc-label>
                     <xocs:item-toc-section-title>4-chloro-N-(3-(4-(4-(piperidin-1-ylmethyl)phenyl)-1H-imidazol-2-yl)-1H-pyrazol-4-yl)benzamide (<ce:bold>10h</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.8.9</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-chloro-N-(3-(4-(4-(piperidin-1-ylmethyl)phenyl)-1H-imidazol-2-yl)-1H-pyrazol-4-yl)benzamide (<ce:bold>10i</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.9</xocs:item-toc-label>
                  <xocs:item-toc-section-title>6-chloro-2-methyl-N-(3-(4-(4-(morpholinomethyl)phenyl)-1H-imidazol-2-yl)-1H-pyrazol-4-yl)pyrimidin-4-amine (<ce:bold>10j</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.10</xocs:item-toc-label>
                  <xocs:item-toc-section-title>1-(4-(3-chloropropoxy)phenyl)ethan-1-one (<ce:bold>12</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.11</xocs:item-toc-label>
                  <xocs:item-toc-section-title>1-(4-(3-morpholinopropoxy)phenyl)ethan-1-one (<ce:bold>13</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.12</xocs:item-toc-label>
                  <xocs:item-toc-section-title>2-bromo-1-(4-(3-morpholinopropoxy)phenyl)ethan-1-one (<ce:bold>14</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.13</xocs:item-toc-label>
                  <xocs:item-toc-section-title>2-(4-(3-morpholinopropoxy)phenyl)-2-oxoethyl 4-nitro-1H-pyrazole-3-carboxylate (<ce:bold>15</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.14</xocs:item-toc-label>
                  <xocs:item-toc-section-title>2-(4-(3-morpholinopropoxy)phenyl)-2-oxoethyl 4-nitro-1H-pyrazole-3-carboxylate (<ce:bold>16</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.15</xocs:item-toc-label>
                  <xocs:item-toc-section-title>2-(4-(3-morpholinopropoxy)phenyl)-2-oxoethyl 4-nitro-1H-pyrazole-3-carboxylate (<ce:bold>17</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.16</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedure for the preparation of the target compounds (<ce:bold>18a</ce:bold>)</xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.16.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>6-chloro-5-methyl-2-(methylthio)-N-(3-(5-(4-(3-morpholinopropoxy) phenyl)-1H-imidazol-2-yl)-1H-pyrazol-4-yl) pyrimidin-4-amine (<ce:bold>18a</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Biological evaluation</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>
                     <ce:italic>In vitro</ce:italic> kinases assays</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>
                     <ce:italic>In vitro</ce:italic> anti-proliferative assays</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Western blot</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Cell cycle assays</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Binding mechanism explored by molecular modeling</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgment</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:appendices">
            <xocs:item-toc-label>Appendix A</xocs:item-toc-label>
            <xocs:item-toc-section-title>Supplementary data</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>SHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1054</xocs:ref-first-fp>
            <xocs:ref-last-lp>1066</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1507</xocs:ref-first-fp>
            <xocs:ref-last-lp>1513</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>ELSAYED</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>10440</xocs:ref-first-fp>
            <xocs:ref-last-lp>10462</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>COPPO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>171</xocs:ref-first-fp>
            <xocs:ref-last-lp>179</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>JUNG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>APOPTOSISINDUCEDBYTANSHINONEIIACRYPTOTANSHINONEMEDIATEDBYDISTINCTJAKSTAT35SHP12SIGNALINGINCHRONICMYELOIDLEUKEMIAK562CELLSEVIDENCEBASEDCOMPLEMENTARYALTERNATIVEMEDICINE</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>NAIR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>756</xocs:ref-first-fp>
            <xocs:ref-last-lp>763</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>SAGLAM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>526</xocs:ref-first-fp>
            <xocs:ref-last-lp>543</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>TAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>5323</xocs:ref-first-fp>
            <xocs:ref-last-lp>5334</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>1991</xocs:ref-first-fp>
            <xocs:ref-last-lp>1998</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>LIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>6906</xocs:ref-first-fp>
            <xocs:ref-last-lp>6913</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>TOH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>104</xocs:ref-first-fp>
            <xocs:ref-last-lp>118</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>15941</xocs:ref-first-fp>
            <xocs:ref-last-lp>15951</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>WEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1015</xocs:ref-first-fp>
            <xocs:ref-last-lp>1025</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>ZHU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>HARRISON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>787</xocs:ref-first-fp>
            <xocs:ref-last-lp>798</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>VANNUCCHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>426</xocs:ref-first-fp>
            <xocs:ref-last-lp>435</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>VERSTOVSEK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>799</xocs:ref-first-fp>
            <xocs:ref-last-lp>807</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>XING</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>1043</xocs:ref-first-fp>
            <xocs:ref-last-lp>1049</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>QUINTASCARDAMA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>127</xocs:ref-first-fp>
            <xocs:ref-last-lp>140</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>IOANNIDIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>262</xocs:ref-first-fp>
            <xocs:ref-last-lp>276</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>PARDANANI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>643</xocs:ref-first-fp>
            <xocs:ref-last-lp>651</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>ARKENAU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>1307</xocs:ref-first-fp>
            <xocs:ref-last-lp>1313</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>CARMENA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>842</xocs:ref-first-fp>
            <xocs:ref-last-lp>854</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>KEEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>927</xocs:ref-first-fp>
            <xocs:ref-last-lp>936</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>BISCHOFF</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>3052</xocs:ref-first-fp>
            <xocs:ref-last-lp>3065</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>FU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>10</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>HUANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>2854</xocs:ref-first-fp>
            <xocs:ref-last-lp>2865</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref28">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>4367</xocs:ref-first-fp>
            <xocs:ref-last-lp>4378</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref29">
            <xocs:ref-normalized-surname>DENNIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>461</xocs:ref-first-fp>
            <xocs:ref-last-lp>469</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref30">
            <xocs:ref-normalized-surname>GEUNSMEYER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>5189</xocs:ref-first-fp>
            <xocs:ref-last-lp>5207</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref31">
            <xocs:ref-normalized-surname>CARPINELLI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>3158</xocs:ref-first-fp>
            <xocs:ref-last-lp>3168</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref32">
            <xocs:ref-normalized-surname>MANFREDI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>4106</xocs:ref-first-fp>
            <xocs:ref-last-lp>4111</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref33">
            <xocs:ref-normalized-surname>DEES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>4775</xocs:ref-first-fp>
            <xocs:ref-last-lp>4784</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref34">
            <xocs:ref-normalized-surname>DAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>268</xocs:ref-first-fp>
            <xocs:ref-last-lp>278</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref35">
            <xocs:ref-normalized-surname>ZHU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>988</xocs:ref-first-fp>
            <xocs:ref-last-lp>994</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref36">
            <xocs:ref-normalized-surname>TIAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1533</xocs:ref-first-fp>
            <xocs:ref-last-lp>1540</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref37">
            <xocs:ref-normalized-surname>DURLACHER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>585</xocs:ref-first-fp>
            <xocs:ref-last-lp>601</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref38">
            <xocs:ref-normalized-surname>ZHENG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>3084</xocs:ref-first-fp>
            <xocs:ref-last-lp>3098</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref39">
            <xocs:ref-normalized-surname>YANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>2947</xocs:ref-first-fp>
            <xocs:ref-last-lp>2961</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref40">
            <xocs:ref-normalized-surname>HOWARD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>379</xocs:ref-first-fp>
            <xocs:ref-last-lp>388</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref41">
            <xocs:ref-normalized-surname>SAMANTA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>6468</xocs:ref-first-fp>
            <xocs:ref-last-lp>6472</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref42">
            <xocs:ref-normalized-surname>XUE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>447</xocs:ref-first-fp>
            <xocs:ref-last-lp>461</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref43">
            <xocs:ref-normalized-surname>GOERGUEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>5202</xocs:ref-first-fp>
            <xocs:ref-last-lp>5213</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref44">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>3217</xocs:ref-first-fp>
            <xocs:ref-last-lp>3226</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref45">
            <xocs:ref-normalized-surname>KE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>533</xocs:ref-first-fp>
            <xocs:ref-last-lp>545</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref46">
            <xocs:ref-normalized-surname>LIANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>3898</xocs:ref-first-fp>
            <xocs:ref-last-lp>3923</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref47">
            <xocs:ref-normalized-surname>SHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1054</xocs:ref-first-fp>
            <xocs:ref-last-lp>1066</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref48">
            <xocs:ref-normalized-surname>BROMBERG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>2468</xocs:ref-first-fp>
            <xocs:ref-last-lp>2473</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref49">
            <xocs:ref-normalized-surname>KOLLAREDDY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>27</xocs:ref-first-fp>
            <xocs:ref-last-lp>33</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref50">
            <xocs:ref-normalized-surname>MILLS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>6489</xocs:ref-first-fp>
            <xocs:ref-last-lp>6498</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref51">
            <xocs:ref-normalized-surname>PETERSEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>68</xocs:ref-first-fp>
            <xocs:ref-last-lp>76</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref52">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>934</xocs:ref-first-fp>
            <xocs:ref-last-lp>948</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref53">
            <xocs:ref-normalized-surname>KASHEM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>70</xocs:ref-first-fp>
            <xocs:ref-last-lp>83</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref54">
            <xocs:ref-normalized-surname>TROTT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>455</xocs:ref-first-fp>
            <xocs:ref-last-lp>461</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>O</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref55">
            <xocs:ref-normalized-surname>HOWARD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>379</xocs:ref-first-fp>
            <xocs:ref-last-lp>388</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref56">
            <xocs:ref-normalized-surname>JAIMEFIGUEROA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>2522</xocs:ref-first-fp>
            <xocs:ref-last-lp>2526</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref57">
            <xocs:ref-normalized-surname>ELKINS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>7841</xocs:ref-first-fp>
            <xocs:ref-last-lp>7848</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref58">
            <xocs:ref-normalized-surname>MORRIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>2785</xocs:ref-first-fp>
            <xocs:ref-last-lp>2791</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref59">
            <xocs:ref-normalized-surname>OBOYLE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>33</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref60">
            <xocs:ref-normalized-surname>MARLOW</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>352</xocs:ref-first-fp>
            <xocs:ref-last-lp>358</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref61">
            <xocs:ref-normalized-surname>MAIER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>3696</xocs:ref-first-fp>
            <xocs:ref-last-lp>3713</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref62">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>1157</xocs:ref-first-fp>
            <xocs:ref-last-lp>1174</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref63">
            <xocs:ref-normalized-surname>JORGENSEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1983</xocs:ref-pub-year>
            <xocs:ref-first-fp>926</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref64">
            <xocs:ref-normalized-surname>RYCKAERT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1977</xocs:ref-pub-year>
            <xocs:ref-first-fp>327</xocs:ref-first-fp>
            <xocs:ref-last-lp>341</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref65">
            <xocs:ref-normalized-surname>DARDEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1993</xocs:ref-pub-year>
            <xocs:ref-first-fp>10089</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref66">
            <xocs:ref-normalized-surname>ONUFRIEV</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>383</xocs:ref-first-fp>
            <xocs:ref-last-lp>394</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref67">
            <xocs:ref-normalized-surname>SANNER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1996</xocs:ref-pub-year>
            <xocs:ref-first-fp>305</xocs:ref-first-fp>
            <xocs:ref-last-lp>320</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>ZHENGX2021X112934</xocs:refkey3>
         <xocs:refkey4ai>ZHENGX2021X112934XY</xocs:refkey4ai>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:open-research>
         <xocs:or-embargo-opening-date>2022-12-13T00:00:00.000Z</xocs:or-embargo-opening-date>
      </xocs:open-research>
      <xocs:self-archiving>
         <xocs:sa-start-date>2022-12-13T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2020 Elsevier Masson SAS. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:funding-list has-funding-info="1">
         <xocs:funding-addon-generated-timestamp>2020-10-14T01:52:04.898Z</xocs:funding-addon-generated-timestamp>
         <xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/eoas</xocs:funding-addon-type>
         <xocs:funding>
            <xocs:funding-agency-acronym>NSFC</xocs:funding-agency-acronym>
            <xocs:funding-agency>National Natural Science Foundation of China</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100001809</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/1814991</xocs:funding-agency-country>
         </xocs:funding>
      </xocs:funding-list>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(20)30906-5</xocs:pii-formatted>
         <xocs:pii-unformatted>S0223523420309065</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S0223523420309065</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2020.112934</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2021-01-23T03:49:46.267728Z</xocs:timestamp>
         <xocs:cover-date-start>2021-01-01</xocs:cover-date-start>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/MAIN/application/pdf/030a6b4d249f94858aa9f39dbace7459/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>3417636</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>13</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S0223523420309065-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/PREVIEW/image/png/7ff60589b8c332d6a28bf8d7bae328c2/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>59778</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx19.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx19/DOWNSAMPLED/image/jpeg/cc69eac566ac9df5f609d0da81c0d57d/fx19.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx19</xocs:file-basename>
               <xocs:filename>fx19.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>648</xocs:filesize>
               <xocs:pixel-height>27</xocs:pixel-height>
               <xocs:pixel-width>33</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-sc1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/sc1/DOWNSAMPLED/image/jpeg/df7ada1e28effa49cfee8b6eae88a036/sc1.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>34799</xocs:filesize>
               <xocs:pixel-height>341</xocs:pixel-height>
               <xocs:pixel-width>713</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/gr6/DOWNSAMPLED/image/jpeg/d760aab14c2f42270161ee6f0e727741/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>158293</xocs:filesize>
               <xocs:pixel-height>877</xocs:pixel-height>
               <xocs:pixel-width>535</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx5/DOWNSAMPLED/image/jpeg/867924b9c2f8175518b9a652c1b73d08/fx5.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>634</xocs:filesize>
               <xocs:pixel-height>28</xocs:pixel-height>
               <xocs:pixel-width>35</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx23.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx23/DOWNSAMPLED/image/jpeg/2460d4c9ef78cee195494a99c1ccd2f0/fx23.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx23</xocs:file-basename>
               <xocs:filename>fx23.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2609</xocs:filesize>
               <xocs:pixel-height>85</xocs:pixel-height>
               <xocs:pixel-width>128</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx2/DOWNSAMPLED/image/jpeg/8e487884686da54d0639e1bb04a0d347/fx2.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1863</xocs:filesize>
               <xocs:pixel-height>77</xocs:pixel-height>
               <xocs:pixel-width>77</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx9.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx9/DOWNSAMPLED/image/jpeg/cbc30d9a8a2718fd297fe8dee8cb34d6/fx9.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>630</xocs:filesize>
               <xocs:pixel-height>28</xocs:pixel-height>
               <xocs:pixel-width>35</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/gr2/DOWNSAMPLED/image/jpeg/f096990fc199568f624c0402705abc76/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>44934</xocs:filesize>
               <xocs:pixel-height>414</xocs:pixel-height>
               <xocs:pixel-width>712</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx3/DOWNSAMPLED/image/jpeg/a30c1cd5fa0bc85f0dee1d199dcafed7/fx3.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>633</xocs:filesize>
               <xocs:pixel-height>28</xocs:pixel-height>
               <xocs:pixel-width>35</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/gr1/DOWNSAMPLED/image/jpeg/d112af14aa1ecd977eadc7ba16d6e75c/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>22067</xocs:filesize>
               <xocs:pixel-height>173</xocs:pixel-height>
               <xocs:pixel-width>713</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx20.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx20/DOWNSAMPLED/image/jpeg/9fe74766d39e74d63be9eea34b253ea9/fx20.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx20</xocs:file-basename>
               <xocs:filename>fx20.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>924</xocs:filesize>
               <xocs:pixel-height>48</xocs:pixel-height>
               <xocs:pixel-width>40</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-sc2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/sc2/DOWNSAMPLED/image/jpeg/bca91c09225c54db03ace256257d7abd/sc2.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>29942</xocs:filesize>
               <xocs:pixel-height>412</xocs:pixel-height>
               <xocs:pixel-width>713</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx8/DOWNSAMPLED/image/jpeg/b336493f3c16c74c3b7d23fd9f2276ae/fx8.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>962</xocs:filesize>
               <xocs:pixel-height>35</xocs:pixel-height>
               <xocs:pixel-width>55</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx14.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx14/DOWNSAMPLED/image/jpeg/1a6aa50ddf6ce51310127f1b05d7159d/fx14.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx14</xocs:file-basename>
               <xocs:filename>fx14.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>977</xocs:filesize>
               <xocs:pixel-height>39</xocs:pixel-height>
               <xocs:pixel-width>58</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx1/DOWNSAMPLED/image/jpeg/cc6a2da0f1a0f51c46e7ee6ac5321dd7/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>20439</xocs:filesize>
               <xocs:pixel-height>158</xocs:pixel-height>
               <xocs:pixel-width>500</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/gr3/DOWNSAMPLED/image/jpeg/81d4ace40d0ac73f82f52ea626df7812/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>21318</xocs:filesize>
               <xocs:pixel-height>260</xocs:pixel-height>
               <xocs:pixel-width>380</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx18.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx18/DOWNSAMPLED/image/jpeg/f1196fb4bbc0900b386d79030a3f9185/fx18.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx18</xocs:file-basename>
               <xocs:filename>fx18.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>959</xocs:filesize>
               <xocs:pixel-height>35</xocs:pixel-height>
               <xocs:pixel-width>50</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx4/DOWNSAMPLED/image/jpeg/ddb2d286ce418b727aafd77c90f90b1e/fx4.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>840</xocs:filesize>
               <xocs:pixel-height>36</xocs:pixel-height>
               <xocs:pixel-width>40</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx13.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx13/DOWNSAMPLED/image/jpeg/76f664a9654ebbaace3a61ab1af42bd4/fx13.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>590</xocs:filesize>
               <xocs:pixel-height>27</xocs:pixel-height>
               <xocs:pixel-width>29</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx15.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx15/DOWNSAMPLED/image/jpeg/8cdb4e8a392fc6b87e2ed4f6704229c7/fx15.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx15</xocs:file-basename>
               <xocs:filename>fx15.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>643</xocs:filesize>
               <xocs:pixel-height>27</xocs:pixel-height>
               <xocs:pixel-width>33</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/gr4/DOWNSAMPLED/image/jpeg/e144347d82131ddba95f2bd549588013/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>35244</xocs:filesize>
               <xocs:pixel-height>359</xocs:pixel-height>
               <xocs:pixel-width>379</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx24.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx24/DOWNSAMPLED/image/jpeg/d17043199e522cb7e6188ced7f6ef262/fx24.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx24</xocs:file-basename>
               <xocs:filename>fx24.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1069</xocs:filesize>
               <xocs:pixel-height>49</xocs:pixel-height>
               <xocs:pixel-width>41</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx17.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx17/DOWNSAMPLED/image/jpeg/af457e1116f548dcd55c967f0d92f193/fx17.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx17</xocs:file-basename>
               <xocs:filename>fx17.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>645</xocs:filesize>
               <xocs:pixel-height>27</xocs:pixel-height>
               <xocs:pixel-width>33</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx16.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx16/DOWNSAMPLED/image/jpeg/3c4100e36dd372bb73c281ab2b951469/fx16.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx16</xocs:file-basename>
               <xocs:filename>fx16.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>990</xocs:filesize>
               <xocs:pixel-height>35</xocs:pixel-height>
               <xocs:pixel-width>52</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx21.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx21/DOWNSAMPLED/image/jpeg/d9149dc5ac6edf83e1798ef771aa69e5/fx21.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx21</xocs:file-basename>
               <xocs:filename>fx21.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>630</xocs:filesize>
               <xocs:pixel-height>23</xocs:pixel-height>
               <xocs:pixel-width>31</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx12.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx12/DOWNSAMPLED/image/jpeg/13d6071adeb8e8ba9c068fc80b86a0c1/fx12.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>911</xocs:filesize>
               <xocs:pixel-height>48</xocs:pixel-height>
               <xocs:pixel-width>40</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx10.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx10/DOWNSAMPLED/image/jpeg/d4e5215db61db8d31f9f8ce06614bfce/fx10.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>959</xocs:filesize>
               <xocs:pixel-height>39</xocs:pixel-height>
               <xocs:pixel-width>53</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx6/DOWNSAMPLED/image/jpeg/5f653981cfa5c755740717390840d2f6/fx6.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1007</xocs:filesize>
               <xocs:pixel-height>39</xocs:pixel-height>
               <xocs:pixel-width>55</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx11.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx11/DOWNSAMPLED/image/jpeg/8fbfd17d0865c1fea5c8028fe1438bda/fx11.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>633</xocs:filesize>
               <xocs:pixel-height>28</xocs:pixel-height>
               <xocs:pixel-width>35</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx22.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx22/DOWNSAMPLED/image/jpeg/6c3ffa44108cb857f83f8d334d77b84c/fx22.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx22</xocs:file-basename>
               <xocs:filename>fx22.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>767</xocs:filesize>
               <xocs:pixel-height>44</xocs:pixel-height>
               <xocs:pixel-width>36</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/gr5/DOWNSAMPLED/image/jpeg/b6392485aa31a5c744e11c11de6ed567/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>121945</xocs:filesize>
               <xocs:pixel-height>864</xocs:pixel-height>
               <xocs:pixel-width>713</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx7/DOWNSAMPLED/image/jpeg/c010f495666f4602255146a6da5ebc01/fx7.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>633</xocs:filesize>
               <xocs:pixel-height>28</xocs:pixel-height>
               <xocs:pixel-width>35</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx19.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx19/THUMBNAIL/image/gif/6918fc59cae6a06da430785bbdf97edf/fx19.sml</xocs:ucs-locator>
               <xocs:file-basename>fx19</xocs:file-basename>
               <xocs:filename>fx19.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1561</xocs:filesize>
               <xocs:pixel-height>122</xocs:pixel-height>
               <xocs:pixel-width>147</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-sc1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/sc1/THUMBNAIL/image/gif/cafb16b39331080b61b58ca67871198e/sc1.sml</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4154</xocs:filesize>
               <xocs:pixel-height>105</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/gr6/THUMBNAIL/image/gif/d7a4bbbc00ce651527f0dfe3ca19b950/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9333</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>100</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx5/THUMBNAIL/image/gif/5a1be505c80c9bb1a667270beb8fc09b/fx5.sml</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1771</xocs:filesize>
               <xocs:pixel-height>123</xocs:pixel-height>
               <xocs:pixel-width>155</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx23.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx23/THUMBNAIL/image/gif/4d3d14aa2def2eccf4e090a66c245349/fx23.sml</xocs:ucs-locator>
               <xocs:file-basename>fx23</xocs:file-basename>
               <xocs:filename>fx23.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3867</xocs:filesize>
               <xocs:pixel-height>146</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx2/THUMBNAIL/image/gif/65d5b9a4ce0e1fdd957cd25aead76ea6/fx2.sml</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3935</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>164</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx9.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx9/THUMBNAIL/image/gif/111d95b3b4c90f1a643566d6ea69e507/fx9.sml</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1830</xocs:filesize>
               <xocs:pixel-height>123</xocs:pixel-height>
               <xocs:pixel-width>155</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/gr2/THUMBNAIL/image/gif/caaa39b30b5a48ed6f4398f5adf5c724/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4780</xocs:filesize>
               <xocs:pixel-height>127</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx3/THUMBNAIL/image/gif/90305af11fa35ce090381100a33ca80a/fx3.sml</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1751</xocs:filesize>
               <xocs:pixel-height>123</xocs:pixel-height>
               <xocs:pixel-width>155</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/gr1/THUMBNAIL/image/gif/82e89cedb52b61370b571caaf89aa1bc/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2969</xocs:filesize>
               <xocs:pixel-height>53</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx20.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx20/THUMBNAIL/image/gif/da6db59aadf936d8a8bb66bba17b15f1/fx20.sml</xocs:ucs-locator>
               <xocs:file-basename>fx20</xocs:file-basename>
               <xocs:filename>fx20.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2729</xocs:filesize>
               <xocs:pixel-height>215</xocs:pixel-height>
               <xocs:pixel-width>180</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-sc2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/sc2/THUMBNAIL/image/gif/72f4a5309a1720a5f69eee8a279ddbca/sc2.sml</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3347</xocs:filesize>
               <xocs:pixel-height>126</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx8/THUMBNAIL/image/gif/26345b96e58c6a7fb31f36f6fa2e1342/fx8.sml</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3970</xocs:filesize>
               <xocs:pixel-height>139</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx14.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx14/THUMBNAIL/image/gif/e076f0340bbbff1057d68aeb5daa949c/fx14.sml</xocs:ucs-locator>
               <xocs:file-basename>fx14</xocs:file-basename>
               <xocs:filename>fx14.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4015</xocs:filesize>
               <xocs:pixel-height>147</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx1/THUMBNAIL/image/gif/e393e590307737657bd15a606ee58e13/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4983</xocs:filesize>
               <xocs:pixel-height>69</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/gr3/THUMBNAIL/image/gif/e6f6a33bb25f4c740aca17422d17982f/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5326</xocs:filesize>
               <xocs:pixel-height>150</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx18.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx18/THUMBNAIL/image/gif/6044832c5c4275bfef45c3467f5e3d28/fx18.sml</xocs:ucs-locator>
               <xocs:file-basename>fx18</xocs:file-basename>
               <xocs:filename>fx18.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4197</xocs:filesize>
               <xocs:pixel-height>153</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx4/THUMBNAIL/image/gif/925e2b78768ee375e8f00623364a6cae/fx4.sml</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2353</xocs:filesize>
               <xocs:pixel-height>162</xocs:pixel-height>
               <xocs:pixel-width>180</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx13.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx13/THUMBNAIL/image/gif/5b68d82a70301a5c992fad4658dc20ba/fx13.sml</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1502</xocs:filesize>
               <xocs:pixel-height>123</xocs:pixel-height>
               <xocs:pixel-width>131</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx15.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx15/THUMBNAIL/image/gif/a8ae11bd2e18ccf536fe37f301a1e94a/fx15.sml</xocs:ucs-locator>
               <xocs:file-basename>fx15</xocs:file-basename>
               <xocs:filename>fx15.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1645</xocs:filesize>
               <xocs:pixel-height>123</xocs:pixel-height>
               <xocs:pixel-width>148</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/gr4/THUMBNAIL/image/gif/a8ded93c5e4196e1d12140735cf90e02/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>12709</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>173</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx24.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx24/THUMBNAIL/image/gif/4eddbd7d2389cca00cda6168c87a6128/fx24.sml</xocs:ucs-locator>
               <xocs:file-basename>fx24</xocs:file-basename>
               <xocs:filename>fx24.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2955</xocs:filesize>
               <xocs:pixel-height>220</xocs:pixel-height>
               <xocs:pixel-width>185</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx17.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx17/THUMBNAIL/image/gif/181aabee517597b10f04a21b0c60bb21/fx17.sml</xocs:ucs-locator>
               <xocs:file-basename>fx17</xocs:file-basename>
               <xocs:filename>fx17.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1372</xocs:filesize>
               <xocs:pixel-height>123</xocs:pixel-height>
               <xocs:pixel-width>148</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx16.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx16/THUMBNAIL/image/gif/f4fcb0123c3a170abb241929cf2d62d4/fx16.sml</xocs:ucs-locator>
               <xocs:file-basename>fx16</xocs:file-basename>
               <xocs:filename>fx16.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4176</xocs:filesize>
               <xocs:pixel-height>146</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx21.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx21/THUMBNAIL/image/gif/9397bd5f36760e33bea685fab5ab9d6c/fx21.sml</xocs:ucs-locator>
               <xocs:file-basename>fx21</xocs:file-basename>
               <xocs:filename>fx21.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1748</xocs:filesize>
               <xocs:pixel-height>106</xocs:pixel-height>
               <xocs:pixel-width>141</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx12.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx12/THUMBNAIL/image/gif/21c105663c911c97440fabec5f620cb5/fx12.sml</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2740</xocs:filesize>
               <xocs:pixel-height>215</xocs:pixel-height>
               <xocs:pixel-width>180</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx10.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx10/THUMBNAIL/image/gif/93a0233c8f3c8faa2598e14dae072fc4/fx10.sml</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4045</xocs:filesize>
               <xocs:pixel-height>161</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx6/THUMBNAIL/image/gif/ab1e11b4f4f5ab0a5b42262b4227657f/fx6.sml</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3985</xocs:filesize>
               <xocs:pixel-height>153</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx11.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx11/THUMBNAIL/image/gif/5c596eb5561baad26fb6e3db63caef69/fx11.sml</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1768</xocs:filesize>
               <xocs:pixel-height>123</xocs:pixel-height>
               <xocs:pixel-width>155</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx22.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx22/THUMBNAIL/image/gif/72dc5ca09e2fe1deb8f7656913448e35/fx22.sml</xocs:ucs-locator>
               <xocs:file-basename>fx22</xocs:file-basename>
               <xocs:filename>fx22.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2603</xocs:filesize>
               <xocs:pixel-height>197</xocs:pixel-height>
               <xocs:pixel-width>162</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/gr5/THUMBNAIL/image/gif/642a575b407ad835e1f0dd272e540d3c/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>6878</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>135</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx7/THUMBNAIL/image/gif/ce6f03b5e966ad04939cfa4f43f193c8/fx7.sml</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1792</xocs:filesize>
               <xocs:pixel-height>123</xocs:pixel-height>
               <xocs:pixel-width>155</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx19_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx19/HIGHRES/image/jpeg/696413b07fdd7a49924230b7e0e73838/fx19_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx19</xocs:file-basename>
               <xocs:filename>fx19_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2800</xocs:filesize>
               <xocs:pixel-height>122</xocs:pixel-height>
               <xocs:pixel-width>147</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-sc1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/sc1/HIGHRES/image/jpeg/91c77a8e116681bedbcda9343cca007c/sc1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>279202</xocs:filesize>
               <xocs:pixel-height>1512</xocs:pixel-height>
               <xocs:pixel-width>3158</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-gr6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/gr6/HIGHRES/image/jpeg/969f1787a68f0ec22c72f353128fa53c/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1320339</xocs:filesize>
               <xocs:pixel-height>3886</xocs:pixel-height>
               <xocs:pixel-width>2370</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx5/HIGHRES/image/jpeg/acef2083821c26f022bb541e316818ca/fx5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3088</xocs:filesize>
               <xocs:pixel-height>123</xocs:pixel-height>
               <xocs:pixel-width>155</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx23_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx23/HIGHRES/image/jpeg/a232bd9c2e9221173522832d13a19384/fx23_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx23</xocs:file-basename>
               <xocs:filename>fx23_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>18872</xocs:filesize>
               <xocs:pixel-height>378</xocs:pixel-height>
               <xocs:pixel-width>568</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx2/HIGHRES/image/jpeg/6aa5f52c8f51443f0938dc7fa88c74bb/fx2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>12840</xocs:filesize>
               <xocs:pixel-height>340</xocs:pixel-height>
               <xocs:pixel-width>341</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx9_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx9/HIGHRES/image/jpeg/2428a3a64d27cebb99ed7e6ffc133487/fx9_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3074</xocs:filesize>
               <xocs:pixel-height>123</xocs:pixel-height>
               <xocs:pixel-width>155</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/gr2/HIGHRES/image/jpeg/ad0dfb452654aa19ea302bae20bf5b24/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>357916</xocs:filesize>
               <xocs:pixel-height>1830</xocs:pixel-height>
               <xocs:pixel-width>3151</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx3/HIGHRES/image/jpeg/c1b6e31765a8c71c6d25391c138c5577/fx3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3091</xocs:filesize>
               <xocs:pixel-height>123</xocs:pixel-height>
               <xocs:pixel-width>155</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/gr1/HIGHRES/image/jpeg/a663054f82c0db8ff4eff256b1968bc3/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>170923</xocs:filesize>
               <xocs:pixel-height>768</xocs:pixel-height>
               <xocs:pixel-width>3158</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx20_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx20/HIGHRES/image/jpeg/7e9ea6cbe89845f662a81596f57f0245/fx20_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx20</xocs:file-basename>
               <xocs:filename>fx20_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4821</xocs:filesize>
               <xocs:pixel-height>215</xocs:pixel-height>
               <xocs:pixel-width>180</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-sc2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/sc2/HIGHRES/image/jpeg/23a08e4dcc0a93f3111c8e1680c636ee/sc2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>252600</xocs:filesize>
               <xocs:pixel-height>1824</xocs:pixel-height>
               <xocs:pixel-width>3158</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx8/HIGHRES/image/jpeg/d03641d12938f0e9657edea92be963e6/fx8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5313</xocs:filesize>
               <xocs:pixel-height>155</xocs:pixel-height>
               <xocs:pixel-width>244</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx14_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx14/HIGHRES/image/jpeg/227139dbbeb51b2ea124ac85d48d5390/fx14_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx14</xocs:file-basename>
               <xocs:filename>fx14_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5402</xocs:filesize>
               <xocs:pixel-height>173</xocs:pixel-height>
               <xocs:pixel-width>258</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx1/HIGHRES/image/jpeg/0f89f81802519a47b2665ba0bb9f93ca/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>147492</xocs:filesize>
               <xocs:pixel-height>698</xocs:pixel-height>
               <xocs:pixel-width>2213</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/gr3/HIGHRES/image/jpeg/83daa17e9bbac7af6a17fb4df383fb3e/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>160955</xocs:filesize>
               <xocs:pixel-height>1152</xocs:pixel-height>
               <xocs:pixel-width>1682</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx18_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx18/HIGHRES/image/jpeg/341fac3f16630bae5d5192b2ff9c5acf/fx18_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx18</xocs:file-basename>
               <xocs:filename>fx18_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4860</xocs:filesize>
               <xocs:pixel-height>155</xocs:pixel-height>
               <xocs:pixel-width>222</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx4/HIGHRES/image/jpeg/19af4fc61f2b463f93bc0e973ed947c8/fx4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3940</xocs:filesize>
               <xocs:pixel-height>162</xocs:pixel-height>
               <xocs:pixel-width>180</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx13_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx13/HIGHRES/image/jpeg/64ae0a6290c6f10ac63f7f04c9ce73ca/fx13_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2493</xocs:filesize>
               <xocs:pixel-height>123</xocs:pixel-height>
               <xocs:pixel-width>131</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx15_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx15/HIGHRES/image/jpeg/922607bfde48156346e11ecf2b12d179/fx15_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx15</xocs:file-basename>
               <xocs:filename>fx15_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2748</xocs:filesize>
               <xocs:pixel-height>123</xocs:pixel-height>
               <xocs:pixel-width>148</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/gr4/HIGHRES/image/jpeg/44a2c851c5f4955b2bf20ea7b262e03b/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>320461</xocs:filesize>
               <xocs:pixel-height>1592</xocs:pixel-height>
               <xocs:pixel-width>1681</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx24_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx24/HIGHRES/image/jpeg/037a614acb44e1e2432188277483a98a/fx24_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx24</xocs:file-basename>
               <xocs:filename>fx24_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5586</xocs:filesize>
               <xocs:pixel-height>220</xocs:pixel-height>
               <xocs:pixel-width>185</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx17_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx17/HIGHRES/image/jpeg/6cf595d2bfe0b5ebfe1d6db55b935bfd/fx17_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx17</xocs:file-basename>
               <xocs:filename>fx17_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2744</xocs:filesize>
               <xocs:pixel-height>123</xocs:pixel-height>
               <xocs:pixel-width>148</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx16_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx16/HIGHRES/image/jpeg/b8fd59178e3e34a69dc5493891f7d30c/fx16_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx16</xocs:file-basename>
               <xocs:filename>fx16_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5076</xocs:filesize>
               <xocs:pixel-height>155</xocs:pixel-height>
               <xocs:pixel-width>233</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx21_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx21/HIGHRES/image/jpeg/557ead737e09402f88ca076e1dbb09da/fx21_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx21</xocs:file-basename>
               <xocs:filename>fx21_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3051</xocs:filesize>
               <xocs:pixel-height>106</xocs:pixel-height>
               <xocs:pixel-width>141</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx12_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx12/HIGHRES/image/jpeg/b23dca5c9f385826ce831edcb9613cf3/fx12_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4766</xocs:filesize>
               <xocs:pixel-height>215</xocs:pixel-height>
               <xocs:pixel-width>180</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx10_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx10/HIGHRES/image/jpeg/b2f428d087c562ad61c1e28b03619a37/fx10_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5019</xocs:filesize>
               <xocs:pixel-height>173</xocs:pixel-height>
               <xocs:pixel-width>236</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx6/HIGHRES/image/jpeg/ccd88af4af3b531a4901decd6e7e60ff/fx6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5190</xocs:filesize>
               <xocs:pixel-height>173</xocs:pixel-height>
               <xocs:pixel-width>247</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx11_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx11/HIGHRES/image/jpeg/c749a1b7931c82b417ef8f032b91efe6/fx11_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3092</xocs:filesize>
               <xocs:pixel-height>123</xocs:pixel-height>
               <xocs:pixel-width>155</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx22_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx22/HIGHRES/image/jpeg/cbc02766d978d7dd8369587ddca8c9d5/fx22_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx22</xocs:file-basename>
               <xocs:filename>fx22_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4551</xocs:filesize>
               <xocs:pixel-height>197</xocs:pixel-height>
               <xocs:pixel-width>162</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/gr5/HIGHRES/image/jpeg/1591e9bb97bb95ad72d3c40e7a3840e9/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>946207</xocs:filesize>
               <xocs:pixel-height>3827</xocs:pixel-height>
               <xocs:pixel-width>3158</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-fx7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/fx7/HIGHRES/image/jpeg/b3ed74d7ded22da9c7ebec37f38e2069/fx7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3082</xocs:filesize>
               <xocs:pixel-height>123</xocs:pixel-height>
               <xocs:pixel-width>155</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-mmc1.docx</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/mmc1/MAIN/application/vnd.openxmlformats-officedocument.wordprocessingml.document/8e089734af94e0eff0d5d7d92dacc882/mmc1.docx</xocs:ucs-locator>
               <xocs:file-basename>mmc1</xocs:file-basename>
               <xocs:filename>mmc1.docx</xocs:filename>
               <xocs:extension>docx</xocs:extension>
               <xocs:filesize>4583761</xocs:filesize>
               <xocs:attachment-type>APPLICATION</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-mmc2.zip</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/mmc2/MAIN/application/zip/1aad66e11157f5760731df31d125f146/mmc2.zip</xocs:ucs-locator>
               <xocs:file-basename>mmc2</xocs:file-basename>
               <xocs:filename>mmc2.zip</xocs:filename>
               <xocs:extension>zip</xocs:extension>
               <xocs:filesize>7133783</xocs:filesize>
               <xocs:attachment-type>APPLICATION</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-si2.svg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/STRIPIN/image/svg+xml/5c1845101f20e648b9359c2f66ef21a2/si2.svg</xocs:ucs-locator>
               <xocs:file-basename>si2</xocs:file-basename>
               <xocs:filename>si2.svg</xocs:filename>
               <xocs:extension>svg</xocs:extension>
               <xocs:filesize>20170</xocs:filesize>
               <xocs:attachment-type>ALTIMG</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-si3.svg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/STRIPIN/image/svg+xml/461ffdb2002849ea3636bdc5d9322443/si3.svg</xocs:ucs-locator>
               <xocs:file-basename>si3</xocs:file-basename>
               <xocs:filename>si3.svg</xocs:filename>
               <xocs:extension>svg</xocs:extension>
               <xocs:filesize>1239</xocs:filesize>
               <xocs:attachment-type>ALTIMG</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-si4.svg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/STRIPIN/image/svg+xml/998c2ce554d054a0f4bff34f388ba643/si4.svg</xocs:ucs-locator>
               <xocs:file-basename>si4</xocs:file-basename>
               <xocs:filename>si4.svg</xocs:filename>
               <xocs:extension>svg</xocs:extension>
               <xocs:filesize>1613</xocs:filesize>
               <xocs:attachment-type>ALTIMG</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-si1.svg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420309065/STRIPIN/image/svg+xml/b8b86a900b3ad3f06867f4608daa0d4e/si1.svg</xocs:ucs-locator>
               <xocs:file-basename>si1</xocs:file-basename>
               <xocs:filename>si1.svg</xocs:filename>
               <xocs:extension>svg</xocs:extension>
               <xocs:filesize>40090</xocs:filesize>
               <xocs:attachment-type>ALTIMG</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420309065-am.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/egi:10JSTDWVGK6/MAIN/application/pdf/5dbf710da90571fcbe0e92bceca1afb1/am.pdf</xocs:ucs-locator>
               <xocs:file-basename>am</xocs:file-basename>
               <xocs:filename>am.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>false</xocs:pdf-optimized>
               <xocs:filesize>1417549</xocs:filesize>
               <xocs:attachment-type>AAM-PDF</xocs:attachment-type>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="fla" version="5.6" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>112934</aid>
            <ce:article-number>112934</ce:article-number>
            <ce:pii>S0223-5234(20)30906-5</ce:pii>
            <ce:doi>10.1016/j.ejmech.2020.112934</ce:doi>
            <ce:copyright type="limited-transfer" year="2020">Elsevier Masson SAS</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig. 1</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="fspara0010" view="all">Chemical structures of JAK inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0025" role="short">Fig. 1</ce:alt-text>
               <ce:link locator="gr1" xlink:href="pii:S0223523420309065/gr1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig. 2</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0015" view="all">Chemical structures of Aurora inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0030" role="short">Fig. 2</ce:alt-text>
               <ce:link locator="gr2" xlink:href="pii:S0223523420309065/gr2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig3">
               <ce:label>Fig. 3</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="fspara0020" view="all">Design of novel s3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0035" role="short">Fig. 3</ce:alt-text>
               <ce:link locator="gr3" xlink:href="pii:S0223523420309065/gr3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig4">
               <ce:label>Fig. 4</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="fspara0025" view="all">Western blot analysis of p-Aurora A, p-Aurora B, p-STAT3 and p-STAT5 with various concentrations of compound <ce:bold>10e</ce:bold> in K562 and HCT116 cells. GAPDH was used as a loading control.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0040" role="short">Fig. 4</ce:alt-text>
               <ce:link locator="gr4" xlink:href="pii:S0223523420309065/gr4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig5">
               <ce:label>Fig. 5</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="fspara0030" view="all">Compound <ce:bold>10e</ce:bold> induced cell cycle arrest at G2 phase in K562 and HCT116 cells.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0045" role="short">Fig. 5</ce:alt-text>
               <ce:link locator="gr5" xlink:href="pii:S0223523420309065/gr5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig6">
               <ce:label>Fig. 6</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="fspara0035" view="all">Binding pose of ligands (AT9283 and <ce:bold>10e</ce:bold>) to JAK2 (2W1I), JAK3 (3ZEP), Aurora A (2W1G) and Aurora B (4AF3), respectively. The important hydrogen bonds were plotted as red lines. The ligands and key residues were displayed in stick modes. The carbon atoms of AT9283 and <ce:bold>10e</ce:bold> were colored in green and yellow, respectively. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0050" role="short">Fig. 6</ce:alt-text>
               <ce:link locator="gr6" xlink:href="pii:S0223523420309065/gr6" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch1">
               <ce:label>Scheme 1</ce:label>
               <ce:caption id="cap0040">
                  <ce:simple-para id="fspara0040" view="all">The synthesis of compounds <ce:bold>10a-10j</ce:bold>. Reagents and conditions: (a) DHP, PTSA, THF; (b) NBS, AIBN, Acetonitrile; (c) K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, KI, Acetonitrile; (d) Br<ce:inf loc="post">2</ce:inf>, CH<ce:inf loc="post">3</ce:inf>COOH, HBr; (e) K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, KI, Acetonitrile; (f) CH<ce:inf loc="post">3</ce:inf>COONH<ce:inf loc="post">4</ce:inf>, CH<ce:inf loc="post">3</ce:inf>COOH, Reflux; (g) H<ce:inf loc="post">2</ce:inf>, Pd/C, CH<ce:inf loc="post">3</ce:inf>OH; (h) standard amide and aminopyrimidine coupling methods (for specific reagents, see the experimental section).</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0055" role="short">Scheme 1</ce:alt-text>
               <ce:link locator="sc1" xlink:href="pii:S0223523420309065/sc1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch2">
               <ce:label>Scheme 2</ce:label>
               <ce:caption id="cap0045">
                  <ce:simple-para id="fspara0045" view="all">The synthesis of compounds <ce:bold>18a</ce:bold>. Reagents and conditions: (a) Trimethylene chlorobromide, K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, KI, Acetonitrile; (b)Morpholine, K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, KI, Acetonitrile; (c) Br<ce:inf loc="post">2</ce:inf>, CH<ce:inf loc="post">3</ce:inf>COOH, HBr; (d) Compound <ce:bold>2</ce:bold>, K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, KI, Acetonitrile; (e) CH<ce:inf loc="post">3</ce:inf>COONH<ce:inf loc="post">4</ce:inf>, CH<ce:inf loc="post">3</ce:inf>COOH, Reflux; (f) H<ce:inf loc="post">2</ce:inf>, Pd/C, CH<ce:inf loc="post">3</ce:inf>OH; (g) Chlor pyrimidine, NaI, DIPEA, DMF.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0060" role="short">Scheme 2</ce:alt-text>
               <ce:link locator="sc2" xlink:href="pii:S0223523420309065/sc2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl1" rowsep="0">
               <ce:label>Table 1</ce:label>
               <ce:caption id="cap0050">
                  <ce:simple-para id="tspara0010" view="all">Enzymatic activities and <ce:italic>In vitro</ce:italic> anti-proliferative activities in tumor cell lines of compounds <ce:bold>10a-10j</ce:bold>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0065" role="short">Table 1</ce:alt-text>
               <ce:link locator="fx2" xlink:href="pii:S0223523420309065/fx2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
               <tgroup cols="9">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <colspec colname="col7" colnum="7"/></colspec>
                  <colspec colname="col8" colnum="8"/></colspec>
                  <colspec colname="col9" colnum="9"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">Compd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">R<sup loc="post">1</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">R<sup loc="post">2</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" nameend="col9" namest="col4" role="colgroup">IC<inf loc="post">50</inf>(μM)</entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">JAK2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">JAK3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Aurora A</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Aurora B</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">K562</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">HCT116</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10a</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx3" xlink:href="pii:S0223523420309065/fx3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0070" role="short">Image 3</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx4" xlink:href="pii:S0223523420309065/fx4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0075" role="short">Image 4</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NT</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NT</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NT</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NT</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10b</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx5" xlink:href="pii:S0223523420309065/fx5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0080" role="short">Image 5</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx6" xlink:href="pii:S0223523420309065/fx6" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0085" role="short">Image 6</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.014</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.024</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.359</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.652</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10c</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx7" xlink:href="pii:S0223523420309065/fx7" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0090" role="short">Image 7</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx8" xlink:href="pii:S0223523420309065/fx8" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0095" role="short">Image 8</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.178</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.569</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.466</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.65</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.34</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.21</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10d</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx9" xlink:href="pii:S0223523420309065/fx9" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0100" role="short">Image 9</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx10" xlink:href="pii:S0223523420309065/fx10" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0105" role="short">Image 10</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.094</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.064</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.514</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NT</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.63</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10e</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx11" xlink:href="pii:S0223523420309065/fx11" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0110" role="short">Image 11</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx12" xlink:href="pii:S0223523420309065/fx12" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0115" role="short">Image 12</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.166</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.057</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.939</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.583</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6.726</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">15.054</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10f</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx13" xlink:href="pii:S0223523420309065/fx13" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0120" role="short">Image 13</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx14" xlink:href="pii:S0223523420309065/fx14" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0125" role="short">Image 14</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NT</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NT</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NT</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NT</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NT</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NT</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10g</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx15" xlink:href="pii:S0223523420309065/fx15" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0130" role="short">Image 15</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx16" xlink:href="pii:S0223523420309065/fx16" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0135" role="short">Image 16</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NT</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NT</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.523</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NT</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10h</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx17" xlink:href="pii:S0223523420309065/fx17" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0140" role="short">Image 17</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx18" xlink:href="pii:S0223523420309065/fx18" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0145" role="short">Image 18</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NT</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NT</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.055</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NT</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.592</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10i</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx19" xlink:href="pii:S0223523420309065/fx19" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0150" role="short">Image 19</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx20" xlink:href="pii:S0223523420309065/fx20" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0155" role="short">Image 20</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.016</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.013</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.132</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NT</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.503</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10j</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx21" xlink:href="pii:S0223523420309065/fx21" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0160" role="short">Image 21</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx22" xlink:href="pii:S0223523420309065/fx22" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0165" role="short">Image 22</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.008</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.023</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.145</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NT</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10.048</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AT9283</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.0022</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.0012</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.026</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.062</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.748</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.09</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:legend>
                  <ce:simple-para id="tspara0015" view="all">NT (Not Test).</ce:simple-para>
               </ce:legend>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl2" rowsep="0">
               <ce:label>Table 2</ce:label>
               <ce:caption id="cap0055">
                  <ce:simple-para id="tspara0020" view="all">Enzymatic activities and <ce:italic>In vitro</ce:italic> anti-proliferative activities in tumor cell lines of compounds <ce:bold>18a</ce:bold>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0170" role="short">Table 2</ce:alt-text>
               <ce:link locator="fx23" xlink:href="pii:S0223523420309065/fx23" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
               <tgroup cols="8">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <colspec colname="col7" colnum="7"/></colspec>
                  <colspec colname="col8" colnum="8"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">Compd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">R<sup loc="post">3</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" nameend="col8" namest="col3" role="colgroup">IC<inf loc="post">50</inf>(μM)</entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">JAK2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">JAK3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Aurora A</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Aurora B</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">K562</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">HCT116</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">18a</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx24" xlink:href="pii:S0223523420309065/fx24" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0175" role="short">Image 24</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NT</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NT</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NT</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NT</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">9.88</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">16.14</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AT9283</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.0022</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.0012</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.026</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.062</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.748</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.09</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:legend>
                  <ce:simple-para id="tspara0025" view="all">NT (Not Test).</ce:simple-para>
               </ce:legend>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl3" rowsep="0">
               <ce:label>Table 3</ce:label>
               <ce:caption id="cap0060">
                  <ce:simple-para id="tspara0030" view="all">
                     <ce:italic>In vitro</ce:italic> anti-proliferative activities of compound <ce:bold>10e</ce:bold> against normal cells (IC<ce:inf loc="post">50</ce:inf> μM).</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0180" role="short">Table 3</ce:alt-text>
               <tgroup cols="3">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Compound</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">HCoEpiC</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">HUVEC</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10e</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">31.509</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">28.978</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AT9283</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.367</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.793</entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl4" rowsep="0">
               <ce:label>Table 4</ce:label>
               <ce:caption id="cap0065">
                  <ce:simple-para id="tspara0035" view="all">Binding free energies of ligands (<ce:bold>10e</ce:bold> and AT9283) to JAK2, JAK3, Aurora A and Aurora B calculated using MM-GBSA method. The unit for binding free energy is kcal/mol.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0185" role="short">Table 4</ce:alt-text>
               <tgroup cols="11">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <colspec colname="col7" colnum="7"/></colspec>
                  <colspec colname="col8" colnum="8"/></colspec>
                  <colspec colname="col9" colnum="9"/></colspec>
                  <colspec colname="col10" colnum="10"/></colspec>
                  <colspec colname="col11" colnum="11"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">ΔGexp<cross-ref id="crosref0505" refid="tbl4fna">
                              <sup loc="post">a</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">ΔGcal<cross-ref id="crosref0510" refid="tbl4fnb">
                              <sup loc="post">b</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">ΔEvdw</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">ΔEele</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">ΔEgb</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">ΔEsurf</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">ΔΔGcal<cross-ref id="crosref0515" refid="tbl4fnc">
                              <sup loc="post">c</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">ΔΔGexp<cross-ref id="crosref0520" refid="tbl4fnd">
                              <sup loc="post">d</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">ΔEele+ΔEgb</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">JAK2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>10e</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−9.30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−42.28</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−52.70</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−16.46</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">33.08</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−6.20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="1" role="rowgroup">−2.57</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="1" role="rowgroup">−2.85</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="1" role="rowgroup">−11.48</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">(2W1I)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AT9283</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−11.87</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−45.13</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−44.92</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−27.3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">32.44</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−5.34</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">JAK3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>10e</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−9.94</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−38.35</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−42.65</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−23.14</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">32.44</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−4.99</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="1" role="rowgroup">−2.30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="1" role="rowgroup">−3.54</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="1" role="rowgroup">−2.57</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">(3ZEP)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AT9283</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−12.24</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−41.88</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−43.45</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−27.47</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">34.20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−5.16</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Aurora A</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>10e</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−8.27</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−40.72</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−43.40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−23.63</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">31.52</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−5.19</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="1" role="rowgroup">−2.13</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="1" role="rowgroup">−1.71</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="1" role="rowgroup">−1.62</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">(2W1G)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AT9283</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−10.40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−42.43</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−43.48</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−30.92</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">37.19</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−5.2</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="1" role="rowhead rowgroup">Aurora B (4AF3)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>10e</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−8.55</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−41.31</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−45.05</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−26.13</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">36.89</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−5.2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="1" role="rowgroup">−1.33</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="1" role="rowgroup">−1.61</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="1" role="rowgroup">−0.61</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AT9283</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−9.89</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−42.92</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−47.41</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−23.19</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">33.35</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">−5.71</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl4fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0015" view="all">The experimental values were derived from the experimental <ce:italic>ki</ce:italic> values using the equation Δ<ce:italic>G</ce:italic>exp = −<ce:italic>RT</ce:italic>lnIC<ce:inf loc="post">50</ce:inf>.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl4fnb">
                  <ce:label>b</ce:label>
                  <ce:note-para id="ntpara0020" view="all">Δ<ce:italic>Gcal</ce:italic> = Δ<ce:italic>E</ce:italic>ele + Δ<ce:italic>E</ce:italic>vdw + Δ<ce:italic>G</ce:italic>gb + Δ<ce:italic>Gsurf</ce:italic>.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl4fnc">
                  <ce:label>c</ce:label>
                  <ce:note-para id="ntpara0025" view="all">ΔΔG<ce:inf loc="post">cal</ce:inf> = ΔG<ce:inf loc="post">cal</ce:inf>(AT9283)- ΔG<ce:inf loc="post">cal</ce:inf>(<ce:bold>10e</ce:bold>).</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl4fnd">
                  <ce:label>d</ce:label>
                  <ce:note-para id="ntpara0030" view="all">ΔΔG<ce:inf loc="post">exp</ce:inf> = ΔG<ce:inf loc="post">exp</ce:inf>(AT9283)- ΔG<ce:inf loc="post">exp</ce:inf>(<ce:bold>10e</ce:bold>).</ce:note-para>
               </ce:table-footnote>
            </ce:table>
         </ce:floats>
         <head>
            <ce:dochead id="dhead0010">
               <ce:textfn>Research paper</ce:textfn>
            </ce:dochead>
            <ce:title id="title0010">Design, synthesis, biological activity evaluation of 3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives as potent JAK 2/3 and aurora A/B kinases multi-targeted inhibitors</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author id="au1" author-id="S0223523420309065-50d9649622671249ec0d90e40d018941">
                  <ce:given-name>You-Guang</ce:given-name>
                  <ce:surname>Zheng</ce:surname>
                  <ce:cross-ref id="crosref0010" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0015" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0020" refid="cor1">
                     <ce:sup loc="post">∗</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0025" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au2" author-id="S0223523420309065-3a7bd0219baa017d688dd30081b27d0d">
                  <ce:given-name>Jin-An</ce:given-name>
                  <ce:surname>Wang</ce:surname>
                  <ce:cross-ref id="crosref0030" refid="aff3">
                     <ce:sup loc="post">c</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0035" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au3" author-id="S0223523420309065-9e0721230b0750180a8e78f6bd7a9179">
                  <ce:given-name>Long</ce:given-name>
                  <ce:surname>Meng</ce:surname>
                  <ce:cross-ref id="crosref0040" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0045" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0050" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au4" author-id="S0223523420309065-c27cbb414454c38361b3f115e2390574">
                  <ce:given-name>Xin</ce:given-name>
                  <ce:surname>Pei</ce:surname>
                  <ce:cross-ref id="crosref0055" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0060" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au5" author-id="S0223523420309065-13d0e2943019a73f803bbdb9ec774e61">
                  <ce:given-name>Ling</ce:given-name>
                  <ce:surname>Zhang</ce:surname>
                  <ce:cross-ref id="crosref0065" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0070" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au6" author-id="S0223523420309065-010601d095a4f606ecbbb55fe488580f">
                  <ce:given-name>Lin</ce:given-name>
                  <ce:surname>An</ce:surname>
                  <ce:cross-ref id="crosref0075" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0080" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au7" author-id="S0223523420309065-a3d9c91c9bc7377a147d1db4e5d2d162">
                  <ce:given-name>Cheng-Lin</ce:given-name>
                  <ce:surname>Li</ce:surname>
                  <ce:cross-ref id="crosref0085" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0090" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au8" author-id="S0223523420309065-115d531f693d72aeaf58d20f923ef991">
                  <ce:given-name>Ying-Long</ce:given-name>
                  <ce:surname>Miao</ce:surname>
                  <ce:cross-ref id="crosref0095" refid="aff3">
                     <ce:sup loc="post">c</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:affiliation id="aff1" affiliation-id="S0223523420309065-a32dedfac0424923086eb0f068ef6a1f">
                  <ce:label>a</ce:label>
                  <ce:textfn>College of Pharmacy, Xuzhou Medical University, Xuzhou, 221004, PR China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>College of Pharmacy</sa:organization>
                     <sa:organization>Xuzhou Medical University</sa:organization>
                     <sa:city>Xuzhou</sa:city>
                     <sa:postal-code>221004</sa:postal-code>
                     <sa:country>PR China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0010">College of Pharmacy, Xuzhou Medical University, Xuzhou, 221004, PR China</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff2" affiliation-id="S0223523420309065-aebc62deb5dc85a543ad350d05263843">
                  <ce:label>b</ce:label>
                  <ce:textfn>Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, 221004, PR China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy</sa:organization>
                     <sa:organization>Xuzhou Medical University</sa:organization>
                     <sa:city>Xuzhou</sa:city>
                     <sa:postal-code>221004</sa:postal-code>
                     <sa:country>PR China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0015">Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, 221004, PR China</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff3" affiliation-id="S0223523420309065-f4c2faca7e7b68a7cd7b73d5c84b6347">
                  <ce:label>c</ce:label>
                  <ce:textfn>Center for Computational Biology and Department of Molecular Biosciences, University of Kansas, Lawrence, KS, 66047, USA</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Center for Computational Biology and Department of Molecular Biosciences</sa:organization>
                     <sa:organization>University of Kansas</sa:organization>
                     <sa:city>Lawrence</sa:city>
                     <sa:state>KS</sa:state>
                     <sa:postal-code>66047</sa:postal-code>
                     <sa:country>USA</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0020">Center for Computational Biology and Department of Molecular Biosciences, University of Kansas, Lawrence, KS 66047, USA</ce:source-text>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>∗</ce:label>
                  <ce:text>Corresponding author. College of Pharmacy, Xuzhou Medical University, Xuzhou, 221004, PR China.</ce:text>
                  <sa:affiliation>
                     <sa:organization>College of Pharmacy</sa:organization>
                     <sa:organization>Xuzhou Medical University</sa:organization>
                     <sa:city>Xuzhou</sa:city>
                     <sa:postal-code>221004</sa:postal-code>
                     <sa:country>PR China</sa:country>
                  </sa:affiliation>
               </ce:correspondence>
               <ce:footnote id="fn1">
                  <ce:label>1</ce:label>
                  <ce:note-para id="ntpara0010" view="all">Youguang Zheng, Jin-An Wang and Long Meng contributed equally to this work.</ce:note-para>
               </ce:footnote>
            </ce:author-group>
            <ce:date-received day="21" month="8" year="2020"/></ce:date-received>
            <ce:date-revised day="6" month="10" year="2020"/></ce:date-revised>
            <ce:date-accepted day="9" month="10" year="2020"/></ce:date-accepted>
            <ce:abstract id="abs0010" xml:lang="en" view="all" class="author"><ce:abstract-sec id="abssec0010" view="all">
                  <ce:simple-para id="abspara0010" view="all">In this study, a series of 3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives were designed, synthesized, and evaluated for their biological activities. Upon performing kinase assays, most of the compounds exhibited potent inhibition against JAK2/3 and Aurora A/B with the IC<ce:inf loc="post">50</ce:inf> values ranging from 0.008 to 2.52 μM. Among these derivatives, compound <ce:bold>10e</ce:bold> expressed the most moderate inhibiting activities against all the four kinases with the IC<ce:inf loc="post">50</ce:inf> values of 0.166 μM (JAK2), 0.057 μM (JAK3), 0.939 μM (Aurora A), and 0.583 μM (Aurora B), respectively. Moreover, most of the derived compounds exhibited potent cytotoxicity against human chronic myeloid leukemia cells K562 and human colon cancer cells HCT116, while compound <ce:bold>10e</ce:bold> expressed antiproliferative activities against K562 (IC<ce:inf loc="post">50=</ce:inf>6.726  μM). According to western blot analysis, compound <ce:bold>10e</ce:bold> down-regulated the phosphorylation of STAT3, STAT5, Aurora A, and Aurora B in a dose-dependent manner in K562 and HCT116 cells. Cell cycle analysis revealed that compound <ce:bold>10e</ce:bold> inhibited the proliferation of cells by inducing cell cycle arrest in the G2 phase. The molecular modeling suggested that compound <ce:bold>10e</ce:bold> could maintain a binding mode similar to the binding mode of AT9832, a common JAK 2/3 and Aurora A/B kinases multi-target kinase inhibitor. Therefore, compound <ce:bold>10e</ce:bold> might be a potential agent for cancer therapy deserving further research.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical" id="abs0015" view="all">
               <ce:section-title id="sectitle0015">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abssec0015" view="all">
                  <ce:simple-para id="abspara0015" view="all">
                     <ce:display>
                        <ce:figure id="undfig1">
                           <ce:alt-text id="alttext0010" role="short">Image 1</ce:alt-text>
                           <ce:link locator="fx1" xlink:href="pii:S0223523420309065/fx1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            
            <ce:keywords id="kwrds0010" xml:lang="en" view="all" class="keyword">
               <ce:section-title id="sectitle0025">Keywords</ce:section-title>
               <ce:keyword id="kwrd0010">
                  <ce:text>JAK2/3</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0015">
                  <ce:text>Aurora kinases</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0020">
                  <ce:text>Pyrazole derivatives</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0025">
                  <ce:text>Multi-targeted inhibitors</ce:text>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec1" role="introduction" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0030">Introduction</ce:section-title>
                  <ce:para id="p0035" view="all">The Janus kinases (JAKs) family, consisting of four structurally related kinases, JAK1, JAK2, JAK3, and TYK2, regulates the JAK/STAT signaling pathway [<ce:cross-ref id="crosref0100" refid="bib1">1</ce:cross-ref>,<ce:cross-ref id="crosref0105" refid="bib2">2</ce:cross-ref>]. The JAK/STAT pathway plays a vital role in the oncogenesis in the immune system [<ce:cross-ref id="crosref0110" refid="bib3">3</ce:cross-ref>], and mediates signaling by cytokines, which control survival, proliferation, and differentiation of several cell types, such as human chronic myeloid leukemia K562 cells [<ce:cross-refs id="crosrefs0010" refid="bib4 bib5 bib6">4–6</ce:cross-refs>], human colorectal cancer HCT-116 cells [<ce:cross-refs id="crosrefs0015" refid="bib7 bib8 bib9">7–9</ce:cross-refs>] and other cancer cells [<ce:cross-refs id="crosrefs0020" refid="bib10 bib11 bib12 bib13 bib14">10–14</ce:cross-refs>]. In recent years, the JAK kinase inhibitors that target the JAK/STAT pathway, such as Ruxolitinib, has been approved by FDA [<ce:cross-ref id="crosref0115" refid="bib15">15</ce:cross-ref>], extensively studied [<ce:cross-refs id="crosrefs0025" refid="bib16 bib17 bib18">16–18</ce:cross-refs>] and provided a great value for the treatment of myeloproliferative neoplasias and beyond [<ce:cross-ref id="crosref0120" refid="bib19">19</ce:cross-ref>]. In addition, some JAK inhibitors have been developed and introduced into clinical trials, such as AZD1480 [<ce:cross-ref id="crosref0125" refid="bib20">20</ce:cross-ref>], Fedratinib [<ce:cross-ref id="crosref0130" refid="bib21">21</ce:cross-ref>], AT9283 [<ce:cross-ref id="crosref0135" refid="bib22">22</ce:cross-ref>] and so on (<ce:cross-ref id="crosref0140" refid="fig1">Fig. 1</ce:cross-ref>
                     <ce:float-anchor refid="fig1"/></ce:float-anchor>).</ce:para>
                  <ce:para id="p0040" view="all">Aurora kinases belong to serine/threonine kinases that are involved in chromosome condensation, spindle dynamics, kinetochore-microtubule interactions, chromosome orientation, and establishment of the metaphase plate during mitosis [<ce:cross-ref id="crosref0145" refid="bib23">23</ce:cross-ref>]. The family includes three kinases designated as Aurora A, B, and C, which possess a very similar sequence, particularly in the carboxy-terminal catalytic domain [<ce:cross-ref id="crosref0150" refid="bib24">24</ce:cross-ref>]. Overexpression of aurora kinases in several human tumors has made them appealing targets for the development of anticancer therapies [<ce:cross-refs id="crosrefs0030" refid="bib23 bib24 bib25 bib26">23–26</ce:cross-refs>]. Over the past decades, some Aurora kinase inhibitors have been developed for the treatment of cancer, such as VX-680 [<ce:cross-ref id="crosref0155" refid="bib27">27</ce:cross-ref>], AT9283 [<ce:cross-ref id="crosref0160" refid="bib22">22</ce:cross-ref>], CYC-116 [<ce:cross-ref id="crosref0165" refid="bib28">28</ce:cross-ref>], AZD-1152 [<ce:cross-ref id="crosref0170" refid="bib29">29</ce:cross-ref>], AMG-900 [<ce:cross-ref id="crosref0175" refid="bib30">30</ce:cross-ref>], PHA-739358 [<ce:cross-ref id="crosref0180" refid="bib31">31</ce:cross-ref>], MLN8054 [<ce:cross-ref id="crosref0185" refid="bib32">32</ce:cross-ref>], MLN8237 [<ce:cross-ref id="crosref0190" refid="bib33">33</ce:cross-ref>] and ENMD2076 [<ce:cross-ref id="crosref0195" refid="bib34">34</ce:cross-ref>] (<ce:cross-ref id="crosref0200" refid="fig2">Fig. 2</ce:cross-ref>
                     <ce:float-anchor refid="fig2"/></ce:float-anchor>
                     <ce:float-anchor refid="fig3"/></ce:float-anchor>).</ce:para>
                  <ce:para id="p0045" view="all">Although recent studies have identified a significant number of single-targeted selective kinase inhibitors and proven their efficacy in treatment for specific cancers [<ce:cross-refs id="crosrefs0035" refid="bib35 bib36 bib37">35–37</ce:cross-refs>], the mortality rate caused by cancer remains high. Therefore, the multi-targeted kinase inhibitors could exhibit more potent therapeutic effects by synergistic effects as well as by the combination of various antitumor mechanisms [<ce:cross-ref id="crosref0210" refid="bib38">38</ce:cross-ref>]. Meanwhile, studies have also confirmed that the Aurora kinase and JAKs multi-target inhibitors can inhibit the growth of tumor cells more effectively than the selective aurora kinase inhibitors [<ce:cross-ref id="crosref0215" refid="bib39">39</ce:cross-ref>]. AT9283 is a multi-target kinase inhibitor, which can effectively inhibit the activities of Aurora A, Aurora B, JAK2, JAK3, and ABL1 kinases [<ce:cross-ref id="crosref0220" refid="bib40">40</ce:cross-ref>]. According to the reported crystal structure study, AT9283 complexed with Aurora-A by forming hydrogen-bonds to the backbone carbonyl groups of Glu211, as well as to the backbone NH and carbonyl groups of Ala213 of the protein hinge region [<ce:cross-ref id="crosref0225" refid="bib40">40</ce:cross-ref>].</ce:para>
                  <ce:para id="p0050" view="all">In this paper, retaining the hydrogen-bonded pharmacophore of AT9283, a series of 3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives were rationally designed and synthesized as JAK 2/3 and Aurora A/B kinases multi-target inhibitors (<ce:cross-ref id="optJJRl8A00UZ" refid="fig3">Fig. 3</ce:cross-ref>).</ce:para>
               </ce:section>
               <ce:section id="sec2" role="results" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0035">Results and discussion</ce:section-title>
                  <ce:section id="sec2.1" view="all">
                     <ce:label>2.1</ce:label>
                     <ce:section-title id="sectitle0040">Chemistry</ce:section-title>
                     <ce:para id="p0055" view="all">As depicted in <ce:cross-ref id="crosref0230" refid="sch1">Scheme 1</ce:cross-ref>
                        <ce:float-anchor refid="sch1"/></ce:float-anchor>, <ce:italic>N</ce:italic>-protection of 4-nitropyrazol-3-carboxylic acid (<ce:bold>1</ce:bold>) was performed by treating with DHP reagent to obtain compound (<ce:bold>2</ce:bold>). Compound <ce:bold>(6)</ce:bold> was synthesized from compound <ce:bold>(3)</ce:bold> by bromomethylation and <ce:italic>N</ce:italic>-alkylation, followed by bromination of ketones at α-position. Compound <ce:bold>(2)</ce:bold> reacted with compound (<ce:bold>6</ce:bold>) to produce compound (<ce:bold>7</ce:bold>), which was treated with ammonium acetate and acetic acid to afford compound (<ce:bold>8</ce:bold>). Then after, compounds (<ce:bold>8</ce:bold>) were reduced to its amino derivatives (<ce:bold>9</ce:bold>) using H<ce:inf loc="post">2</ce:inf>, and Pd/C. The target compounds (<ce:bold>10</ce:bold>) were prepared by reacting compound (<ce:bold>9</ce:bold>) with various benzoic acids or chloropyrimidines.</ce:para>
                     <ce:para id="p0060" view="all">The overall synthetic route of compounds <ce:bold>18a</ce:bold> starting from 4-hydroxyacetophenone (<ce:bold>11</ce:bold>), has been outlined in <ce:cross-ref id="crosref0235" refid="sch2">Scheme 2</ce:cross-ref>
                        <ce:float-anchor refid="sch2"/></ce:float-anchor>. Compounds (<ce:bold>17</ce:bold>) were obtained upon sequential <ce:italic>O</ce:italic>-alkylation, <ce:italic>N</ce:italic>-alkylation, bromination of ketones at α position, followed by esterification, cyclization, and reduction. Further, the target compounds (<ce:bold>18a</ce:bold>) were prepared by treating compound (<ce:bold>17</ce:bold>) with different chloropyrimidines.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.2" view="all">
                     <ce:label>2.2</ce:label>
                     <ce:section-title id="sectitle0045">Biological activities</ce:section-title>
                     <ce:para id="p0065" view="all">The target compounds were evaluated for their enzymatic activities against Aurora A, Aurora B, JAK2, and JAK3. Additionally, the <ce:italic>in vitro</ce:italic> antiproliferative effects of the targeted compounds against human chronic myeloid leukemia cells K562 and human colon cancer cells HCT116 were also carried out. The results were summarized in <ce:cross-ref id="crosref0240" refid="tbl1">Table 1</ce:cross-ref>
                        <ce:float-anchor refid="tbl1"/></ce:float-anchor>.</ce:para>
                     <ce:section id="sec2.2.1" view="all">
                        <ce:label>2.2.1</ce:label>
                        <ce:section-title id="sectitle0050">
                           <ce:italic>In vitro</ce:italic> inhibition activities studies of kinases</ce:section-title>
                        <ce:para id="p0070" view="all">As shown in <ce:cross-ref id="crosref0245" refid="tbl1">Table 1</ce:cross-ref>, most of the compounds (<ce:bold>10a-10j</ce:bold>) exhibited potent inhibition against JAK2/3 and Aurora A/B with the IC<ce:inf loc="post">50</ce:inf> values ranging from 0.008 to 2.52 μM. Among these derivatives, compound <ce:bold>10e</ce:bold> expressed the most moderate inhibiting activities against all the four kinases with the IC<ce:inf loc="post">50</ce:inf> values, 0.166 μM (JAK2), 0.057 μM (JAK3), 0.939 μM (Aurora A), and 0.583 μM (Aurora B), respectively. Compounds (<ce:bold>10b</ce:bold>, <ce:bold>10d</ce:bold>, <ce:bold>10e</ce:bold>, and <ce:bold>10i</ce:bold>) containing –Cl and–OCH<ce:inf loc="post">3</ce:inf> groups at the benzene ring of R<ce:sup loc="post">2</ce:sup> exhibited selective inhibiting activities against JAKs (approximately 20-fold selectivity), while compound <ce:bold>10c</ce:bold> bearing a nitro group at the benzene ring of R<ce:sup loc="post">2</ce:sup> showed pan-inhibiting activities against JAK2/3 and Aurora A/B. In addition, replacement of the benzoyl group of R<ce:sup loc="post">2</ce:sup> with a pyrimidine group (compound <ce:bold>10j</ce:bold>) increased the inhibition activities against JAK2/3 and Aurora A (JAK2 IC<ce:inf loc="post">50</ce:inf> = 0.008  μM, JAK3 IC<ce:inf loc="post">50</ce:inf> = 0.023  μM, and Aurora A IC<ce:inf loc="post">50</ce:inf> = 0.145  μM).</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.2" view="all">
                        <ce:label>2.2.2</ce:label>
                        <ce:section-title id="sectitle0055">Antiproliferation assay</ce:section-title>
                        <ce:para id="p0075" view="all">Most of our target compounds were tested against human chronic myeloid leukemia cell lines (K562) and human colorectal cancer cell line (HCT116), in which overexpression of JAKs and Aurora kinases remains prominent [<ce:cross-refs id="crosrefs0040" refid="bib40 bib41 bib42 bib43">40–43</ce:cross-refs>]. The results of the antiproliferative activities are shown in <ce:cross-refs id="crosrefs0045" refid="tbl1 tbl2">Tables 1 and 2</ce:cross-refs>
                           <ce:float-anchor refid="tbl2"/></ce:float-anchor>. Most compounds exhibit potent cytotoxicity against both of these tumor cell lines. In K562 cell lines, compounds <ce:bold>10b-10e</ce:bold> (IC<ce:inf loc="post">50</ce:inf> values of 2.630–6.726 μM) having the morpholine ring at the side chain shown more potent antiproliferation activity in comparison to the compounds (<ce:bold>10 g</ce:bold> and <ce:bold>10 h</ce:bold>) with piperidine ring (IC<ce:inf loc="post">50</ce:inf> values > 10 μM). It was noted, compounds having –Cl, –OCH<ce:inf loc="post">3</ce:inf>, and–NO<ce:inf loc="post">2</ce:inf> groups at the benzene ring (<ce:bold>10b-10e</ce:bold>) exhibited significant improvement to their proliferative inhibition; compound <ce:bold>10c</ce:bold> and <ce:bold>10d</ce:bold> that contained electron-withdrawing groups (Cl and NO<ce:inf loc="post">2</ce:inf>) expressed slightly higher K562 proliferative inhibition (the IC<ce:inf loc="post">50=</ce:inf>4.34 μM, 2.63 μM, respectively) compare to <ce:bold>10b</ce:bold> having an electron-donating group (CH<ce:inf loc="post">3</ce:inf>O-).</ce:para>
                        <ce:para id="p0080" view="all">We also synthesized one compound bearing longer side chain at 4-position of the benzene ring (<ce:bold>18a</ce:bold>). As indicated in <ce:cross-ref id="crosref0250" refid="tbl2">Table 2</ce:cross-ref>, Extension of the side chain (compound <ce:bold>18a</ce:bold>) displayed no significant change to cytotoxicity against K562 and HCT116.</ce:para>
                        <ce:para id="p0085" view="all">Compound <ce:bold>10e</ce:bold>, which expressed the most potent inhibition on kinases and cancer cells, was selected for further study.</ce:para>
                        <ce:para id="p0090" view="all">In addition, <ce:italic>in vitro</ce:italic> anti-proliferative activities of compound <ce:bold>10e</ce:bold> against human normal colon epithelial cells (HCoEpiC) and human umbilical vein endothelial cells (HUVEC) had been tested (<ce:cross-ref id="crosref0255" refid="tbl3">Table 3</ce:cross-ref>
                           <ce:float-anchor refid="tbl3"/></ce:float-anchor>). The result showed that <ce:bold>10e</ce:bold> has significantly lower toxic effect on HCoEpiC (IC<ce:inf loc="post">50</ce:inf> = 31.509 μM) and HUVEC (IC<ce:inf loc="post">50</ce:inf> = 28.978 μM) than AT9283 (IC<ce:inf loc="post">50</ce:inf> = 2.367 μM, 1.793 μM, respectively).</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.3" view="all">
                        <ce:label>2.2.3</ce:label>
                        <ce:section-title id="sectitle0060">Compound <ce:bold>10e</ce:bold> blocks JAKs and Aurora kinases phosphorylation in K562 and HCT116 cell</ce:section-title>
                        <ce:para id="p0095" view="all">Western blot analysis was performed to evaluate the performance of compound <ce:bold>10e</ce:bold> in a cellular context according to the published research works [<ce:cross-refs id="crosrefs0050" refid="bib44 bib45 bib46 bib47">44–47</ce:cross-refs>]. The phosphorylation of Aurora A, Aurora B, STAT3, and STAT5 was investigated in K562 and HCT116 cells by treating with various concentrations of compound <ce:bold>10e</ce:bold> (control, 1, 10, and 20 μM). The results demonstrated that multi-target kinase inhibitor <ce:bold>10e</ce:bold> also led to decreased levels of p-STAT3 and STAT5, which could be correlated with JAKs inhibition, indicating the inhibition of intracellular JAK-STATs pathway. Furthermore, compound <ce:bold>10e</ce:bold> down-regulated the phosphorylation of Aurora A and Aurora B in a dose-dependent manner in K562 and HCT116 cells, respectively (<ce:cross-ref id="crosref0260" refid="fig4">Fig. 4</ce:cross-ref>). According to the above results, compound <ce:bold>10e</ce:bold> could be considered as a potential JAKs and Aurora kinases inhibitor.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.4" view="all">
                        <ce:label>2.2.4</ce:label>
                        <ce:section-title id="sectitle0065">Cell cycle arrest</ce:section-title>
                        <ce:para id="p0100" view="all">As per the previous reports, the JAK-STATs pathway and Aurora kinases could play important roles in controlling cell cycle progression [<ce:cross-ref id="crosref0265" refid="bib48">48</ce:cross-ref>,<ce:cross-ref id="crosref0270" refid="bib49">49</ce:cross-ref>]. AT9283, which is a multi-target kinase inhibitor, induces common cancer cell-cycle arrest at the G2 phase [<ce:cross-ref id="crosref0275" refid="bib50">50</ce:cross-ref>,<ce:cross-ref id="crosref0280" refid="bib51">51</ce:cross-ref>]. Accordingly, we tested the effects of <ce:bold>10e</ce:bold> on cell-cycle progression in K562 and HCT116 cells using flow cytometry. As shown in <ce:cross-ref id="crosref0285" refid="fig5">Fig. 5</ce:cross-ref>, a dose-dependent G2 phase transition arrest was observed in K562 and HCT116 cells when treated with <ce:bold>10e</ce:bold>. Exposure of compound <ce:bold>10e</ce:bold> in K562 cell at 10 μM concentration resulted in 16.27% of cell arrest at the G2 phase, compared with 7.73% in untreated cultures and 14.99% in AT9283 (10 μM) treated cultures (<ce:cross-ref id="crosref0290" refid="fig5">Fig. 5</ce:cross-ref>A). On the other hand, exposure of compound <ce:bold>10e</ce:bold> in HCT116 cells at 10 μM resulted in 16.16% of cell arrest at the G2 phase, while the values for cell arrest in untreated cultures and in AT9283 (10 μM) treated cultures were 10.46% and 25.19%, respectively (<ce:cross-ref id="crosref0295" refid="fig5">Fig. 5</ce:cross-ref>B).</ce:para>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec2.3" view="all">
                     <ce:label>2.3</ce:label>
                     <ce:section-title id="sectitle0070">Binding mechanism of <ce:bold>10e</ce:bold> to the JAK2, JAK3, Aurora A and Aurora B</ce:section-title>
                     <ce:para id="p0105" view="all">Considering the above-mentioned integrated molecular modeling approach, RMSDs of kinase backbone atoms (<ce:cross-ref id="crosref0300" refid="appsec1">Fig S3</ce:cross-ref>) and ligand heavy atoms (<ce:cross-ref id="crosref0305" refid="appsec1">Fig S4</ce:cross-ref>) of the initial structures were calculated to assess the stability of the complex. In comparison to AT9832, the binding of <ce:bold>10e</ce:bold> induced large fluctuations of kinases (<ce:cross-ref id="crosref0310" refid="appsec1">Fig S3</ce:cross-ref>), indicating that the binding of <ce:bold>10e</ce:bold> was less stable than AT9832, and also the stability of <ce:bold>10e</ce:bold> in these kinases was less than that of AT9832 (<ce:cross-ref id="crosref0315" refid="appsec1">Fig S4</ce:cross-ref>). The above results were very consistent with our experimental data, which represented the lower binding affinities of <ce:bold>10e</ce:bold> (<ce:cross-ref id="crosref0320" refid="tbl4">Table 4</ce:cross-ref>
                        <ce:float-anchor refid="tbl4"/></ce:float-anchor>). These results encouraged us to explore the binding mechanism of <ce:bold>10e</ce:bold> further, by analyzing the MD trajectories.</ce:para>
                     <ce:para id="p0110" view="all">To explore the binding mechanism of <ce:bold>10e</ce:bold> to kinases, MM-GBSA was employed to calculate the binding affinities of both <ce:bold>10e</ce:bold> and AT9832 with these kinases. The information on binding free energy obtained from MM-GBA calculations is given in <ce:cross-ref id="crosref0325" refid="tbl4">Table 4</ce:cross-ref>. The calculated differences of binding free energy between AT9832 and <ce:bold>10e</ce:bold> to JAK2, JAK3, Aurora A, and Aurora B were −2.85, −3.54, −1.71, and −1.61 kcal/mol, which were very consistent with the corresponding experimental data (−2.57, −2.30, −2.13 and −1.33 kcal/mol, respectively) (<ce:cross-ref id="crosref0330" refid="tbl4">Table 4</ce:cross-ref>). The calculated difference of binding free energy between AT9832 and <ce:bold>10e</ce:bold> correlated properly to the experimental data (R<ce:sup loc="post">2=</ce:sup>0.48, <ce:cross-ref id="crosref0335" refid="appsec1">Fig S5</ce:cross-ref>). Thus, our current analysis of binding free energies could be considered as reliable.</ce:para>
                     <ce:para id="p0115" view="all">As shown in <ce:cross-ref id="crosref0340" refid="tbl4">Table 4</ce:cross-ref>, the van der Waals interactions (Δ<ce:italic>E</ce:italic>vdw), electrostatic interactions (Δ<ce:italic>E</ce:italic>ele), and nonpolar solvation energies (Δ<ce:italic>G</ce:italic>surf) were favorable for the binding of the ligands to kinases, while polar solvation energies (Δ<ce:italic>G</ce:italic>gb) heavily impaired the bindings. The van der Waals interaction was the main driving force for the binding of the inhibitors to kinases, which was consistent with the results of our previous simulations [<ce:cross-ref id="crosref0345" refid="bib52">52</ce:cross-ref>]. However, the electrostatic interactions (Δ<ce:italic>E</ce:italic>ele+Δ<ce:italic>G</ce:italic>gb) between AT9832 and <ce:bold>10e</ce:bold> seemed to differ mostly. The differences of electrostatic interaction between AT9832 and <ce:bold>10e</ce:bold> to the JAK2, JAK3, Aurora A, and Aurora B were −11.48, −2.57, −1.62, and −0.61 kcal/mol. Thus, less electrostatic interactions of <ce:bold>10e</ce:bold> largely impaired the binding affinity of <ce:bold>10e</ce:bold>.</ce:para>
                     <ce:para id="p0120" view="all">Next, snapshots from the last 150 ns trajectories were used for clustering to obtain a representative binding pose. As shown in <ce:cross-ref id="crosref0350" refid="fig6">Fig. 6</ce:cross-ref>
                        <ce:float-anchor refid="fig6"/></ce:float-anchor>, the hydrogen bonds formed between the hinge region of the kinases and the compounds (AT9832 and <ce:bold>10e</ce:bold>) were the main interactions between ligands and kinases. For most of the kinases (JAK3, Aurora A, and Aurora B), the residues in the hinge could form three important hydrogen bonds between the ligands and the kinases. However, smaller distance and larger occupancy of these hydrogen bonds were identified in AT9832 than that of <ce:bold>10e</ce:bold> (<ce:cross-ref id="crosref0355" refid="fig6">Fig. 6</ce:cross-ref> and <ce:cross-ref id="crosref0360" refid="appsec1">Table S1</ce:cross-ref>), suggesting that the interactions of AT9832 to the kinases were stronger than that of <ce:bold>10e</ce:bold> to the same kinases. In the case of JAK2, AT9832 formed three strong hydrogen bonds with the residues E930 and L932 in the hinge region with distances of 2.8, 3.0, and 2.8 Å (<ce:cross-ref id="crosref0365" refid="fig6">Fig. 6</ce:cross-ref>A), respectively. However, <ce:bold>10e</ce:bold> could form only one hydrogen bond between the residues E930 in the hinge region with a distance of 3.2 Å (<ce:cross-ref id="crosref0370" refid="fig6">Fig. 6</ce:cross-ref>B). <ce:bold>10e</ce:bold> could form two other weaker hydrogen bonds to residues G993 and S936 of JAK2 (<ce:cross-ref id="crosref0375" refid="fig6">Fig. 6</ce:cross-ref>B and <ce:cross-ref id="crosref0380" refid="appsec1">Table S1</ce:cross-ref>). In summary, the current molecular modeling suggested that the <ce:bold>10e</ce:bold> could maintain a binding mode similar to AT9832, although it has a less binding affinity.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec3" role="conclusion" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0075">Conclusions</ce:section-title>
                  <ce:para id="p0125" view="all">In summary, we designed and synthesized 3-(4-phenyl-1Himidazol-2-yl)-1H-pyrazole derivatives as potent JAK 2/3 and aurora A/B kinases multi-targeted inhibitors.</ce:para>
                  <ce:para id="p0130" view="all">Most of the compounds exhibited potent inhibition against JAK2/3 and Aurora A/B with the IC<ce:inf loc="post">50</ce:inf> values ranging from 0.008 to 2.52 μM. Among these derivatives, compound <ce:bold>10e</ce:bold> expressed the most moderate inhibiting activities against all the four kinases with the IC<ce:inf loc="post">50</ce:inf> values, 0.166 μM (JAK2), 0.057 μM (JAK3), 0.939 μM (Aurora A), and 0.583 μM (Aurora B), respectively. Additionally, anti-proliferation assays shown that the compounds having a morpholine ring at the side chain (<ce:bold>10b-10e</ce:bold>) exhibited higher anti-proliferative activities against K562 and HTC116. In addition, <ce:bold>10e</ce:bold> has significantly lower toxic effect on human normal cells than JAK 2/3 and Aurora A/B kinases multi-target kinase inhibitor (AT9832). Furthermore, compound <ce:bold>10e</ce:bold> down-regulated the phosphorylation of STAT3, STAT5, Aurora A, and Aurora B in K562 and HCT116 cells. Cell cycle analysis revealed that compound <ce:bold>10e</ce:bold> inhibited the proliferation of cells by inducing cell cycle arrest in the G2 phase. The molecular modeling suggested that the <ce:bold>10e</ce:bold> could maintain a binding mode similar to AT9832, although it had a less binding affinity. Overall, compound <ce:bold>10e</ce:bold> is a potential anticancer agent that exhibits potent JAK 2/3 and aurora A/B kinases multi-targeted inhibitors.</ce:para>
               </ce:section>
               <ce:section id="sec4" view="all">
                  <ce:label>4</ce:label>
                  <ce:section-title id="sectitle0080">Experimental</ce:section-title>
                  <ce:section id="sec4.1" view="all">
                     <ce:label>4.1</ce:label>
                     <ce:section-title id="sectitle0085">Chemistry</ce:section-title>
                     <ce:para id="p0135" view="all">Unless otherwise noted, all reagents were purchased from commercial sources and used without further purification. All compounds were routinely monitored by thin-layer chromatography with silica gel GF-254 glass plates and viewed under UV light at 254 nm. The <ce:sup loc="post">1</ce:sup>H NMR and <ce:sup loc="post">13</ce:sup>C NMR spectra were determined in DMSO‑<ce:italic>d</ce:italic>
                        <ce:inf loc="post">6</ce:inf> on a JNM-ECZ400 s/L spectrometer. Chemical shifts (<ce:italic>δ</ce:italic>) were reported in parts per million (ppm) relative to tetramethylsilane (TMS), which was used as an internal standard. The mass spectra (MS) were obtained from Agilent 1100LC/MS Spectrometry Services. HR-MS was obtained using a Q-tof high resolution mass spectrometer. The purity was obtained using Agilent 1260 HPLC instrument with ZORBAX SB-C18 chromatographic column. Melting point was obtained using X-4A melting point analyzer.</ce:para>
                     <ce:section id="sec4.1.1" view="all">
                        <ce:label>4.1.1</ce:label>
                        <ce:section-title id="sectitle0090">4-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-3-carboxylic acid (2)</ce:section-title>
                        <ce:para id="p0140" view="all">To a solution of 4-nitropyrazole-3-carboxylicacid (5.0 g, 31.8 mmol) in THF (40 mL) was added 3,4-dihydro-2H-pyran (DHP, 8.04 g, 95.5 mmol) and p-toluenesulfonic acid monohydrate (PTSA, 0.30 g, 0.15 mmol). The reaction mixture was stirred at RT and monitored by thin layer chromatography. After completion of the reaction, the solvent was removed under vacuum and the product was dissolved in water (30 mL), and washed with acetic ether (3 × 20 mL). The organic layer was washed with saline (50 mL) and was dried (anhydrous sodium sulfate). The solvent was removed under vacuum and the crude product was purified by chromatographic column to afford 7.29 g compound <ce:bold>2</ce:bold>. Light yellow oil, yield: 95%.<ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) <ce:italic>δ</ce:italic> (ppm):8.50 (s, 1H), 5.48 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 1H), 4.11 (d, <ce:italic>J</ce:italic> = 12.0 Hz, 1H), 3.74 (t, <ce:italic>J</ce:italic> = 12.0 Hz, 1H), 2.29 (d, <ce:italic>J</ce:italic> = 11.8 Hz, 1H), 1.99 (s, 1H), 1.87 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 1H), 1.68 (s, 3H).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.2" view="all">
                        <ce:label>4.1.2</ce:label>
                        <ce:section-title id="sectitle0095">1-(4-(bromomethyl)phenyl)ethan-1-one (4)</ce:section-title>
                        <ce:para id="p0145" view="all">The mixture of 4′-methylacetophenone (10 mL, 74.5 mmol), NBS(14.6 g, 82.0 mmol), AIBN(1.23 g, 7.49 mmol) and 80 mL acetonitrile was stirred at 90 °C under argon atmosphere for 4 h, then concentrated under vacuum to give a residue which was dissolved in water (30 mL) and washed with dichloromethane (3 × 50 mL). The dichloromethane solution was washed with 1 M hydrochloric acid solution (50 mL), saturated sodium bicarbonate solution and brine (3 × 50 mL), dried over anhydrous sodium sulfate and concentrated. The crude product was recrystallized from ethyl acetate (25.5 mL) and petroleum ether (255 mL) to afford 15.1 g pure product. White solid, yield: 95%. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) <ce:italic>δ</ce:italic> (ppm):7.92 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 2H), 7.47 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 2H), 4.49 (s, 2H), 2.60 (s, 3H).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.3" view="all">
                        <ce:label>4.1.3</ce:label>
                        <ce:section-title id="sectitle0100">General procedure for the preparation of the compounds (<ce:bold>5</ce:bold>)</ce:section-title>
                        <ce:para id="p0150" view="all">To a solution of compound <ce:bold>4</ce:bold> (31.8 mmol) in acetonitrile (30 mL) was added potassium carbonate (23.5 mmol), catalytic amount of potassium iodide and different secondary amines (23.5 mmol). The reaction mixture was stirred at 90 °C for 4h, then concentrated under vacuum to give a residue which was purified by chromatographic column.</ce:para>
                        <ce:section id="sec4.1.3.1" view="all">
                           <ce:label>4.1.3.1</ce:label>
                           <ce:section-title id="sectitle0105">1-(4-(morpholinomethyl)phenyl)ethan-1-one (<ce:bold>5a</ce:bold>)</ce:section-title>
                           <ce:para id="p0155" view="all">Yield: 90%. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>-<ce:italic>d6</ce:italic>) <ce:italic>δ</ce:italic> (ppm):7.88 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 2H), 7.41 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 2H), 3.68 (s, 4H), 3.52 (s, 2H), 2.56 (s, 3H), 2.42 (s, 4H). HR-MS (calculated for C<ce:inf loc="post">13</ce:inf>H<ce:inf loc="post">18</ce:inf>NO<ce:inf loc="post">2</ce:inf> (M + H)<ce:sup loc="post">+</ce:sup> 220.1337; found 220.1334) (<ce:cross-ref id="crosref0385" refid="fig4">Fig. 4</ce:cross-ref>
                              <ce:float-anchor refid="fig4"/></ce:float-anchor>).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.2" view="all">
                           <ce:label>4.1.3.2</ce:label>
                           <ce:section-title id="sectitle0110">1-(4-(piperidin-1-ylmethyl)phenyl)ethan-1-one (<ce:bold>5b</ce:bold>)</ce:section-title>
                           <ce:para id="p0160" view="all">Yield: 90%. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>-<ce:italic>d6</ce:italic>) <ce:italic>δ</ce:italic> (ppm):7.89 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 2H), 7.41 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 2H), 3.51 (s, 2H), 2.57 (s, 3H), 2.37 (s, 4H), 1.54–1.60 (m, 4H), 1.43 (d, <ce:italic>J</ce:italic> = 4.0 Hz, 2H). HR-MS (calculated for C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">20</ce:inf>NO (M + H)<ce:sup loc="post">+</ce:sup> 218.1545; found 218.1542).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.3" view="all">
                           <ce:label>4.1.3.3</ce:label>
                           <ce:section-title id="sectitle0115">1-(4-(pyrrolidin-1-ylmethyl)phenyl)ethan-1-one (<ce:bold>5c</ce:bold>)</ce:section-title>
                           <ce:para id="p0165" view="all">Yield: 84%. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>-<ce:italic>d6</ce:italic>) <ce:italic>δ</ce:italic> (ppm):7.88 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 2H), 7.41 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 2H), 3.65 (s, 2H), 2.57 (s, 3H), 2.50 (s, 4H), 1.77 (s, 4H). HR-MS (calculated for C<ce:inf loc="post">13</ce:inf>H<ce:inf loc="post">18</ce:inf>NO (M + H)<ce:sup loc="post">+</ce:sup> 204.1388; found 204.1381).</ce:para>
                        </ce:section>
                     </ce:section>
                     <ce:section id="sec4.1.4" view="all">
                        <ce:label>4.1.4</ce:label>
                        <ce:section-title id="sectitle0120">General procedure for the preparation of the compounds (<ce:bold>6</ce:bold>)</ce:section-title>
                        <ce:para id="p0170" view="all">To a solution of compound <ce:bold>5</ce:bold> (0.48 mmol) in 48% HBr solution (2 mL) was added 0.96 mL bromine (0.5 M in acetic acid) at 60 °C. After completion of the reaction, the solvent was removed under vacuum and the product was used for the next step without being purified.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.5" view="all">
                        <ce:label>4.1.5</ce:label>
                        <ce:section-title id="sectitle0125">General procedure for the preparation of the compounds (<ce:bold>7</ce:bold>)</ce:section-title>
                        <ce:para id="p0175" view="all">To a solution of compound <ce:bold>2</ce:bold> (10 mmol), potassium carbonate (10 mmol) and catalytic amount of potassium in acetonitrile (10 mL) was added compound <ce:bold>6</ce:bold> (10 mmol) at RT. The mixture was stirred overnight, then filtered. The filtrate was removed under vacuum and the crude product was purified by chromatographic column to afford compound <ce:bold>7</ce:bold>.</ce:para>
                        <ce:section id="sec4.1.5.1" view="all">
                           <ce:label>4.1.5.1</ce:label>
                           <ce:section-title id="sectitle0130">2-Oxo-2-(4-(pyrrolidin-1-ylmethyl)phenyl)ethyl 4-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrrole-3-carboxylate (<ce:bold>7c</ce:bold>)</ce:section-title>
                           <ce:para id="p0180" view="all">Yield: 63%. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>-<ce:italic>d6</ce:italic>) <ce:italic>δ</ce:italic> (ppm):8.42 (s, 1H), 7.91 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 2H), 7.53 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 2H), 5.61 (s, 2H), 5.46 (d, <ce:italic>J</ce:italic> = 9.2 Hz, 1H), 4.09 (d, <ce:italic>J</ce:italic> = 11.6 Hz, 1H), 3.79 (s, 2H), 3.70–3.75 (m, 1H), 2.65 (s, 4H), 2.23–2.27 (m, 1H), 1.85–2.03 (m, 6H), 1.68 (s, 3H). HR-MS (calculated for C<ce:inf loc="post">22</ce:inf>H<ce:inf loc="post">27</ce:inf>N<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">6</ce:inf> (M + H)<ce:sup loc="post">+</ce:sup> 443.1930; found 443.1921).</ce:para>
                        </ce:section>
                     </ce:section>
                     <ce:section id="sec4.1.6" view="all">
                        <ce:label>4.1.6</ce:label>
                        <ce:section-title id="sectitle0135">General procedure for the preparation of the compounds (<ce:bold>8</ce:bold>)</ce:section-title>
                        <ce:para id="p0185" view="all">To a solution of compound <ce:bold>7</ce:bold> (10 mmol) in acetic acid (30 mL) was added ammonium acetate (120 mmol). The mixture was stirred 130 °C for 4 h. Then the solvent was removed under vacuum and the residue was poured slowly into saturated sodium bicarbonate solution while stirring constantly. The solid formed was filtered off and purified by chromatographic column to afford compound <ce:bold>8</ce:bold>.</ce:para>
                        <ce:section id="sec4.1.6.1" view="all">
                           <ce:label>4.1.6.1</ce:label>
                           <ce:section-title id="sectitle0140">4-(4-(2-(4-nitro-1H-pyrazol-3-yl)-1H-imidazol-4-yl)benzyl)morpholine (<ce:bold>8a</ce:bold>)</ce:section-title>
                           <ce:para id="p0190" view="all">Yellow solid, Yield: 46.2%. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm):8.59 (s, 1H), 7.78 (s, 3H), 7.29 (d, <ce:italic>J</ce:italic> = 4.0 Hz, 2H), 3.55 (s, 4H), 3.44 (s, 2H), 2.34 (s, 4H). HR-MS (calculated for C<ce:inf loc="post">17</ce:inf>H<ce:inf loc="post">19</ce:inf>N<ce:inf loc="post">6</ce:inf>O<ce:inf loc="post">3</ce:inf> (M + H)<ce:sup loc="post">+</ce:sup> 355.1518; found 355.1512).</ce:para>
                        </ce:section>
                     </ce:section>
                     <ce:section id="sec4.1.7" view="all">
                        <ce:label>4.1.7</ce:label>
                        <ce:section-title id="sectitle0145">General procedure for the preparation of the compounds (<ce:bold>9</ce:bold>)</ce:section-title>
                        <ce:para id="p0195" view="all">A solution of compound <ce:bold>8</ce:bold> (4 mmol) and 10% Pd/C (1.3 mmol) in 40 mL methanol under hydrogen was stirred at 40 °C for 12 h. Then the mixture was cool to RT, then filtered. The filtrate was removed under vacuum and the crude product was used for next step without being purified.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.8" view="all">
                        <ce:label>4.1.8</ce:label>
                        <ce:section-title id="sectitle0150">General procedure for the preparation of the target compounds (<ce:bold>10a-10i</ce:bold>)</ce:section-title>
                        <ce:para id="p0200" view="all">To a solution of compound <ce:bold>9</ce:bold> (1.67 mmol) in dichloromethane (10 mL) was added triethylamine (2 mmol), then added the solution of acyl chloride (2 mmol) in dichloromethane (5 mL) drop by drop at 0 °C. The mixture was heated to RT and stirred for 4h. After completion of the reaction, the solvent was removed under vacuum and the residue was dissolved in water (10 mL) and extracted with acetic ether (3 × 20 mL). The acetic ether solution was washed with brine (50 mL), dried over anhydrous sodium sulfate and concentrated. The crude product was purified by chromatographic column to afford the target compounds.</ce:para>
                        <ce:section id="sec4.1.8.1" view="all">
                           <ce:label>4.1.8.1</ce:label>
                           <ce:section-title id="sectitle0155">N-(3-(4-(4-(morpholinomethyl)phenyl)-1H-imidazol-2-yl)-1H-pyrazol-4-yl)benzamide (<ce:bold>10a</ce:bold>)</ce:section-title>
                           <ce:para id="p0205" view="all">While solid, yield 31.3%, Mp 220.7–221.3 °C. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 11.55 (s, 1H), 8.29 (s, 1H), 8.04 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 2H), 7.81 (d, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 7.59–7.67 (m, 4H), 7.33 (d, <ce:italic>J</ce:italic> = 7.4 Hz, 2H), 3.56 (s, 4H), 3.46 (s, 2H), 2.34 (s, 4H);<ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm):163.23, 142.61, 140.34, 134.55, 134.42, 132.56, 131.95, 129.89, 129.51, 127.43, 127.30, 124.95, 124.72, 120.16, 120.03, 66.49, 62.62, 53.44; HR-MS (calculated for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">25</ce:inf>N<ce:inf loc="post">6</ce:inf>O<ce:inf loc="post">2</ce:inf> (M + H)<ce:sup loc="post">+</ce:sup> 429.2039; found 429.2028); purity: 96.84%.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.8.2" view="all">
                           <ce:label>4.1.8.2</ce:label>
                           <ce:section-title id="sectitle0160">4-methoxy-N-(3-(4-(4-(morpholinomethyl)phenyl)-1H-imidazol-2-yl)-1H-pyrazol-4-yl)benzamide (<ce:bold>10b</ce:bold>)</ce:section-title>
                           <ce:para id="p0210" view="all">While solid, yield 14.5%, Mp 283.6–284.0 °C. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm):12.98 (s, 1H), 12.97 (s, 1H), 11.42 (s, 1H), 8.26 (s, 1H), 7.99 (d, <ce:italic>J</ce:italic> = 8.8 Hz,2H), 7.81 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H), 7.67 (s, 1H), 7.35 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 2H), 7.12 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 2H), 3.87 (s, 3H), 3.55 (t, <ce:italic>J</ce:italic> = 4.0 4H), 3.47 (s, 2H), 2.35 (s, 4H); <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm):162.91, 162.67, 140.39, 136.61, 133.44, 129.86, 129.28, 129.12, 127.97, 126.70, 124.76, 120.41, 114.67, 113.64, 109.79, 66.77, 62.74, 56.05, 53.71; HR-MS (calculated for C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">27</ce:inf>N<ce:inf loc="post">6</ce:inf>O<ce:inf loc="post">3</ce:inf> (M + H)<ce:sup loc="post">+</ce:sup> 459.2144; found 459.2137); purity:97.83%.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.8.3" view="all">
                           <ce:label>4.1.8.3</ce:label>
                           <ce:section-title id="sectitle0165">4-methoxy-N-(3-(4-(4-(morpholinomethyl)phenyl)-1H-imidazol-2-yl)-1H-pyrazol-4-yl)benzamide (<ce:bold>10c</ce:bold>)</ce:section-title>
                           <ce:para id="p0215" view="all">Yellow solid, yield 26.6%, Mp 273.8–274.1 °C. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm):13.09 (s, 1H), 12.96 (s, 1H), 11.71 (s, 1H), 8.39 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 1H), 8.32 (s, 1H), 8.24 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 1H), 7.78 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 2H), 7.67 (s, 1H), 7.32 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 2H), 3.56 (s, 4H), 3.46 (s, 2H), 2.35 (s, 4H); <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm):161.63, 149.99, 142.41, 140.47, 140.09, 136.64, 133.32, 132.17, 129.77, 128.98, 124.86, 124.61, 120.47, 119.79, 113.71, 66.51, 62.90, 53.72; HR-MS (calculated for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">24</ce:inf>N<ce:inf loc="post">7</ce:inf>O<ce:inf loc="post">4</ce:inf> (M + H)<ce:sup loc="post">+</ce:sup> 474.1890; found 474.1881); purity: 95.72%.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.8.4" view="all">
                           <ce:label>4.1.8.4</ce:label>
                           <ce:section-title id="sectitle0170">4-chloro-N-(3-(4-(4-(morpholinomethyl)phenyl)-1H-imidazol-2-yl)-1H-pyrazol-4-yl)benzamide (<ce:bold>10d</ce:bold>)</ce:section-title>
                           <ce:para id="p0220" view="all">While solid, yield 23.6%, Mp 296.7–297.1 °C. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm):11.52 (s, 1H), 8.28 (s, 1H), 8.03 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H), 7.78 (d, <ce:italic>J</ce:italic> = 8.0 Hz,2H), 7.66 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 3H), 7.35 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 2H), 3.56 (s, 4H), 3.47 (s, 2H), 2.35 (s, 4H); <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm):162.28, 142.65, 140.45, 137.35, 133.44, 133.28, 131.98, 129.91, 129.55. 129.32, 129.21, 124.79, 120.24, 120.00, 113.62, 66.63, 62.80, 53.67; HR-MS (calculated for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">24</ce:inf>ClN<ce:inf loc="post">6</ce:inf>O<ce:inf loc="post">2</ce:inf> (M + H)<ce:sup loc="post">+</ce:sup> 463.1649; found 463.1639); purity: 96.33%.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.8.5" view="all">
                           <ce:label>4.1.8.5</ce:label>
                           <ce:section-title id="sectitle0175">3-chloro-N-(3-(4-(4-(morpholinomethyl)phenyl)-1H-imidazol-2-yl)-1H-pyrazol-4-yl)benzamide (<ce:bold>10e</ce:bold>)</ce:section-title>
                           <ce:para id="p0225" view="all">While solid, yield 27.3%, Mp 266.4–266.8 °C. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 11.47 (s, 1H), 8.31 (s, 1H), 8.00 (s, 2H), 7.63–7.82 (m, 5H), 7.32 (d, <ce:italic>J</ce:italic> = 4.8 Hz, 2H), 3.55 (s, 4H), 3.45 (s, 2H), 2.34 (s, 4H); <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm):161.84, 142.63, 140.50, 136.44, 134.33, 133.40, 132.44, 132.04, 131.54, 129.89, 126.92, 126.46, 125.02, 124.71, 120.34, 119.86, 113.74, 66.49, 62.71, 53.65; HR-MS (calculated for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">24</ce:inf>ClN<ce:inf loc="post">6</ce:inf>O<ce:inf loc="post">2</ce:inf> (M + H)<ce:sup loc="post">+</ce:sup> 463.1649; found 463.1630); purity: 95.26%.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.8.6" view="all">
                           <ce:label>4.1.8.6</ce:label>
                           <ce:section-title id="sectitle0180">4-nitro-N-(3-(4-(4-(pyrrolidin-1-ylmethyl)phenyl)-1H-imidazol-2-yl)-1H-pyrazol-4-yl)benzamide (<ce:bold>10f</ce:bold>)</ce:section-title>
                           <ce:para id="p0230" view="all">Yellow solid, yield 23.6%. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm):13.10 (s, 1H), 11.60 (s, 1H), 10.78 (s, 1H), 8.43 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H), 8.37 (s, 1H), 8.29 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 2H), 7.93 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 2H), 7.84 (s, 1H), 7.64 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 2H), 4.37 (d, <ce:italic>J</ce:italic> = 4.4 Hz, 2H), 3.08 (s, 2H), 2.50 (s, 2H), 2.03 (s, 1H), 1.89 (s, 1H); <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm):161.65, 149.98, 142.62, 140.14, 140.07, 134.53, 132.13, 130.73, 129.00, 125.00, 124.79, 124.42, 120.72, 119.89, 114.34, 58.36, 53.38, 23.30; HR-MS (calculated for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">24</ce:inf>N<ce:inf loc="post">7</ce:inf>O<ce:inf loc="post">3</ce:inf> (M + H)<ce:sup loc="post">+</ce:sup> 458.1949; found 458.1937).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.8.7" view="all">
                           <ce:label>4.1.8.7</ce:label>
                           <ce:section-title id="sectitle0185">4-methoxy-N-(3-(4-(4-(piperidin-1-ylmethyl)phenyl)-1H-imidazol-2-yl)-1H-pyrazol-4-yl)benzamide (<ce:bold>10g</ce:bold>)</ce:section-title>
                           <ce:para id="p0235" view="all">While solid, yield 18.3%, Mp 242.7–243.4 °C. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm):11.42 (s, 1H), 8.26 (s, 1H), 8.00 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H), 7.81 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 2H), 7.66 (s, 1H), 7.34 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 2H), 7.11 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H), 3.86 (s, 3H), 3.46 (s, 2H), 2.34 (s, 4H), 1.48 (s, 4H), 1.36 (s, 2H); <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm):162.90, 162.61, 142.75, 140.42, 133.38, 131.79, 129.81, 129.30, 129.18, 126.73, 124.70, 120.38, 119.82, 114.65, 113.58, 62.63, 56.04, 54.30, 25.99, 24.45; HR-MS (calculated for C<ce:inf loc="post">26</ce:inf>H<ce:inf loc="post">29</ce:inf>N<ce:inf loc="post">6</ce:inf>O<ce:inf loc="post">2</ce:inf> (M + H)<ce:sup loc="post">+</ce:sup> 457.2352; found 457.2346); purity: 97.20%.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.8.8" view="all">
                           <ce:label>4.1.8.8</ce:label>
                           <ce:section-title id="sectitle0190">4-chloro-N-(3-(4-(4-(piperidin-1-ylmethyl)phenyl)-1H-imidazol-2-yl)-1H-pyrazol-4-yl)benzamide (<ce:bold>10h</ce:bold>)</ce:section-title>
                           <ce:para id="p0240" view="all">While solid, yield 14.2%, Mp 292.8–293.1 °C. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm):11.43 (s, 1H), 10.66 (s, 1H), 8.34 (s, 1H), 8.01–8.05 (m, 2H), 7.96 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 2H), 7.84 (s, 1H), 7.76 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 1H), 7.71 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 1H), 7.66 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 2H), 4.25 (s, 2H), 3.33 (s, 3H), 2.83 (s, 2H), 1.67–1.78 (m, 5H), 1.36 (s, 1H); <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm):161.15, 142.20, 139.22, 135.67, 134.79, 133.70, 131.67, 131.24, 130.86, 126.20, 125.76, 124.20, 119.69, 119.16, 114.04, 58.60, 51.35, 22.05, 21.35; HR-MS (calculated for C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">26</ce:inf>ClN<ce:inf loc="post">6</ce:inf>O (M + H)<ce:sup loc="post">+</ce:sup> 461.1856; found 461.1850); purity: 99.50%.</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.8.9" view="all">
                           <ce:label>4.1.8.9</ce:label>
                           <ce:section-title id="sectitle0195">3-chloro-N-(3-(4-(4-(piperidin-1-ylmethyl)phenyl)-1H-imidazol-2-yl)-1H-pyrazol-4-yl)benzamide (<ce:bold>10i</ce:bold>)</ce:section-title>
                           <ce:para id="p0245" view="all">While solid, yield 19.4%, Mp 259.9–261.3 °C. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm):11.43 (s, 1H), 10.68 (s, 1H), 8.34 (s, 1H), 8.01–8.05 (m, 2H), 7.96 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 2H), 7.84 (s, 1H), 7.76 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 1H), 7.71 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 1H), 7.66 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 2H), 4.25 (s, 2H), 3.29 (s, 2H), 2.84 (s, 2H), 1.78 (s, 4H), 1.67 (s, 1H), 1.36 (s, 1H); <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm):161.15, 142.20, 139.22, 135.67, 134.79, 133.70, 131.67, 131.24, 130.86, 126.20, 125.76, 124.41, 124.20, 119.69, 119.48, 119.26, 114.04, 58.60, 51.35, 22.05, 21.35; HR-MS (calculated for C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">26</ce:inf>ClN<ce:inf loc="post">6</ce:inf>O (M + H)<ce:sup loc="post">+</ce:sup> 461.1856; found 461.1836); purity: 97.01%.</ce:para>
                        </ce:section>
                     </ce:section>
                     <ce:section id="sec4.1.9" view="all">
                        <ce:label>4.1.9</ce:label>
                        <ce:section-title id="sectitle0200">6-chloro-2-methyl-N-(3-(4-(4-(morpholinomethyl)phenyl)-1H-imidazol-2-yl)-1H-pyrazol-4-yl)pyrimidin-4-amine (<ce:bold>10j</ce:bold>)</ce:section-title>
                        <ce:para id="p0250" view="all">The mixture of compound 9 (0.32 g, 1.0 mmol), 4,6-dichloro-2-methylpyrimidine (0.13 g, 0.83 mmol), sodium iodide (0.15 g, 1.0 mmol), N,N-diisopropylethylamine (0.13 g, 1.0 mmol) and 3 mL DMF was stirred at 90 °C under argon atmosphere for 4 h. Then the mixture was cool to RT, poured in ice water (30 mL) and stirred for 30 min. The solid formed was filtered off and purified by chromatographic column to afford 0.131 g compound <ce:bold>10j</ce:bold>.</ce:para>
                        <ce:para id="p0255" view="all">While solid, yield 29.5%, Mp 287.2–287.7 °C.<ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm):10.02 (s, 1H), 8.37 (s, 1H), 7.84 (d, <ce:italic>J</ce:italic> = 7.2 Hz, 1H), 7.78 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 1H), 7.63 (s, 1H), 7.30 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 2H), 6.90 (s, 1H), 3.55 (s, 4H), 3.44 (s, 2H), 2.46–2.47 (m, 3H), 2.34 (s, 4H); <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm):168.46, 168.37, 164.49, 160.37, 142.33, 140.52, 136.27, 133.40, 129.88, 129.77, 124.90, 120.98, 120.11, 113.48, 66.51, 62.93, 53.71, 25.87; HR-MS (calculated for C<ce:inf loc="post">22</ce:inf>H<ce:inf loc="post">24</ce:inf>ClN<ce:inf loc="post">8</ce:inf>O (M + H)<ce:sup loc="post">+</ce:sup> 451.1761; found 451.1753); purity: 99.64%.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.10" view="all">
                        <ce:label>4.1.10</ce:label>
                        <ce:section-title id="sectitle0205">1-(4-(3-chloropropoxy)phenyl)ethan-1-one (<ce:bold>12</ce:bold>)</ce:section-title>
                        <ce:para id="p0260" view="all">To the solution of 4′-hydroxyacetophenone (1.36 g, 10 mmol) and 1-bromo-3-chloropropane (1.56 g, 10 mmol) in 10 mL acetonitrile was added potassium carbonate (1.38 g, 10 mmol) and catalytic amount of potassium. The mixture as stirred at 85 °C for 4 h, then was cool to RT and filtered. The filtrate was removed under vacuum and the crude product was purified by chromatographic column to afford 2.02 g compound <ce:bold>12</ce:bold> (yield 95.2%).<ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>-<ce:italic>d6</ce:italic>) <ce:italic>δ</ce:italic> (ppm):<ce:italic>δ</ce:italic> 7.91 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 2H), 6.91 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 2H), 4.16 (t, <ce:italic>J</ce:italic> = 6.0 Hz, 2H), 3.73 (t, <ce:italic>J</ce:italic> = 5.6 Hz, 2H), 2.53 (s, 3H), 2.21–2.27 (m, 2H); HR-MS (calculated for C<ce:inf loc="post">11</ce:inf>H<ce:inf loc="post">14</ce:inf>O<ce:inf loc="post">2</ce:inf>Cl (M + H)<ce:sup loc="post">+</ce:sup> 213.0682; found 213.0677).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.11" view="all">
                        <ce:label>4.1.11</ce:label>
                        <ce:section-title id="sectitle0210">1-(4-(3-morpholinopropoxy)phenyl)ethan-1-one (<ce:bold>13</ce:bold>)</ce:section-title>
                        <ce:para id="p0265" view="all">To a solution of compound <ce:bold>12</ce:bold> (2.12 g, 10 mmol) and morpholine (0.87 g, 10 mmol) in acetonitrile (10 mL) was added potassium carbonate (1.38 g, 10 mmol), catalytic amount of potassium iodide. The reaction mixture was stirred at 85 °C for 4h, then concentrated under vacuum and the residue was purified by chromatographic column to give 2.2 g compound <ce:bold>13</ce:bold> (yield 83.6%).<ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>-<ce:italic>d6</ce:italic>) <ce:italic>δ</ce:italic> (ppm):7.89 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 2H), 6.90 (d, <ce:italic>J</ce:italic> = 12 Hz, 2H), 3.99–4.08 (m, 1H), 3.63–3.70 (m, 3H), 2.48–2.52 (m, 3H), 2.39–2.45 (m, 4H), 1.91–2.00 (m, 2H); HR-MS (calculated for C<ce:inf loc="post">15</ce:inf>H<ce:inf loc="post">22</ce:inf>NO<ce:inf loc="post">3</ce:inf> (M + H)<ce:sup loc="post">+</ce:sup> 264.1599; found 264.1596) (<ce:cross-ref id="crosref0390" refid="fig5">Fig. 5</ce:cross-ref>
                           <ce:float-anchor refid="fig5"/></ce:float-anchor>).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.12" view="all">
                        <ce:label>4.1.12</ce:label>
                        <ce:section-title id="sectitle0215">2-bromo-1-(4-(3-morpholinopropoxy)phenyl)ethan-1-one (<ce:bold>14</ce:bold>)</ce:section-title>
                        <ce:para id="p0270" view="all">To a solution of compound <ce:bold>13</ce:bold> (2.63 g, 10 mmol) in 48% HBr solution (20 mL) was added 20 mL solution of bromine in acetic acid(0.5 M) at 60 °C. After completion of the reaction, the solvent was removed under vacuum and the product was used for the next step without being purified.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.13" view="all">
                        <ce:label>4.1.13</ce:label>
                        <ce:section-title id="sectitle0220">2-(4-(3-morpholinopropoxy)phenyl)-2-oxoethyl 4-nitro-1H-pyrazole-3-carboxylate (<ce:bold>15</ce:bold>)</ce:section-title>
                        <ce:para id="p0275" view="all">To a solution of compound <ce:bold>2</ce:bold> (2.41 g, 10 mmol), potassium carbonate (1.38 g, 10 mmol) and catalytic amount of potassium in acetonitrile (10 mL) was added compound <ce:bold>14</ce:bold> (4.21 g, 10 mmol) at RT. The mixture was stirred overnight, then filtered. The filtrate was removed under vacuum and the crude product was purified by chromatographic column to afford 3.26 g compound <ce:bold>15</ce:bold> (yield 65.0%).<ce:sup loc="post">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>-<ce:italic>d6</ce:italic>) <ce:italic>δ</ce:italic> (ppm):8.40 (s, 1H), 7.90 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 2H), 6.94 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 2H), 5.57 (s, 2H), 5.45 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 1H), 4.09 (t, <ce:italic>J</ce:italic> = 8.0 Hz, 3H), 3.71 (s, 5H), 2.53 (t, <ce:italic>J</ce:italic> = 8.0 Hz, 3H), 2.48 (s, 3H), 2.20–2.25 (m, 1H), 1.87–2.01 (m, 4H), 1.66 (s, 3H); HR-MS (calculated for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">31</ce:inf>N<ce:inf loc="post">4</ce:inf>O<ce:inf loc="post">8</ce:inf> (M + H)<ce:sup loc="post">+</ce:sup> 503.2142; found 503.2130).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.14" view="all">
                        <ce:label>4.1.14</ce:label>
                        <ce:section-title id="sectitle0225">2-(4-(3-morpholinopropoxy)phenyl)-2-oxoethyl 4-nitro-1H-pyrazole-3-carboxylate (<ce:bold>16</ce:bold>)</ce:section-title>
                        <ce:para id="p0280" view="all">To a solution of compound <ce:bold>15</ce:bold> (5.02 g, 10 mmol) in acetic acid (25 mL) was added ammonium acetate (9.24 g, 120 mmol). The mixture was stirred 125 °C for 4 h. Then the solvent was removed under vacuum and the residue was poured slowly into saturated sodium bicarbonate solution while stirring constantly. The solid formed was filtered off and used for next step without being purified.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.15" view="all">
                        <ce:label>4.1.15</ce:label>
                        <ce:section-title id="sectitle0230">2-(4-(3-morpholinopropoxy)phenyl)-2-oxoethyl 4-nitro-1H-pyrazole-3-carboxylate (<ce:bold>17</ce:bold>)</ce:section-title>
                        <ce:para id="p0285" view="all">A solution of compound <ce:bold>16</ce:bold> (1.59 g, 4 mmol) and 10% Pd/C (0.14 g, 1.3 mmol) in 40 mL methanol under hydrogen was stirred at 40 °C for 12 h. Then the mixture was cool to RT, then filtered. The filtrate was removed under vacuum and the crude product was used for next step without being purified.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.16" view="all">
                        <ce:label>4.1.16</ce:label>
                        <ce:section-title id="sectitle0235">General procedure for the preparation of the target compounds (<ce:bold>18a</ce:bold>)</ce:section-title>
                        <ce:para id="p0290" view="all">The mixture of compound <ce:bold>17</ce:bold> (1.0 mmol), chlor pyrimidine derivative (0.83 mmol), sodium iodide (0.15 g, 1.0 mmol), N,N-diisopropylethylamine (0.13 g, 1.0 mmol) and 5 mL DMF was stirred at 90 °C under argon atmosphere for 4 h. Then the mixture was cool to RT, poured in ice water (50 mL) and stirred for 30 min, and extracted with ethyl acetate (3 × 40 mL). The combined organic layer was washed with brine (2 × 100 mL) and dried (Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>). The solvent was removed under vacuum and the product was purified by chromatographic column.</ce:para>
                        <ce:section id="sec4.1.16.1" view="all">
                           <ce:label>4.1.16.1</ce:label>
                           <ce:section-title id="sectitle0240">6-chloro-5-methyl-2-(methylthio)-N-(3-(5-(4-(3-morpholinopropoxy) phenyl)-1H-imidazol-2-yl)-1H-pyrazol-4-yl) pyrimidin-4-amine (<ce:bold>18a</ce:bold>)</ce:section-title>
                           <ce:para id="p0295" view="all">While solid, yield 24.0%, Mp 245.3–245.9 °C. <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm):<ce:italic>δ</ce:italic> 10.38 (s, 1H), 8.30 (s, 1H), 7.74 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 2H), 7.55 (s, 1H), 6.94 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 2H), 4.01 (t, <ce:italic>J</ce:italic> = 4.0 Hz, 2H), 3.56 (s, 4H), 2.53 (s, 5H), 2.28–2.40 (m, 7H), 1.87 (s, 2H); <ce:sup loc="post">13</ce:sup>C NMR (100 MHz, DMSO‑<ce:italic>d</ce:italic>
                              <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> (ppm):168.76, 158.08, 156.58, 143.25, 142.40, 140.58, 127.31, 126.61, 126.21, 120.54, 119.88, 115.10, 112.58, 107.52, 66.58, 66.28, 55.36, 53.82, 26.32, 14.34, 13.04; HR-MS (calculated for C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">30</ce:inf>N<ce:inf loc="post">8</ce:inf>O<ce:inf loc="post">2</ce:inf>SCl (M + H)<ce:sup loc="post">+</ce:sup> 541.1901; found 541.1897); purity: 99.72%.</ce:para>
                        </ce:section>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec4.2" view="all">
                     <ce:label>4.2</ce:label>
                     <ce:section-title id="sectitle0245">Biological evaluation</ce:section-title>
                     <ce:section id="sec4.2.1" view="all">
                        <ce:label>4.2.1</ce:label>
                        <ce:section-title id="sectitle0250">
                           <ce:italic>In vitro</ce:italic> kinases assays</ce:section-title>
                        <ce:para id="p0300" view="all">Theses assays were carried out as described previously [<ce:cross-ref id="crosref0395" refid="bib53">53</ce:cross-ref>]. All of the enzymatic reactions were conducted at 30 °C for 40 min. The 50  μl reaction mixture contains 40 mM Tris, pH 7.4, 10 mM MgCl<ce:inf loc="post">2</ce:inf>, 0.1 mg/mL BSA, 1 mM DTT, 10 μM ATP, Kinase and the enzyme substrate. The compounds were diluted in 10% DMSO and 5  μl of the dilution was added to a 50  μl reaction so that the final concentration of DMSO is 1% in all of reactions. The assay was performed using Kinase-Glo Plus luminescence kinase assay kit. It measures kinase activity by quantitating the amount of ATP remaining in solution following a kinase reaction. The luminescent signal from the assay is correlated with the amount of ATP present and is inversely correlated with the amount of kinase activity. The IC<ce:inf loc="post">50</ce:inf> values were calculated using nonlinear regression with normalized dose-response fit using Prism GraphPad sofeware.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.2" view="all">
                        <ce:label>4.2.2</ce:label>
                        <ce:section-title id="sectitle0255">
                           <ce:italic>In vitro</ce:italic> anti-proliferative assays</ce:section-title>
                        <ce:para id="p0305" view="all">The cytotoxicity of each compound was determined using CCK-8 assay. Cells were seeded in 96-well plates and then treated with different concentrations of drugs. After 72 h of incubation, CCK-8 staining was performed to determine the OD value and calculate the inhibition rate. The IC<ce:inf loc="post">50</ce:inf> values were calculated by using LOGIT method.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.3" view="all">
                        <ce:label>4.2.3</ce:label>
                        <ce:section-title id="sectitle0260">Western blot</ce:section-title>
                        <ce:para id="p0310" view="all">Western blot analysis was performed according to previously published researches [<ce:cross-refs id="crosrefs0055" refid="bib44 bib45 bib46 bib47">44–47</ce:cross-refs>]. Cells were treated with compounds at different concentrations for 48h, then harvested and washed in ice-cold PBS, added cold RIPA buffer. The cells were centrifuged and the supernatant was collected as whole cell lysate. Protein concentration was determined by BCA method. Western blot analyses were conducted after separation by SDS/PAGE electrophoresis and transfer to nitrocellulose filter membrane. After blocking the membranes with 5% fat-free milk, primary antibody was added, shocked at 4 °C for overnight and washed with TBST. Then second antibody was added, shocked for 1h, washed with TBST. GAPDH was used as a loading control. The protein bands were visualized using the G: BOX chemiXR5.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.4" view="all">
                        <ce:label>4.2.4</ce:label>
                        <ce:section-title id="sectitle0265">Cell cycle assays</ce:section-title>
                        <ce:para id="p0315" view="all">Cells were treated with compounds at different concentrations for 48h and washed with PBS twice. 5 × 10<ce:sup loc="post">5</ce:sup> cells were collected, added 100 μL RNase A at 37 °C for 30 min, stained with propidium iodide (400 μL) at 4 °C for 30 min and then analyzed using flow cytometry.</ce:para>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec4.3" view="all">
                     <ce:label>4.3</ce:label>
                     <ce:section-title id="sectitle0270">Binding mechanism explored by molecular modeling</ce:section-title>
                     <ce:para id="p0320" view="all">In order to explore the binding mechanism of our active compound <ce:bold>10e</ce:bold>, an integrated molecular modeling approach, which combines the docking calculation and molecular dynamics (MD) simulations, was performed (<ce:cross-ref id="crosref0400" refid="appsec1">Fig S1</ce:cross-ref>). Initial ligand-protein complex structures were obtained using the Autodock Vina. The best binding pose obtained from AutoDock Vina was selected for further refinement using MD simulations. The final binding pose was identified by clustering the trajectories from MD simulations.</ce:para>
                     <ce:para id="p0325" view="all">AutoDock Vina (version 1.1.2) [<ce:cross-ref id="crosref0405" refid="bib54">54</ce:cross-ref>], which is a widely used molecular docking and virtual screening application, was selected to predict the binding pose of our active compound MZ-1E to the JAK2, JAK3, Aurora A and Aurora B, respectively. The compound AT9832 was chosen as reference. Corresponding X-ray structures of JAK2, JAK3, Aurora A and Aurora B were download from PDB with ID of 2W1I [<ce:cross-ref id="crosref0410" refid="bib55">55</ce:cross-ref>], 3ZEP [<ce:cross-ref id="crosref0415" refid="bib56">56</ce:cross-ref>], 2W1G [<ce:cross-ref id="crosref0420" refid="bib55">55</ce:cross-ref>] and 4AF3 [<ce:cross-ref id="crosref0425" refid="bib57">57</ce:cross-ref>], respectively. All non-protein atoms including water and ligand in the X-ray structures were deleted and polar hydrogen atoms were added using MGLTools (version 1.5.6) [<ce:cross-ref id="crosref0430" refid="bib58">58</ce:cross-ref>]. The center of the ligand in the X-ray structures was used as target binding site grid center for docking. SMILES of <ce:bold>10e</ce:bold> and AT9832 were converted to the PDBQT format using Open Babel (version 2.3.2) [<ce:cross-ref id="crosref0435" refid="bib59">59</ce:cross-ref>] with the following options: -gen3d and -p 7.0. Then, docking calculations were performed with AutoDock Vina to obtain the initial binding pose. The exhaustiveness parameter was set to 30. In order to validate the parameters and software, the compound AT9832 with experimental structures was docked into JAK2 and AURKA, respectively. The root mean square deviations (RMSDs) of the AT9832 between the calculated and crystal determined one are very small (below 1.0 Å) (<ce:cross-ref id="crosref0440" refid="appsec1">Fig S2</ce:cross-ref>), suggesting our docking protocol is reliable.</ce:para>
                     <ce:para id="p0330" view="all">Then, the best docking models of each system were used as initial structure for MD simulations. The missing hydrogen atoms were added using <ce:italic>tleap</ce:italic> in AMBER18 [<ce:cross-ref id="crosref0445" refid="bib60">60</ce:cross-ref>]. The ff14SB force field [<ce:cross-ref id="crosref0450" refid="bib61">61</ce:cross-ref>] and GAFF [<ce:cross-ref id="crosref0455" refid="bib62">62</ce:cross-ref>] were employed to model the protein and ligand, respectively. The kinase-ligand complex was solvated in a cubic box of TIP3P water molecules [<ce:cross-ref id="crosref0460" refid="bib63">63</ce:cross-ref>] with a minimum distance of 10 Å between the protein surface and box edge. The system was first energy minimized with 2 kcal/(mol Å<ce:sup loc="post">2</ce:sup>) harmonic position restraints applied on the heavy atoms of protein and ligand. Then, the system was heated from 0 to 300 K in the constant volume and temperature (NVT) canonical ensemble for 1 ns, imposing position restraints of 2.0 kcal/(mol Å<ce:sup loc="post">2</ce:sup>) on the heavy atoms of protein and ligand. The system was further equilibrated in the isothermal−isobaric (NPT) ensemble for 1 ns, reducing the position restraints to 1.0 kcal/(mol Å<ce:sup loc="post">2</ce:sup>). Finally, 300 ns production MD simulations were carried out in the NPT ensemble without any constraints. All the simulations were performed using the GPU version of AMBER18 [<ce:cross-ref id="crosref0465" refid="bib60">60</ce:cross-ref>]. The bond lengths of hydrogen–heavy atoms were constrained using the SHAKE algorithm [<ce:cross-ref id="crosref0470" refid="bib64">64</ce:cross-ref>]. A distance cutoff of 9.0 Å was used for the van der Waals and short-range electrostatic interactions. Long-range electrostatic interactions were computed with the particle-mesh Ewald summation method [<ce:cross-ref id="crosref0475" refid="bib65">65</ce:cross-ref>]. A 2-fs integration time step was used in all MD simulations.</ce:para>
                     <ce:para id="p0335" view="all">The MD simulations became stable after 150 ns as there were small fluctuations in the protein backbone RMSDs from 150 ns to 300 ns (<ce:cross-ref id="crosref0480" refid="appsec1">Fig S3</ce:cross-ref>). Thus, snapshots were extracted from the last 150ns MD trajectories to obtain refined binding pose and binding free energy (<ce:italic>ΔG</ce:italic>) calculation with MM/GBSA approach. The <ce:italic>ΔG</ce:italic> in the MM<ce:italic>/</ce:italic>GBSA approach was calculated according to equation <ce:cross-ref id="crosref0485" refid="fd1">(1)</ce:cross-ref>,<ce:display>
                           <ce:formula id="fd1">
                              <ce:label>(1)</ce:label>
                              <mml:math display="block" altimg="si1.svg" alttext="Equation 1.">
                                 <mml:mrow>
                                    <mml:mi>Δ</mml:mi>
                                    <mml:msub>
                                       <mml:mtext>G</mml:mtext>
                                       <mml:mrow>
                                          <mml:mi>b</mml:mi>
                                          <mml:mi>i</mml:mi>
                                          <mml:mi>n</mml:mi>
                                          <mml:mi>d</mml:mi>
                                          <mml:mi>i</mml:mi>
                                          <mml:mi>n</mml:mi>
                                          <mml:mi>g</mml:mi>
                                       </mml:mrow>
                                    </mml:msub>
                                    <mml:mo linebreak="badbreak">=</mml:mo>
                                    <mml:mi>Δ</mml:mi>
                                    <mml:mtext>H</mml:mtext>
                                    <mml:mo linebreak="goodbreak">−</mml:mo>
                                    <mml:mtext>T</mml:mtext>
                                    <mml:mi>Δ</mml:mi>
                                    <mml:mtext>S</mml:mtext>
                                    <mml:mo linebreak="goodbreak">=</mml:mo>
                                    <mml:mi>Δ</mml:mi>
                                    <mml:msub>
                                       <mml:mi>E</mml:mi>
                                       <mml:mrow>
                                          <mml:mi>e</mml:mi>
                                          <mml:mi>l</mml:mi>
                                          <mml:mi>e</mml:mi>
                                       </mml:mrow>
                                    </mml:msub>
                                    <mml:mo linebreak="goodbreak">+</mml:mo>
                                    <mml:mi>Δ</mml:mi>
                                    <mml:msub>
                                       <mml:mi>E</mml:mi>
                                       <mml:mrow>
                                          <mml:mi>v</mml:mi>
                                          <mml:mi>d</mml:mi>
                                          <mml:mi>w</mml:mi>
                                       </mml:mrow>
                                    </mml:msub>
                                    <mml:mo linebreak="goodbreak">+</mml:mo>
                                    <mml:mi>Δ</mml:mi>
                                    <mml:msub>
                                       <mml:mi>G</mml:mi>
                                       <mml:mrow>
                                          <mml:mi>g</mml:mi>
                                          <mml:mi>b</mml:mi>
                                       </mml:mrow>
                                    </mml:msub>
                                    <mml:mo linebreak="goodbreak">+</mml:mo>
                                    <mml:mi>Δ</mml:mi>
                                    <mml:msub>
                                       <mml:mi>G</mml:mi>
                                       <mml:mrow>
                                          <mml:mi>s</mml:mi>
                                          <mml:mi>u</mml:mi>
                                          <mml:mi>r</mml:mi>
                                          <mml:mi>f</mml:mi>
                                       </mml:mrow>
                                    </mml:msub>
                                    <mml:mo linebreak="goodbreak">−</mml:mo>
                                    <mml:mi>T</mml:mi>
                                    <mml:mi>Δ</mml:mi>
                                    <mml:mi>S</mml:mi>
                                 </mml:mrow>
                              </mml:math>
                           </ce:formula>
                        </ce:display>where Δ<ce:italic>E</ce:italic>
                        <ce:inf loc="post">vdw</ce:inf> and Δ<ce:italic>E</ce:italic>
                        <ce:inf loc="post">ele</ce:inf> were the non-bonded van der Waals and electrostatic interaction energies between the ligands and kinases in the gas phase, respectively. The Δ<ce:italic>G</ce:italic>
                        <ce:inf loc="post">gb</ce:inf> and Δ<ce:italic>G</ce:italic>
                        <ce:inf loc="post">surf</ce:inf> were the polar and non-polar interaction energies between the ligand and protein, respectively. The Δ<ce:italic>G</ce:italic>
                        <ce:inf loc="post">gb</ce:inf> was computed using the <ce:italic>pbsa</ce:italic> program in Amber 18 [<ce:cross-ref id="crosref0490" refid="bib60">60</ce:cross-ref>]. The dielectric constants of solvent and solute were set to 80.0 and 1.0, respectively. The OBC solvation model [<ce:cross-ref id="crosref0495" refid="bib66">66</ce:cross-ref>] was used in this study. The Δ<ce:italic>G</ce:italic>
                        <ce:inf loc="post">surf</ce:inf> term was calculated as:<ce:display>
                           <ce:formula id="fd2">
                              <ce:label>(2)</ce:label>
                              <mml:math display="block" altimg="si2.svg" alttext="Equation 2.">
                                 <mml:mrow>
                                    <mml:mi>Δ</mml:mi>
                                    <mml:msub>
                                       <mml:mi>G</mml:mi>
                                       <mml:mrow>
                                          <mml:mi>s</mml:mi>
                                          <mml:mi>u</mml:mi>
                                          <mml:mi>r</mml:mi>
                                          <mml:mi>f</mml:mi>
                                       </mml:mrow>
                                    </mml:msub>
                                    <mml:mo linebreak="badbreak">=</mml:mo>
                                    <mml:mi>γ</mml:mi>
                                    <mml:mo linebreak="goodbreak">∗</mml:mo>
                                    <mml:mi>S</mml:mi>
                                    <mml:mi>A</mml:mi>
                                    <mml:mi>S</mml:mi>
                                    <mml:mi>A</mml:mi>
                                    <mml:mo linebreak="goodbreak">+</mml:mo>
                                    <mml:mi>β</mml:mi>
                                 </mml:mrow>
                              </mml:math>
                           </ce:formula>
                        </ce:display>where SASA was the solvent accessible surface area as computed using the MSMS program [<ce:cross-ref id="crosref0500" refid="bib67">67</ce:cross-ref>]. The <mml:math altimg="si3.svg">
                           <mml:mi>γ</mml:mi>
                        </mml:math> and <mml:math altimg="si4.svg">
                           <mml:mi>β</mml:mi>
                        </mml:math> coefficients were set to 0.0072 kcal/(mol Å<ce:sup loc="post">2</ce:sup>) and 0 kcal/mol, respectively. The fluctuation of entropy is quite large, thus we do not include this energy term in the current study.</ce:para>
                  </ce:section>
               </ce:section>
            </ce:sections>
            <ce:conflict-of-interest id="coi0010" view="all">
               <ce:section-title id="sectitle0275">Declaration of competing interest</ce:section-title>
               <ce:para id="p0340" view="all">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</ce:para>
            </ce:conflict-of-interest>
            <ce:acknowledgment id="ack0010" view="all">
               <ce:section-title id="sectitle0280">Acknowledgment</ce:section-title>
               <ce:para id="p0345" view="all">The authors are grateful for the financial support by <ce:grant-sponsor id="gs1" sponsor-id="https://doi.org/10.13039/501100001809" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">National Natural Science Foundation of China</ce:grant-sponsor> (<ce:grant-number refid="gs1">81602951</ce:grant-number>); <ce:grant-sponsor id="gs2" sponsor-id="https://doi.org/10.13039/501100004608" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Natural Science Foundation of Jiangsu Province</ce:grant-sponsor> (<ce:grant-number refid="gs2">BK20130216</ce:grant-number>); <ce:grant-sponsor id="gs4" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Six talent peaks project in Jiangsu Province</ce:grant-sponsor>(<ce:grant-number refid="gs4">2016-SWYY-062</ce:grant-number>); <ce:grant-sponsor id="gs3" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Science and technology project of Xuzhou City</ce:grant-sponsor> (<ce:grant-number refid="gs3">KC16SG255</ce:grant-number>).</ce:para>
            </ce:acknowledgment>
            <ce:appendices view="all">
               <ce:section id="appsec1" view="extended">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0285">Supplementary data</ce:section-title>
                  <ce:para id="p0350" view="all">The following are the Supplementary data to this article:<ce:display>
                        <ce:e-component id="mmc1">
                           <ce:label>Multimedia component 1</ce:label>
                           <ce:alt-text id="alttext0015" role="short">Multimedia component 1</ce:alt-text>
                           <ce:link locator="mmc1" xlink:href="pii:S0223523420309065/mmc1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/46.1" xlink:type="simple"/></ce:link>
                        </ce:e-component>
                     </ce:display>
                     <ce:display>
                        <ce:e-component id="mmc2">
                           <ce:label>Multimedia component 2</ce:label>
                           <ce:alt-text id="alttext0020" role="short">Multimedia component 2</ce:alt-text>
                           <ce:link locator="mmc2" xlink:href="pii:S0223523420309065/mmc2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/46.1" xlink:type="simple"/></ce:link>
                        </ce:e-component>
                     </ce:display>
                  </ce:para>
               </ce:section>
               <ce:section id="appsec2" view="compact-standard">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0290">Supplementary data</ce:section-title>
                  <ce:para id="p0355" view="all">Supplementary data to this article can be found online at <ce:inter-ref id="intref0010" xlink:href="https://doi.org/10.1016/j.ejmech.2020.112934" xlink:type="simple">https://doi.org/10.1016/j.ejmech.2020.112934</ce:inter-ref>.</ce:para>
               </ce:section>
            </ce:appendices>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0295">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.Y.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.P.</ce:given-name>
                                 <ce:surname>Zhong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.T.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.Q.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.Y.</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of an orally available Janus kinase 3 selective covalent inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1054</sb:first-page>
                              <sb:last-page>1066</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0025">L.Y. Shi, Z.P. Zhong, X.T. Li, Y.Q. Zhou, Z.Y. Pan, Discovery of an orally available Janus kinase 3 selective covalent inhibitor, J. Med. Chem., 62 (2019) 1054-1066.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.Q.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.Y.</ce:given-name>
                                 <ce:surname>Diao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.T.</ce:given-name>
                                 <ce:surname>Luo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.Y.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.T.</ce:given-name>
                                 <ce:surname>Qi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.L.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.Y.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Ge</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.F.</ce:given-name>
                                 <ce:surname>Liang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.J.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Liang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.L.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.L.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.F.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis and structure-activity relationship study of aminopyridine derivatives as novel inhibitors of Janus kinase 2</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>29</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1507</sb:first-page>
                              <sb:last-page>1513</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0030">W.Q. Wang, Y.Y. Diao, W.J. Li, Y.T. Luo, T.Y. Yang, Y.Y. Zhao, T.T. Qi, F.L. Xu, X.Y. Ma, H. Ge, Y.F. Liang, Z.J. Zhao, X. Liang, R. Wang, L.L. Zhu, H.L. Li, Y.F. Xu, Design, synthesis and structure-activity relationship study of aminopyridine derivatives as novel inhibitors of Janus kinase 2, Bioorganic & Medicinal Chemistry Letters, 29 (2019) 1507-1513.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.S.A.</ce:given-name>
                                 <ce:surname>Elsayed</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Nielsen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.H.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Pommier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Agama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.S.</ce:given-name>
                                 <ce:surname>Low</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Cushman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Application of sequential palladium catalysis for the discovery of Janus kinase inhibitors in the benzo c pyrrolo 2,3-h 1,6 naphthyridin-5-one (BPN) series</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>10440</sb:first-page>
                              <sb:last-page>10462</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0035">M.S.A. Elsayed, J.J. Nielsen, S. Park, J. Park, Q.Y. Liu, C.H. Kim, Y. Pommier, K. Agama, P.S. Low, M. Cushman, Application of Sequential Palladium Catalysis for the Discovery of Janus Kinase Inhibitors in the Benzo c pyrrolo 2,3-h 1,6 naphthyridin-5-one (BPN) Series, Journal of Medicinal Chemistry, 61 (2018) 10440-10462.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Coppo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Flamant</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>De Mas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Jarrier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Guillier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.-L.</ce:given-name>
                                 <ce:surname>Bonnet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Lacout</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Guilhot</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Vainchenker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.G.</ce:given-name>
                                 <ce:surname>Turhan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>BCR-ABL activates STAT3 via JAK and MEK pathways in human cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Br. J. Haematol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>134</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>171</sb:first-page>
                              <sb:last-page>179</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0040">P. Coppo, S. Flamant, V. De Mas, P. Jarrier, M. Guillier, M.-L. Bonnet, C. Lacout, F. Guilhot, W. Vainchenker, A.G. Turhan, BCR-ABL activates STAT3 via JAK and MEK pathways in human cells, Br. J. Haematol., 134 (2006) 171-179.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Jung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.-R.</ce:given-name>
                                 <ce:surname>Kwon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.-J.</ce:given-name>
                                 <ce:surname>Jeong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.-O.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.J.</ce:given-name>
                                 <ce:surname>Sohn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Yun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.-H.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Apoptosis Induced by Tanshinone IIA and Cryptotanshinone Is Mediated by Distinct JAK/STAT3/5 and SHP1/2 Signaling in Chronic Myeloid Leukemia K562 Cells, Evidence-Based Complementary and Alternative Medicine</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2013</sb:date>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0045">J.H. Jung, T.-R. Kwon, S.-J. Jeong, E.-O. Kim, E.J. Sohn, M. Yun, S.-H. Kim, Apoptosis Induced by Tanshinone IIA and Cryptotanshinone Is Mediated by Distinct JAK/STAT3/5 and SHP1/2 Signaling in Chronic Myeloid Leukemia K562 Cells, Evidence-Based Complementary and Alternative Medicine, (2013).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.R.</ce:given-name>
                                 <ce:surname>Nair</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Tolentino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.F.</ce:given-name>
                                 <ce:surname>Argilagos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Pinilla-Ibarz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Hazlehurst</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leuk. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>36</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>756</sb:first-page>
                              <sb:last-page>763</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0050">R.R. Nair, J.H. Tolentino, R.F. Argilagos, L. Zhang, J. Pinilla-Ibarz, L.A. Hazlehurst, Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML, Leuk. Res., 36 (2012) 756-763.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.S.Y.</ce:given-name>
                                 <ce:surname>Saglam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Alp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Elmazoglu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Menevse</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Hum. Exp. Toxicol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>35</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>526</sb:first-page>
                              <sb:last-page>543</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0055">A.S.Y. Saglam, E. Alp, Z. Elmazoglu, S. Menevse, Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines, Human & Experimental Toxicology, 35 (2016) 526-543.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.-X.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.-B.</ce:given-name>
                                 <ce:surname>Cao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.-T.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.-L.</ce:given-name>
                                 <ce:surname>Xiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TGF beta 1 is essential for MSCs-CAFs differentiation and promotes HCT116 cells migration and invasion via JAK/STAT3 signaling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>OncoTargets Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5323</sb:first-page>
                              <sb:last-page>5334</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0060">H.-X. Tan, Z.-B. Cao, T.-T. He, T. Huang, C.-L. Xiang, Y. Liu, TGF beta 1 is essential for MSCs-CAFs differentiation and promotes HCT116 cells migration and invasion via JAK/STAT3 signaling, OncoTargets Ther., 12 (2019) 5323-5334.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.-W.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.-H.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-J.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.-S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Fei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.-M.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AZD1480, a JAK inhibitor, inhibits cell growth and survival of colorectal cancer via modulating the JAK2/STAT3 signaling pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncol. Rep.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>32</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1991</sb:first-page>
                              <sb:last-page>1998</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0065">S.-W. Wang, J. Hu, Q.-H. Guo, Y. Zhao, J.-J. Cheng, D.-S. Zhang, Q. Fei, J. Li, Y.-M. Sun, AZD1480, a JAK inhibitor, inhibits cell growth and survival of colorectal cancer via modulating the JAK2/STAT3 signaling pathway, Oncol. Rep., 32 (2014) 1991-1998.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.M.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.L.</ce:given-name>
                                 <ce:surname>Zhan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>MiR-203 regulates JAK-STAT pathway in affecting pancreatic cancer cells proliferation and apoptosis by targeting SOCS3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. Rev. Med. Pharmacol. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6906</sb:first-page>
                              <sb:last-page>6913</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0070">X.M. Lin, H. Chen, X.L. Zhan, MiR-203 regulates JAK-STAT pathway in affecting pancreatic cancer cells proliferation and apoptosis by targeting SOCS3, Eur. Rev. Med. Pharmacol. Sci., 23 (2019) 6906-6913.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.B.</ce:given-name>
                                 <ce:surname>Toh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Lim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Hooi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.B.M.A.</ce:given-name>
                                 <ce:surname>Rashid</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.K.-H.</ce:given-name>
                                 <ce:surname>Chow</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/beta-catenin-driven hepatocellular carcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Hepatol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>72</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>104</sb:first-page>
                              <sb:last-page>118</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0075">T.B. Toh, J.J. Lim, L. Hooi, M.B.M.A. Rashid, E.K.-H. Chow, Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/beta-catenin-driven hepatocellular carcinoma, J. Hepatol., (2019).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Hui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>HOXA11-AS regulates JAK-STAT pathway by miR-15a-3p/STAT3 axis to promote the growth and metastasis in liver cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Cell. Biochem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>120</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>15941</sb:first-page>
                              <sb:last-page>15951</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0080">S. Wang, S. Zhang, Y. He, X. Huang, Y. Hui, Y. Tang, HOXA11-AS regulates JAK-STAT pathway by miR-15a-3p/STAT3 axis to promote the growth and metastasis in liver cancer, J. Cell. Biochem., 120 (2019) 15941-15951.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Wen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.S.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.H.</ce:given-name>
                                 <ce:surname>Dellinger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Buettner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Horne</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Yim</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Increasing antitumor activity of JAK inhibitor by simultaneous blocking multiple survival signaling pathways in human ovarian cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Translational Oncology</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1015</sb:first-page>
                              <sb:last-page>1025</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0085">W. Wen, E.S. Han, T.H. Dellinger, J. Wu, Y. Guo, R. Buettner, D.A. Horne, R. Jove, J.H. Yim, Increasing antitumor activity of JAK inhibitor by simultaneous blocking multiple survival signaling pathways in human ovarian cancer, Translational Oncology, 12 (2019) 1015-1025.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Qi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Long noncoding RNA PART1 promotes progression of non-small cell lung cancer cells via JAK-STAT signaling pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Medicine</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0090">D. Zhu, Y. Yu, W. Wang, K. Wu, D. Liu, Y. Yang, C. Zhang, Y. Qi, S. Zhao, Long noncoding RNA PART1 promotes progression of non-small cell lung cancer cells via JAK-STAT signaling pathway, Cancer Medicine, (2019).</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Harrison</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-J.</ce:given-name>
                                 <ce:surname>Kiladjian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.K.</ce:given-name>
                                 <ce:surname>Al-Ali</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Gisslinger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Waltzman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Stalbovskaya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>McQuitty</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Hunter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Levy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Knoops</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Cervantes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Vannucchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Barbui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Barosi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>JAK inhibition with Ruxolitinib versus best available therapy for myelofibrosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>N. Engl. J. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>366</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>787</sb:first-page>
                              <sb:last-page>798</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0095">C. Harrison, J.-J. Kiladjian, H.K. Al-Ali, H. Gisslinger, R. Waltzman, V. Stalbovskaya, M. McQuitty, D.S. Hunter, R. Levy, L. Knoops, F. Cervantes, A.M. Vannucchi, T. Barbui, G. Barosi, JAK inhibition with Ruxolitinib versus best available therapy for myelofibrosis, N. Engl. J. Med., 366 (2012) 787-798.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Vannucchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Kiladjian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Griesshammer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Masszi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Durrant</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Passamonti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.N.</ce:given-name>
                                 <ce:surname>Harrison</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Pane</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Zachee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Mesa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Jones</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Garrett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Pirron</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Habr</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Verstovsek</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Ruxolitinib versus standard therapy for the treatment of polycythemia vera</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>N. Engl. J. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>372</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>426</sb:first-page>
                              <sb:last-page>435</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0100">A.M. Vannucchi, J.J. Kiladjian, M. Griesshammer, T. Masszi, S. Durrant, F. Passamonti, C.N. Harrison, F. Pane, P. Zachee, R. Mesa, S. He, M.M. Jones, W. Garrett, J. Li, U. Pirron, D. Habr, S. Verstovsek, Ruxolitinib versus standard therapy for the treatment of polycythemia vera, N. Engl. J. Med., 372 (2015) 426-435.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Verstovsek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Mesa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Gotlib</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.S.</ce:given-name>
                                 <ce:surname>Levy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Gupta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.F.</ce:given-name>
                                 <ce:surname>DiPersio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.V.</ce:given-name>
                                 <ce:surname>Catalano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Deininger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Miller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.T.</ce:given-name>
                                 <ce:surname>Silver</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Talpaz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.F.</ce:given-name>
                                 <ce:surname>Winton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Harvey</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.O.</ce:given-name>
                                 <ce:surname>Arcasoy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Hexner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Lyons</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Paquette</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Raza</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Vaddi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Erickson-Viitanen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.L.</ce:given-name>
                                 <ce:surname>Koumenis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Sandor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.M.</ce:given-name>
                                 <ce:surname>Kantarjian</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A double-blind, placebo-controlled trial of Ruxolitinib for myelofibrosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>N. Engl. J. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>366</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>799</sb:first-page>
                              <sb:last-page>807</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0105">S. Verstovsek, R.A. Mesa, J. Gotlib, R.S. Levy, V. Gupta, J.F. DiPersio, J.V. Catalano, M. Deininger, C. Miller, R.T. Silver, M. Talpaz, E.F. Winton, J.H. Harvey, Jr., M.O. Arcasoy, E. Hexner, R.M. Lyons, R. Paquette, A. Raza, K. Vaddi, S. Erickson-Viitanen, I.L. Koumenis, W. Sun, V. Sandor, H.M. Kantarjian, A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis, New England Journal of Medicine, 366 (2012) 799-807.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Xing</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Dai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Jabbari</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Cerise</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Higgins</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Gong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>de Jong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Harel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.M.</ce:given-name>
                                 <ce:surname>DeStefano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Rothman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Singh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Petukhova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Mackay-Wiggan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Christiano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Clynes</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1043</sb:first-page>
                              <sb:last-page>1049</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0110">L. Xing, Z. Dai, A. Jabbari, J.E. Cerise, C.A. Higgins, W. Gong, A. de Jong, S. Harel, G.M. DeStefano, L. Rothman, P. Singh, L. Petukhova, J. Mackay-Wiggan, A.M. Christiano, R. Clynes, Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition, Nature Medicine, 20 (2014) 1043-1049.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Quintas-Cardama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kantarjian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Cortes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Verstovsek</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>127</sb:first-page>
                              <sb:last-page>140</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0115">A. Quintas-Cardama, H. Kantarjian, J. Cortes, S. Verstovsek, Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond, Nat. Rev. Drug Discov., 10 (2011) 127-140.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ioannidis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Lamb</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Almeida</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Block</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Davies</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Peng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Su</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.-J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Hoffmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Rivard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Green</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Howard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Pollard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Read</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Alimzhanov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Bebernitz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Bell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Huszar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zinda</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of 5 chloro-N-2- (1S)-1-(5-fluoropyrimidin-2-yl)ethyl -N-4-(5-methyl-1H-pyraz ol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the jak/stat pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>54</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>262</sb:first-page>
                              <sb:last-page>276</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0120">S. Ioannidis, M.L. Lamb, T. Wang, L. Almeida, M.H. Block, A.M. Davies, B. Peng, M. Su, H.-J. Zhang, E. Hoffmann, C. Rivard, I. Green, T. Howard, H. Pollard, J. Read, M. Alimzhanov, G. Bebernitz, K. Bell, M. Ye, D. Huszar, M. Zinda, Discovery of 5 chloro-N-2- (1S)-1-(5-fluoropyrimidin-2-yl)ethyl -N-4-(5-methyl-1H-pyraz ol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the jak/stat pathway, J. Med. Chem., 54 (2011) 262-276.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Pardanani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Harrison</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Cortes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Cervantes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Mesa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Milligan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Masszi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Mishchenko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Jourdan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Vannucchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.W.</ce:given-name>
                                 <ce:surname>Drummond</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Jurgutis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Kuliczkowski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Gheorghita</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Passamonti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Neumann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Patki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Gao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Tefferi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Safety and efficacy of Fedratinib in patients with primary or secondary myelofibrosis A randomized clinical trial</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Jama Oncology</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>643</sb:first-page>
                              <sb:last-page>651</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0125">A. Pardanani, C. Harrison, J.E. Cortes, F. Cervantes, R.A. Mesa, D. Milligan, T. Masszi, E. Mishchenko, E. Jourdan, A.M. Vannucchi, M.W. Drummond, M. Jurgutis, K. Kuliczkowski, E. Gheorghita, F. Passamonti, F. Neumann, A. Patki, G. Gao, A. Tefferi, Safety and efficacy of Fedratinib in patients with primary or secondary myelofibrosis A randomized clinical trial, Jama Oncology, 1 (2015) 643-651.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.T.</ce:given-name>
                                 <ce:surname>Arkenau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Plummer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.R.</ce:given-name>
                                 <ce:surname>Molife</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Olmos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.A.</ce:given-name>
                                 <ce:surname>Yap</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Squires</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lewis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Lock</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Yule</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lyons</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Calvert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Judson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ann. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1307</sb:first-page>
                              <sb:last-page>1313</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0130">H.T. Arkenau, R. Plummer, L.R. Molife, D. Olmos, T.A. Yap, M. Squires, S. Lewis, V. Lock, M. Yule, J. Lyons, H. Calvert, I. Judson, A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies, Ann. Oncol., 23 (2012) 1307-1313.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Carmena</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.C.</ce:given-name>
                                 <ce:surname>Earnshaw</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The cellular geography of aurora kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Mol. Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>842</sb:first-page>
                              <sb:last-page>854</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0135">M. Carmena, W.C. Earnshaw, The cellular geography of aurora kinases, Nat. Rev. Mol. Cell Biol., 4 (2003) 842-854.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Keen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Taylor</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Aurora-kinase inhibitors as anticancer agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>927</sb:first-page>
                              <sb:last-page>936</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0140">N. Keen, S. Taylor, Aurora-kinase inhibitors as anticancer agents, Nat. Rev. Canc., 4 (2004) 927-936.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Bischoff</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Anderson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.F.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Mossie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Ng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Souza</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Schryver</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Flanagan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Clairvoyant</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ginther</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.S.M.</ce:given-name>
                                 <ce:surname>Chan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Novotny</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Slamon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.D.</ce:given-name>
                                 <ce:surname>Plowman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>EMBO J.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3052</sb:first-page>
                              <sb:last-page>3065</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0145">J.R. Bischoff, L. Anderson, Y.F. Zhu, K. Mossie, L. Ng, B. Souza, B. Schryver, P. Flanagan, F. Clairvoyant, C. Ginther, C.S.M. Chan, M. Novotny, D.J. Slamon, G.D. Plowman, A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers, EMBO J., 17 (1998) 3052-3065.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Fu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Bian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Roles of aurora kinases in mitosis and tumorigenesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>10</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0150">J. Fu, M. Bian, Q. Jiang, C. Zhang, Roles of aurora kinases in mitosis and tumorigenesis, Molecular Cancer Research, 5 (2007) 1-10.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.-F.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.-K.</ce:given-name>
                                 <ce:surname>Luo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.-R.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.-H.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Yan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.-R.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.-B.</ce:given-name>
                                 <ce:surname>Wan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.-M.</ce:given-name>
                                 <ce:surname>Zheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.-X.</ce:given-name>
                                 <ce:surname>Zeng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>111</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2854</sb:first-page>
                              <sb:last-page>2865</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0155">X.-F. Huang, S.-K. Luo, J. Xu, J. Li, D.-R. Xu, L.-H. Wang, M. Yan, X.-R. Wang, X.-B. Wan, F.-M. Zheng, Y.-X. Zeng, Q. Liu, Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia, Blood, 111 (2008) 2854-2865.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>[28]</ce:label>
                     <sb:reference id="sref28">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Midgley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Scaerou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.B.</ce:given-name>
                                 <ce:surname>Grabarek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Griffiths</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Jackson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Kontopidis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>McClue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>McInnes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Meades</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mezna</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Plater</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Stuart</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.P.</ce:given-name>
                                 <ce:surname>Thomas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Wood</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.G.</ce:given-name>
                                 <ce:surname>Clarke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.G.</ce:given-name>
                                 <ce:surname>Blake</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.I.</ce:given-name>
                                 <ce:surname>Zheleva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.P.</ce:given-name>
                                 <ce:surname>Lane</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.C.</ce:given-name>
                                 <ce:surname>Jackson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Glover</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.M.</ce:given-name>
                                 <ce:surname>Fischer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of N-Phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>53</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4367</sb:first-page>
                              <sb:last-page>4378</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0160">S. Wang, C.A. Midgley, F. Scaerou, J.B. Grabarek, G. Griffiths, W. Jackson, G. Kontopidis, S.J. McClue, C. McInnes, C. Meades, M. Mezna, A. Plater, I. Stuart, M.P. Thomas, G. Wood, R.G. Clarke, D.G. Blake, D.I. Zheleva, D.P. Lane, R.C. Jackson, D.M. Glover, P.M. Fischer, Discovery of N-Phenyl-4-(thiazol-5-yl)pyrimidin-2-amine Aurora Kinase Inhibitors, Journal of Medicinal Chemistry, 53 (2010) 4367-4378.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>[29]</ce:label>
                     <sb:reference id="sref29">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Dennis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Davies</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Oliver</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>D’Souza</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Pike</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Stockman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Chemother. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>70</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>461</sb:first-page>
                              <sb:last-page>469</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0165">M. Dennis, M. Davies, S. Oliver, R. D’Souza, L. Pike, P. Stockman, Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia, Cancer Chemotherapy and Pharmacology, 70 (2012) 461-469.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>[30]</ce:label>
                     <sb:reference id="sref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Geuns-Meyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.J.</ce:given-name>
                                 <ce:surname>Cee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.L.</ce:given-name>
                                 <ce:surname>Deak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Du</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.L.</ce:given-name>
                                 <ce:surname>Hodous</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Hanh Nho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.R.</ce:given-name>
                                 <ce:surname>Olivieri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.B.</ce:given-name>
                                 <ce:surname>Schenkel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.R.</ce:given-name>
                                 <ce:surname>Vaida</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Andrews</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Bak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Be</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Beltran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.L.</ce:given-name>
                                 <ce:surname>Bush</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.K.</ce:given-name>
                                 <ce:surname>Chaves</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Chung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Dai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Eden</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Hanested</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.-H.J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Ziegler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Radinsky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Kendall</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.F.</ce:given-name>
                                 <ce:surname>Patel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Payton</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of N-(4-(3-(2-Aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthioph en-2-yl)phthalazin-1-amine (AMG 900), A highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cancer cell lines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>58</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5189</sb:first-page>
                              <sb:last-page>5207</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0170">S. Geuns-Meyer, V.J. Cee, H.L. Deak, B. Du, B.L. Hodous, N. Hanh Nho, P.R. Olivieri, L.B. Schenkel, K.R. Vaida, P. Andrews, A. Bak, X. Be, P.J. Beltran, T.L. Bush, M.K. Chaves, G. Chung, Y. Dai, P. Eden, K. Hanested, L. Huang, M.-H.J. Lin, J. Tang, B. Ziegler, R. Radinsky, R. Kendall, V.F. Patel, M. Payton, Discovery of N-(4-(3-(2-Aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthioph en-2-yl)phthalazin-1-amine (AMG 900), A Highly Selective, Orally Bioavailable Inhibitor of Aurora Kinases with Activity against Multidrug-Resistant Cancer Cell Lines, Journal of Medicinal Chemistry, 58 (2015) 5189-5207.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>[31]</ce:label>
                     <sb:reference id="sref31">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Carpinelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Ceruti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Giorgini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Cappella</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Gianellini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Croci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Degrassi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Texido</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Rocchetti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Vianello</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Rusconi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Storici</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Zugnoni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Arrigoni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Soncini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Alli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Patton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Marsiglio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Ballinari</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Pesenti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Fancelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Moll</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Canc. Therapeut.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3158</sb:first-page>
                              <sb:last-page>3168</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0175">P. Carpinelli, R. Ceruti, M.L. Giorgini, P. Cappella, L. Gianellini, V. Croci, A. Degrassi, G. Texido, M. Rocchetti, P. Vianello, L. Rusconi, P. Storici, P. Zugnoni, C. Arrigoni, C. Soncini, C. Alli, V. Patton, A. Marsiglio, D. Ballinari, E. Pesenti, D. Fancelli, J. Moll, PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer, Mol. Canc. Therapeut., 6 (2007) 3158-3168.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>[32]</ce:label>
                     <sb:reference id="sref32">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.G.</ce:given-name>
                                 <ce:surname>Manfredi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Ecsedy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.A.</ce:given-name>
                                 <ce:surname>Meetze</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Balani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Burenkova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Galvin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Hoar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Huck</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>LeRoy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.T.</ce:given-name>
                                 <ce:surname>Ray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.B.</ce:given-name>
                                 <ce:surname>Sells</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Stringer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.G.</ce:given-name>
                                 <ce:surname>Stroud</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.J.</ce:given-name>
                                 <ce:surname>Vos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.S.</ce:given-name>
                                 <ce:surname>Weatherhead</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Wysong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.B.</ce:given-name>
                                 <ce:surname>Bolen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.F.</ce:given-name>
                                 <ce:surname>Claiborne</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U.S.A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>104</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4106</sb:first-page>
                              <sb:last-page>4111</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0180">M.G. Manfredi, J.A. Ecsedy, K.A. Meetze, S.K. Balani, O. Burenkova, W. Chen, K.M. Galvin, K.M. Hoar, J.J. Huck, P.J. LeRoy, E.T. Ray, T.B. Sells, B. Stringer, S.G. Stroud, T.J. Vos, G.S. Weatherhead, D.R. Wysong, M. Zhang, J.B. Bolen, C.F. Claiborne, Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase, Proc. Natl. Acad. Sci. U.S.A., 104 (2007) 4106-4111.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib33">
                     <ce:label>[33]</ce:label>
                     <sb:reference id="sref33">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.C.</ce:given-name>
                                 <ce:surname>Dees</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.B.</ce:given-name>
                                 <ce:surname>Cohen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>von Mehren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.E.</ce:given-name>
                                 <ce:surname>Stinchcombe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Venkatakrishnan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Manfredi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Fingert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.A.</ce:given-name>
                                 <ce:surname>Burris</ce:surname>
                                 <ce:suffix>III</ce:suffix>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Infante</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral Formulations</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4775</sb:first-page>
                              <sb:last-page>4784</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0185">E.C. Dees, R.B. Cohen, M. von Mehren, T.E. Stinchcombe, H. Liu, K. Venkatakrishnan, M. Manfredi, H. Fingert, H.A. Burris, III, J.R. Infante, Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral Formulations, Clin. Canc. Res., 18 (2012) 4775-4784.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib34">
                     <ce:label>[34]</ce:label>
                     <sb:reference id="sref34">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.A.</ce:given-name>
                                 <ce:surname>Dar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.W.</ce:given-name>
                                 <ce:surname>Goff</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Majid</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Berlin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>El-Rifai</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Aurora kinase inhibitors - rising stars in cancer therapeutics?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Canc. Therapeut.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>268</sb:first-page>
                              <sb:last-page>278</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0190">A.A. Dar, L.W. Goff, S. Majid, J. Berlin, W. El-Rifai, Aurora Kinase Inhibitors - Rising Stars in Cancer Therapeutics?, Molecular Cancer Therapeutics, 9 (2010) 268-278.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib35">
                     <ce:label>[35]</ce:label>
                     <sb:reference id="sref35">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.J.</ce:given-name>
                                 <ce:surname>Hou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.L.</ce:given-name>
                                 <ce:surname>Mao</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat hematological malignancies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Drug Discov. Today</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>988</sb:first-page>
                              <sb:last-page>994</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0195">J.Y. Zhu, T.J. Hou, X.L. Mao, Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat hematological malignancies, Drug Discov. Today, 20 (2015) 988-994.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib36">
                     <ce:label>[36]</ce:label>
                     <sb:reference id="sref36">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.B.</ce:given-name>
                                 <ce:surname>Tian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.F.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Heimbach</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.D.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Buchbinder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Aghoghovbia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Hourcade-Potelleret</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Clinical pharmacokinetic and pharmacodynamic overview of nilotinib, a selective tyrosine kinase inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>58</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1533</sb:first-page>
                              <sb:last-page>1540</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0200">X.B. Tian, H.F. Zhang, T. Heimbach, H.D. He, A. Buchbinder, M. Aghoghovbia, F. Hourcade-Potelleret, Clinical pharmacokinetic and pharmacodynamic overview of nilotinib, a selective tyrosine kinase inhibitor, J. Clin. Pharmacol., 58 (2018) 1533-1540.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib37">
                     <ce:label>[37]</ce:label>
                     <sb:reference id="sref37">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.T.</ce:given-name>
                                 <ce:surname>Durlacher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.L.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.W.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.X.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.F.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Exp. Pharmacol. Physiol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>43</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>585</sb:first-page>
                              <sb:last-page>601</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0205">C.T. Durlacher, Z.L. Li, X.W. Chen, Z.X. He, S.F. Zhou, An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor, Clin Exp Pharmacol P, 43 (2016) 585-601.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib38">
                     <ce:label>[38]</ce:label>
                     <sb:reference id="sref38">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Luo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Multi-targeted anticancer agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Top. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3084</sb:first-page>
                              <sb:last-page>3098</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0210">W. Zheng, Y. Zhao, Q. Luo, Y. Zhang, K. Wu, F.Y. Wang, Multi-targeted anticancer agents, Curr. Top. Med. Chem., 17 (2017) 3084-3098.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib39">
                     <ce:label>[39]</ce:label>
                     <sb:reference id="sref39">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.R.</ce:given-name>
                                 <ce:surname>Lawrence</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kazi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Gevariya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Patel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.T.</ce:given-name>
                                 <ce:surname>Luo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Rix</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Schonbrunn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.J.</ce:given-name>
                                 <ce:surname>Lawrence</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Sebti</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dual Aurora A and JAK2 kinase blockade effectively suppresses malignant transformation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2947</sb:first-page>
                              <sb:last-page>2961</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0215">H. Yang, H.R. Lawrence, A. Kazi, H. Gevariya, R. Patel, Y.T. Luo, U. Rix, E. Schonbrunn, N.J. Lawrence, S.M. Sebti, Dual Aurora A and JAK2 kinase blockade effectively suppresses malignant transformation, Oncotarget, 5 (2014) 2947-2961.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib40">
                     <ce:label>[40]</ce:label>
                     <sb:reference id="sref40">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Howard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Berdini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Boulstridge</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.G.</ce:given-name>
                                 <ce:surname>Carr</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Cross</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Curry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Devine</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.R.</ce:given-name>
                                 <ce:surname>Early</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Fazal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.L.</ce:given-name>
                                 <ce:surname>Gill</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Heathcote</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Maman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Matthews</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.L.</ce:given-name>
                                 <ce:surname>McMenamin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.F.</ce:given-name>
                                 <ce:surname>Navarro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>O’Brien</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>O’Reilly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Rees</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Reule</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Tisi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Williams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Vinkovic</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.G.</ce:given-name>
                                 <ce:surname>Wyatt</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>52</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>379</sb:first-page>
                              <sb:last-page>388</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0220">S. Howard, V. Berdini, J.A. Boulstridge, M.G. Carr, D.M. Cross, J. Curry, L.A. Devine, T.R. Early, L. Fazal, A.L. Gill, M. Heathcote, S. Maman, J.E. Matthews, R.L. McMenamin, E.F. Navarro, M.A. O’Brien, M. O’Reilly, D.C. Rees, M. Reule, D. Tisi, G. Williams, M. Vinkovic, P.G. Wyatt, Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity, J. Med. Chem., 52 (2009) 379-388.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib41">
                     <ce:label>[41]</ce:label>
                     <sb:reference id="sref41">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.K.</ce:given-name>
                                 <ce:surname>Samanta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kantarjian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.B.</ce:given-name>
                                 <ce:surname>Arlinghaus</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Janus kinase 2: a critical target in chronic myelogenous leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>66</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6468</sb:first-page>
                              <sb:last-page>6472</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0225">A.K. Samanta, H. Lin, T. Sun, H. Kantarjian, R.B. Arlinghaus, Janus kinase 2: A critical target in chronic myelogenous leukemia, Cancer Research, 66 (2006) 6468-6472.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib42">
                     <ce:label>[42]</ce:label>
                     <sb:reference id="sref42">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Xue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Ramakrishnan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Weisz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Triner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Attili</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Pant</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Gyorffy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zhan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Carter-Su</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Hardiman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.D.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.K.</ce:given-name>
                                 <ce:surname>Dame</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Varani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Brenner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.R.</ce:given-name>
                                 <ce:surname>Fearon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.M.</ce:given-name>
                                 <ce:surname>Shah</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Iron uptake via DMT1 integrates cell cycle with JAK-STAT3 signaling to promote colorectal tumorigenesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Metabol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>447</sb:first-page>
                              <sb:last-page>461</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0230">X. Xue, S.K. Ramakrishnan, K. Weisz, D. Triner, L. Xie, D. Attili, A. Pant, B. Gyorffy, M. Zhan, C. Carter-Su, K.M. Hardiman, T.D. Wang, M.K. Dame, J. Varani, D. Brenner, E.R. Fearon, Y.M. Shah, Iron uptake via DMT1 integrates cell cycle with JAK-STAT3 signaling to promote colorectal tumorigenesis, Cell Metabol., 24 (2016) 447-461.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib43">
                     <ce:label>[43]</ce:label>
                     <sb:reference id="sref43">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Goerguen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Calabrese</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Hideshima</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ecsedy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Perrone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Ikeda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Bianchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Cirstea</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Santo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.-T.</ce:given-name>
                                 <ce:surname>Tai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Nahar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Bandi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.D.</ce:given-name>
                                 <ce:surname>Carrasco</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Raje</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Munshi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Richardson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.C.</ce:given-name>
                                 <ce:surname>Anderson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Anovel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>115</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5202</sb:first-page>
                              <sb:last-page>5213</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0235">G. Goerguen, E. Calabrese, T. Hideshima, J. Ecsedy, G. Perrone, M. Mani, H. Ikeda, G. Bianchi, Y. Hu, D. Cirstea, L. Santo, Y.-T. Tai, S. Nahar, M. Zheng, M. Bandi, R.D. Carrasco, N. Raje, N. Munshi, P. Richardson, K.C. Anderson, Anovel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma, Blood, 115 (2010) 5202-5213.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib44">
                     <ce:label>[44]</ce:label>
                     <sb:reference id="sref44">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Feng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.-X.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.-W.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Hui</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and biological evaluation of 2,4-disubstituted phthalazinones as Aurora kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3217</sb:first-page>
                              <sb:last-page>3226</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0240">W. Wang, X. Feng, H.-X. Liu, S.-W. Chen, L. Hui, Synthesis and biological evaluation of 2,4-disubstituted phthalazinones as Aurora kinase inhibitors, Bioorganic & Medicinal Chemistry, 26 (2018) 3217-3226.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib45">
                     <ce:label>[45]</ce:label>
                     <sb:reference id="sref45">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.-Y.</ce:given-name>
                                 <ce:surname>Ke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.-P.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.-H.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.-H.</ce:given-name>
                                 <ce:surname>Tsai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.C.</ce:given-name>
                                 <ce:surname>Chiu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.-P.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.-C.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.-Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.-H.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.-F.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.-C.</ce:given-name>
                                 <ce:surname>Kuo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-S.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Shih</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.-P.</ce:given-name>
                                 <ce:surname>Hsieh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.-H.</ce:given-name>
                                 <ce:surname>Chi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design and synthesis of BPR1K653 derivatives targeting the back pocket of Aurora kinases for selective isoform inhibition</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>151</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>533</sb:first-page>
                              <sb:last-page>545</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0245">Y.-Y. Ke, C.-P. Chang, W.-H. Lin, C.-H. Tsai, I.C. Chiu, W.-P. Wang, P.-C. Wang, P.-Y. Chen, W.-H. Lin, C.-F. Chang, P.-C. Kuo, J.-S. Song, C. Shih, H.-P. Hsieh, Y.-H. Chi, Design and synthesis of BPR1K653 derivatives targeting the back pocket of Aurora kinases for selective isoform inhibition, European Journal of Medicinal Chemistry, 151 (2018) 533-545.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib46">
                     <ce:label>[46]</ce:label>
                     <sb:reference id="sref46">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Liang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Geng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Chou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Cao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of novel Janus kinase (JAK) and histone deacetylase (HDAC) dual inhibitors for the treatment of hematological malignancies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3898</sb:first-page>
                              <sb:last-page>3923</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0250">X. Liang, J. Zang, X. Li, S. Tang, M. Huang, M. Geng, C.J. Chou, C. Li, Y. Cao, W. Xu, H. Liu, Y. Zhang, Discovery of novel Janus kinase (JAK) and histone deacetylase (HDAC) dual inhibitors for the treatment of hematological malignancies, J. Med. Chem., 62 (2019) 3898-3923.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib47">
                     <ce:label>[47]</ce:label>
                     <sb:reference id="sref47">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zhong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of an orally available Janus kinase 3 selective covalent inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1054</sb:first-page>
                              <sb:last-page>1066</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0255">L. Shi, Z. Zhong, X. Li, Y. Zhou, Z. Pan, Discovery of an orally available Janus kinase 3 selective covalent inhibitor, J. Med. Chem., 62 (2019) 1054-1066.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib48">
                     <ce:label>[48]</ce:label>
                     <sb:reference id="sref48">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bromberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Darnell</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The role of STATs in transcriptional control and their impact on cellular function</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2468</sb:first-page>
                              <sb:last-page>2473</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0260">J. Bromberg, J.E. Darnell, The role of STATs in transcriptional control and their impact on cellular function, Oncogene, 19 (2000) 2468-2473.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib49">
                     <ce:label>[49]</ce:label>
                     <sb:reference id="sref49">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kollareddy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Dzubak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Zheleva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hajduch</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Aurora kinases: structure, functions and their association with cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biomedical Papers-Olomouc</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>152</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>27</sb:first-page>
                              <sb:last-page>33</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0265">M. Kollareddy, P. Dzubak, D. Zheleva, M. Hajduch, Aurora kinases: structure, functions and their association with cancer, Biomedical Papers-Olomouc, 152 (2008) 27-33.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib50">
                     <ce:label>[50]</ce:label>
                     <sb:reference id="sref50">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.C.</ce:given-name>
                                 <ce:surname>Mills</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.A.</ce:given-name>
                                 <ce:surname>Kolb</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.B.</ce:given-name>
                                 <ce:surname>Sampson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Recent advances of cell-cycle inhibitor therapies for pediatric cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>77</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6489</sb:first-page>
                              <sb:last-page>6498</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0270">C.C. Mills, E.A. Kolb, V.B. Sampson, Recent Advances of Cell-Cycle Inhibitor Therapies for Pediatric Cancer, Cancer Research, 77 (2017) 6489-6498.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib51">
                     <ce:label>[51]</ce:label>
                     <sb:reference id="sref51">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Petersen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Yuan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Schneiderjan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.-J.</ce:given-name>
                                 <ce:surname>Cho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.J.</ce:given-name>
                                 <ce:surname>MacDonald</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dasatinib suppression of medulloblastoma survival and migration is markedly enhanced by combining treatment with the aurora kinase inhibitor AT9283</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>354</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>68</sb:first-page>
                              <sb:last-page>76</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0275">W. Petersen, J. Liu, L. Yuan, H. Zhang, M. Schneiderjan, Y.-J. Cho, T.J. MacDonald, Dasatinib suppression of medulloblastoma survival and migration is markedly enhanced by combining treatment with the aurora kinase inhibitor AT9283, Canc. Lett., 354 (2014) 68-76.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib52">
                     <ce:label>[52]</ce:label>
                     <sb:reference id="sref52">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Peng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Luo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Exploring binding mechanisms of VEGFR2 with three drugs lenvatinib, sorafenib, and sunitinib by molecular dynamics simulation and free energy calculation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Biol. Drug Des.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>93</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>934</sb:first-page>
                              <sb:last-page>948</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0280">Y. Wang, C. Peng, G. Wang, Z. Xu, Y. Luo, J. Wang, W. Zhu, Exploring binding mechanisms of VEGFR2 with three drugs lenvatinib, sorafenib, and sunitinib by molecular dynamics simulation and free energy calculation, Chem. Biol. Drug Des., 93 (2019) 934-948.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib53">
                     <ce:label>[53]</ce:label>
                     <sb:reference id="sref53">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Kashem</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Nelson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Yingling</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Pullen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.S.</ce:given-name>
                                 <ce:surname>Prokopowicz</ce:surname>
                                 <ce:suffix>III</ce:suffix>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.W.</ce:given-name>
                                 <ce:surname>Jones</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Wolak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.R.</ce:given-name>
                                 <ce:surname>Rogers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Morelock</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Snow</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Homon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Jakes</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Three mechanistically distinct kinase assays compared: measurement of intrinsic ATPase activity identified the most comprehensive set of ITK inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biomol. Screen</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>70</sb:first-page>
                              <sb:last-page>83</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0285">M.A. Kashem, R.M. Nelson, J.D. Yingling, S.S. Pullen, A.S. Prokopowicz, III, J.W. Jones, J.P. Wolak, G.R. Rogers, M.M. Morelock, R.J. Snow, C.A. Homon, S. Jakes, Three mechanistically distinct kinase assays compared: measurement of intrinsic ATPase activity identified the most comprehensive set of ITK inhibitors, J. Biomol. Screen, 12 (2007) 70-83.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib54">
                     <ce:label>[54]</ce:label>
                     <sb:reference id="sref54">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Trott</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Olson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>AutoDock</ce:given-name>
                                 <ce:surname>Vina</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Comput. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>31</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>455</sb:first-page>
                              <sb:last-page>461</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0290">O. Trott, A.J. Olson, AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, Journal of Computational Chemistry, 31 (2010) 455-461.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib55">
                     <ce:label>[55]</ce:label>
                     <sb:reference id="sref55">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Howard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Berdini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Boulstridge</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.G.</ce:given-name>
                                 <ce:surname>Carr</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Cross</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Curry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Devine</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.R.</ce:given-name>
                                 <ce:surname>Early</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Fazal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.L.</ce:given-name>
                                 <ce:surname>Gill</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Heathcote</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Maman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Matthews</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.L.</ce:given-name>
                                 <ce:surname>McMenamin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.F.</ce:given-name>
                                 <ce:surname>Navarro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>O’Brien</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>O’Reilly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Rees</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Reule</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Tisi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Williams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Vinković</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.G.</ce:given-name>
                                 <ce:surname>Wyatt</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>52</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>379</sb:first-page>
                              <sb:last-page>388</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0295">S. Howard, V. Berdini, J.A. Boulstridge, M.G. Carr, D.M. Cross, J. Curry, L.A. Devine, T.R. Early, L. Fazal, A.L. Gill, M. Heathcote, S. Maman, J.E. Matthews, R.L. McMenamin, E.F. Navarro, M.A. O’Brien, M. O’Reilly, D.C. Rees, M. Reule, D. Tisi, G. Williams, M. Vinkovic, P.G. Wyatt, Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity, Journal of Medicinal Chemistry, 52 (2009) 379-388.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib56">
                     <ce:label>[56]</ce:label>
                     <sb:reference id="sref56">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Jaime-Figueroa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>De Vicente</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Hermann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Jahangir</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Jin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kuglstatter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Lynch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Menke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Niu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Patel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Shao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Soth</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Vu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Yee</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of a series of novel 5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers, as potent JAK3 kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2522</sb:first-page>
                              <sb:last-page>2526</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0300">S. Jaime-Figueroa, J. De Vicente, J. Hermann, A. Jahangir, S. Jin, A. Kuglstatter, S.M. Lynch, J. Menke, L. Niu, V. Patel, A. Shao, M. Soth, M.D. Vu, C. Yee, Discovery of a series of novel 5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers, as potent JAK3 kinase inhibitors, Bioorganic & Medicinal Chemistry Letters, 23 (2013) 2522-2526.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib57">
                     <ce:label>[57]</ce:label>
                     <sb:reference id="sref57">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Elkins</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Santaguida</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Musacchio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Knapp</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Crystal structure of human aurora B in complex with INCENP and VX-680</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7841</sb:first-page>
                              <sb:last-page>7848</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0305">J.M. Elkins, S. Santaguida, A. Musacchio, S. Knapp, Crystal structure of human aurora B in complex with INCENP and VX-680, J. Med. Chem., 55 (2012) 7841-7848.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib58">
                     <ce:label>[58]</ce:label>
                     <sb:reference id="sref58">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.M.</ce:given-name>
                                 <ce:surname>Morris</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Huey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Lindstrom</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Sanner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.K.</ce:given-name>
                                 <ce:surname>Belew</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Goodsell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Olson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Comput. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>30</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2785</sb:first-page>
                              <sb:last-page>2791</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0310">G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, A.J. Olson, AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility, J. Comput. Chem., 30 (2009) 2785-2791.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib59">
                     <ce:label>[59]</ce:label>
                     <sb:reference id="sref59">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.M.</ce:given-name>
                                 <ce:surname>O’Boyle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Banck</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>James</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Morley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Vandermeersch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.R.</ce:given-name>
                                 <ce:surname>Hutchison</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Open Babel: an open chemical toolbox</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Cheminf.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>33</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0315">N.M. O’Boyle, M. Banck, C.A. James, C. Morley, T. Vandermeersch, G.R. Hutchison, Open Babel: an open chemical toolbox, J. Cheminf., 3 (2011) 33.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib60">
                     <ce:label>[60]</ce:label>
                     <sb:reference id="sref60">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Marlow</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Dogan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.K.</ce:given-name>
                                 <ce:surname>Frederick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.G.</ce:given-name>
                                 <ce:surname>Valentine</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Wand</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The role of conformational entropy in molecular recognition by calmodulin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>352</sb:first-page>
                              <sb:last-page>358</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0320">M.S. Marlow, J. Dogan, K.K. Frederick, K.G. Valentine, A.J. Wand, The role of conformational entropy in molecular recognition by calmodulin, Nat. Chem. Biol., 6 (2010) 352-358.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib61">
                     <ce:label>[61]</ce:label>
                     <sb:reference id="sref61">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Maier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Martinez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Kasavajhala</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wickstrom</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.E.</ce:given-name>
                                 <ce:surname>Hauser</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Simmerling</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Chem. Theor. Comput.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3696</sb:first-page>
                              <sb:last-page>3713</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0325">J.A. Maier, C. Martinez, K. Kasavajhala, L. Wickstrom, K.E. Hauser, C. Simmerling, ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB, J. Chem. Theor. Comput., 11 (2015) 3696-3713.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib62">
                     <ce:label>[62]</ce:label>
                     <sb:reference id="sref62">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Wolf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.W.</ce:given-name>
                                 <ce:surname>Caldwell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Kollman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Case</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Development and testing of a general amber force field</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Comput. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1157</sb:first-page>
                              <sb:last-page>1174</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0330">J. Wang, R.M. Wolf, J.W. Caldwell, P.A. Kollman, D.A. Case, Development and testing of a general amber force field, J. Comput. Chem., 25 (2004) 1157-1174.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib63">
                     <ce:label>[63]</ce:label>
                     <sb:reference id="sref63">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.L.</ce:given-name>
                                 <ce:surname>Jorgensen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chandrasekhar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Madura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.W.</ce:given-name>
                                 <ce:surname>Impey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Klein</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Comparison of simple potential functions for simulating liquid water</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Chem. Phys.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>79</sb:volume-nr>
                              </sb:series>
                              <sb:date>1983</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>926</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0335">W.L. Jorgensen, J. Chandrasekhar, J.D. Madura, R.W. Impey, M.L. Klein, Comparison of simple potential functions for simulating liquid water, The Journal of chemical physics, 79 (1983) 926.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib64">
                     <ce:label>[64]</ce:label>
                     <sb:reference id="sref64">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.-P.</ce:given-name>
                                 <ce:surname>Ryckaert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Ciccotti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Berendsen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of< i> n</i>-alkanes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Comput. Phys.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>1977</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>327</sb:first-page>
                              <sb:last-page>341</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0340">J.-P. Ryckaert, G. Ciccotti, H.J. Berendsen, Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of< i> n</i>-alkanes, Journal of Computational Physics, 23 (1977) 327-341.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib65">
                     <ce:label>[65]</ce:label>
                     <sb:reference id="sref65">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Darden</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>York</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Pedersen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Particle mesh Ewald: an N⋅ log (N) method for Ewald sums in large systems</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Chem. Phys.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>98</sb:volume-nr>
                              </sb:series>
                              <sb:date>1993</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>10089</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0345">T. Darden, D. York, L. Pedersen, Particle mesh Ewald: An N⋅ log (N) method for Ewald sums in large systems, The Journal of chemical physics, 98 (1993) 10089.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib66">
                     <ce:label>[66]</ce:label>
                     <sb:reference id="sref66">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Onufriev</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Bashford</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Case</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Exploring protein native states and large-scale conformational changes with a modified generalized born model</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proteins: Structure, Function, and Bioinformatics</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>383</sb:first-page>
                              <sb:last-page>394</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0350">A. Onufriev, D. Bashford, D.A. Case, Exploring protein native states and large-scale conformational changes with a modified generalized born model, Proteins: Structure, Function, and Bioinformatics, 55 (2004) 383-394.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib67">
                     <ce:label>[67]</ce:label>
                     <sb:reference id="sref67">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Sanner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Olson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-C.</ce:given-name>
                                 <ce:surname>Spehner</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Reduced surface: an efficient way to compute molecular surfaces</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biopolymers</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>38</sb:volume-nr>
                              </sb:series>
                              <sb:date>1996</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>305</sb:first-page>
                              <sb:last-page>320</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0355">M.F. Sanner, A.J. Olson, J.-C. Spehner, Reduced surface: an efficient way to compute molecular surfaces, Biopolymers, 38 (1996) 305-320.</ce:source-text>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>